

1 A So I have no idea when it went up, but I know
2 they have a major campaign on their website.

3 Q Right. This is off the CDC website --

4 A Yeah. No, I can see that.

5 Q -- last night. And tell me if everything on
6 there look -- looks accurate.

7 A Okay.

8 Q Does that look accurate?

9 A It's an -- it's actually preventing human
10 error. It's a little -- in other words, one could look at
11 this and say that I was incorrect when I said on the same
12 patient you could reuse that needle and syringe on that --
13 with that medication vial, for example, as long as you threw
14 it out.

15 Q Okay.

16 A Okay. That not what this says. This says you
17 shouldn't do that.

18 Q Okay. I wasn't --

19 A No, no, no. I know. I didn't mean --

20 Q Okay.

21 A I didn't mean anything by that. And all I'm
22 saying is what they're trying to do is reduce the opportunity
23 for anyone to -- to -- reducing the opportunity for human
24 error by making it just one policy and that's it.

25 Q Okay. The --

1 MR. WRIGHT: I'm going to move its admission.

2 MR. STAUDAHER: No objection.

3 THE COURT: All right. What number is that, or
4 letter and number?

5 MR. WRIGHT: What exhibit?

6 THE WITNESS: S1 or -- S1.

7 THE COURT: S1. That would be right.

8 (Defendant's Exhibit S-1 admitted.)

9 BY MR. WRIGHT:

10 Q The part that throws me is the single dose,
11 this differentiation between multi and single, okay. And as I
12 read this, this is a patient safety threat syringe reuse. And
13 it says a single-use vial is a bottle of liquid medication
14 that is given to a patient through a needle and syringe. That
15 part I get. Single-use vials contains only one dose of
16 medication and should only be used once for one patient using
17 a clean needle and clean syringe. Okay? See, I -- I read
18 that literally as meaning --

19 A I would --

20 Q -- a single-use vial has only one dose in it.
21 And after I use one dose, I toss it, which is inconsistent
22 with the label; correct?

23 A The label on -- well, the label doesn't really
24 say, does it?

25 Q What's it say?

1 A I'm sorry. I'm not laughing because --
2 because I can see the -- I mean, I don't happen to agree with
3 that statement. I don't know if it's correct. Because, let's
4 face it, why would you make a vial that contains -- you know,
5 that's not consistent because you don't give all of this at
6 once.

7 Q Right.

8 A You might give it twice or three times in the
9 course of the procedure. So you could then draw it up. But
10 -- and it says it's okay for 12 hours. It says use strict
11 aseptic technique. It says single patient infusion vial.

12 Q Okay. Single patient infusion vial.

13 A I'm telling you, if my computer was working, I
14 would boot it up -- which it isn't somehow. I don't know. I
15 must have -- I left it on. I would boot it up, I would go to
16 the FDA, and I would see what their definition was. I think
17 -- I mean, I can't honestly address the veracity of this
18 statement --

19 Q Okay.

20 A -- because we know this contains more than one
21 dose. In other words --

22 Q Right.

23 A -- you're not going to give them, the patient,
24 all of this at one time probably, unless maybe they weigh 300
25 pounds. Okay. So --

1 Q See, when I looked at the --

2 A No, I -- so I see your point. And the only
3 reason I can, you know -- again, I'd like to see what the FDA,
4 what their definition is. But also, as I said, sometimes in
5 relooking at policies or recommendations, I mean, this wasn't
6 a CDC recommendation to begin with technically. It's an
7 aseptic practice that's part of -- should be part of routine
8 medical care, but anyway. We go -- we -- CDC will go a little
9 more to the extreme to, as I said, prevent human error. On
10 the other hand, that is a definition. And that's why the only
11 way I would know is if I looked it up.

12 Q Okay.

13 A And I actually don't think of it that way
14 myself. So -- but on the other hand, you know, I think
15 they're trying to make it so simple that no one has to think
16 about it.

17 Q Right. And it's -- and it's -- what you think
18 is simple is confusing when you --

19 A Right. I understand that, but when you find
20 that people are not following a procedure that's been in place
21 for 50 years, then you have to decide what is it you need to
22 do to make sure that they follow it, even though you might be
23 going a little more -- a little overboard, so -- in some
24 people's minds. Maybe they just want them to think single,
25 single, single, and that's it.

1 Q See the -- see the next definition of
2 multi-dose says a multi-dose -- a multi-dose vial is a bottle
3 of liquid medication that contains more than one dose of
4 medication. Now, if I'm applying this CDC directive, I would
5 look at that propofol vial there as a multi-dose vial because
6 it contains more than one dose. Agree?

7 A That's your -- see, but -- I can't comment.

8 Q Okay.

9 A Because I can't comment. It's a single --
10 it's a single -- because I don't know the -- as I said, I need
11 to find -- I would need to know how the FDA -- you know, this
12 is an FDA approved label, otherwise it wouldn't be licensed.
13 And it says single patient infusion vial.

14 Q Okay.

15 A So but I honestly don't -- don't know why you
16 couldn't give multiple doses in a short period of time to the
17 same patient from this vial.

18 Q Okey-doke.

19 A But there's a lot of pooling going on with a
20 lot of medications in different settings.

21 Q The -- your -- not your, but one of the
22 articles you sent that talked about the New York -- 2010
23 article about the New York outbreak.

24 A The -- oh, yes, the later one.

25 Q Yes.

1 A Uh-huh.

2 Q Multiple Clusters of Hepatitis Virus
3 Infections Associated with Anesthesia for Outpatient Endoscopy
4 Procedures. The conclusion of it, if I may go through with
5 you, outbreak similar to the one described here -- of course
6 it's talking about the second New York outbreak --

7 A Right.

8 Q -- you commented on. Outbreak similar to the
9 one described here would not have been possible if intravenous
10 anesthesia medications were not administered from a single
11 vial from multiple patients; correct?

12 A True.

13 Q Absolutely. Black and white. For this reason
14 we advocate, now that's the authors of this; correct?

15 A Yes.

16 Q For this reason we advocate eliminating use of
17 all multi-patient vials for anesthesia medications to the
18 greatest extent possible, and educating clinicians on the
19 risks associated with their use. Would you agree with that?

20 A Yes, and it's been stated in many previous
21 publications, even while I was at CDC.

22 Q Okay. And so one thing to do was just plain
23 no multi-use vials at all for anesthesia. That's just taking
24 out human error and misperceptions.

25 A Uh-huh.

1 Q And educating clinicians on the risks
2 associated with their use; correct?

3 A Correct what?

4 Q That that's -- that's something that needs to
5 be done.

6 A Yes.

7 Q Even in --

8 A Yes. Yes.

9 Q This is three years later, three years after
10 the events in this case and still in June of 2010, it's still
11 a lack of understanding on the part of clinicians. Is that
12 fair?

13 A Well, tactfully, yes.

14 Q Tactfully?

15 A Tactfully.

16 Q Okay. This can be accomplished by more
17 clearly labeling medications, e.g., propofol as single patient
18 use only. Would you agree with that?

19 A It is labeled as single patient use.

20 Q Okay. Well, this says this can be
21 accomplished. I mean, you may disagree with --

22 A Those are the --

23 Q -- these authors.

24 A Well, I'm just saying that, you know, they're
25 offering suggestions, but that is what this vial says and --

1 Q Okay. And improving pricing of unit dose
2 single patient use medications to encourage their use. What
3 did that mean?

4 A I can tell you exactly what that means.

5 Q Good.

6 A Multiple-dose vials are much more economical
7 than single-dose vials. The larger the quantity, the cheaper
8 it is per dose, the less expensive it is per dose. And, in
9 fact, that's somewhat how they came to be multiple dose.
10 Larger vials can be used for multiple doses. But it also then
11 led to this problem, contamination, when used along with
12 improper preparation techniques.

13 Q Okay. So improving pricing of unit dose
14 single patient use medications to encourage their use.

15 A Right. Because, actually, when we -- when I
16 was still there we -- you know, we said, you know, wouldn't it
17 be great to get rid of all the multi-dose vials. But in -- in
18 the absence of that you have two choices. You know, two
19 things that you can do is restrict them to a centralized area
20 where you can't go back into those, or -- you know, with a
21 used syringe, or, you know, just not use them at all. So the
22 first works quite well, but it's much more economical,
23 particularly for large corporations, to purchase the multiple
24 dose vials.

25 Q Why do you think that?

1 A Why do I think that?

2 Q Yeah.

3 A From my experience working in hemodialysis
4 settings where I did a lot of very specific activities. It's
5 an area of high specialization, particularly in terms of
6 preventing transmission, and there are a lot of issues with
7 economics in those settings, and that is part of the reason
8 for purchasing large amounts of very expensive drugs that
9 aren't supposed to be reused.

10 Q Okay. How about -- I mean, this is a propofol
11 case.

12 A I know, but --

13 Q No, I mean --

14 A -- really, aren't economics --

15 Q No, I meant --

16 A You know --

17 Q Okay.

18 A -- but that is -- it is an economical issue --

19 Q Okay. Do you --

20 A -- I think.

21 Q Do you --

22 A In many cases it is less expensive per dose to
23 buy in large volume than in small volume.

24 Q Do you -- do you have any -- do you believe
25 like 50 cc propofols are cheaper by volume than 20 ccs?

1 A I have no knowledge in that area.

2 Q Okay. One article I didn't get from you, but
3 you may be familiar with,

4 A Yes.

5 Q Okay. It's called Injection Practices Among
6 Clinicians in United States Healthcare Settings.

7 A First off, that's from the place called the
8 Premier Safety Institute, so it's a private organization.

9 Q I can't find where these things are from.

10 A I can tell you.

11 Q Melissa Schaefer is one of the authors.

12 A The first author is Gina Pugliese. The
13 journal is American Journal of Infection Control. It's aimed
14 at nurse -- infection control nurses in the healthcare
15 facilities.

16 Q Bedside reading for --

17 A Well, for --

18 Q -- your kind.

19 A -- some of us.

20 Q This study or survey in 2010, or at least it
21 was published December 2010, study during --

22 MR. STAUDAHNER: Could I at least see the article?

23 BY MR. WRIGHT:

24 Q -- May and June.

25 MR. STAUDAHNER: I'd like to see the article, if I

1 could.

2 THE COURT: I'm sorry? Oh, you want to see it.

3 MR. WRIGHT: I'm sorry.

4 BY MR. WRIGHT:

5 Q May and June of 2010 is a survey of
6 approximately 5,446 clinicians, 90 percent of whom were
7 registered nurses. Okay?

8 A Uh-huh.

9 Q The -- and it was a survey dealing with
10 injection practices, syringe reuse, and multi-use of vials.
11 The respondents reuse -- I'm going to ask you a question after
12 this -- reuse syringe for additional doses from the same
13 multi-dose vial. Did you follow that?

14 A Uh-huh.

15 Q Okay.

16 A Yes.

17 Q A total of 797 respondents, 15 percent,
18 indicated that they are sometimes or always reusing a syringe
19 for additional doses from the same multi-dose vial for the
20 same patient. Okay?

21 A Yes.

22 Q And then of that group they were then asked --
23 that was 797 respondents -- were then asked about reusing the
24 vial that they had just reused the syringe on. In our study,
25 797 respondents, 15 percent, indicated that they sometimes or

1 always reuse a syringe for additional doses from the same
2 multi-dose vial for the same patient. They were then asked to
3 indicate the disposition of the multi-dose vial. 51 of the
4 797, 6.5 percent, who answered the question on disposition of
5 the vial indicated that they save the vial for reuse on
6 another patient. Okay?

7 A Uh-huh.

8 Q So that -- that's 51 of the practitioners in
9 this survey in 2010 did the double -- double danger; correct?

10 A Yes.

11 Q Okay. And that -- and that double danger
12 being not -- not only did they reuse needle syringe, same
13 patient, to redose, they then put it together with using the
14 remnants, the leftover in the vial on the subsequent patient;
15 correct?

16 A That's 6 percent of those whose said that they
17 reused, or is that 6 percent of the total?

18 Q No, no, 6 percent of the 15 percent.

19 A Okay.

20 Q 51 -- no, I'm -- 51 out of what I told you,
21 5,446.

22 A Actually responded to the survey.

23 Q Right, that's the --

24 A Is that the number of respondents?

25 Q Yes.

1 A And of those 15 percent said they sometimes
2 reused syringes to go to -- to back into a multi-dose vial.

3 Q Right.

4 A And of those 15 percent, 6 percent said --
5 said what they had done with the multi-dose -- but they reused
6 the multi-dose vial.

7 Q Right. So that would work out like 1
8 percent --

9 A Right.

10 Q I mean, 51.

11 A Right.

12 Q I mean, there's 51 practitioners in 2010, I
13 mean, still mixing together these --

14 A That's 1 percent.

15 Q Yes.

16 A Uh-huh.

17 Q Does that surprise you?

18 A It surprises me that it's that low.

19 Q Okay. Because?

20 A Because injection practices are so bad in --
21 in the places that we do the investigations that -- I
22 shouldn't actually -- I shouldn't say that it surprises me in
23 -- if these are general hospital based nurses, then I should
24 say it doesn't surprise me. It should be low. It's never
25 going to be -- I mean, I would be surprised if it was zero.

1 Then I would be suspicious. But it's a small number.

2 Q Well, it's -- it said the --

3 A No, we should be happy with that result.

4 Well, zero is not -- you know, as much as --

5 Q Okay.

6 A -- people would -- as much as we would all
7 like things to either be 100 percent or zero percent, that's
8 not reality. And I think that the fact that it's 1 percent is
9 quite good.

10 Q Okay. Where -- where would you think those
11 infractions were, outpatient or in the hospital?

12 A It could have been either.

13 Q You're right. It said although non-hospital
14 settings --

15 MR. STAUDAHER: Your Honor, I'm just going to move
16 to admit this if we're going to read from the whole document.
17 I mean --

18 MR. WRIGHT: I'm not --

19 MR. STAUDAHER: -- I don't have a problem with that.

20 THE COURT: Well, he can ask her specifically from
21 the document, or he can speak to admit it without your
22 opposition.

23 Go ahead, Mr. Wright.

24 BY MR. WRIGHT:

25 Q Our data indicates that some of the most

1 flagrant -- flagrant infractions, syringe reuse on multiple
2 patients with only a needle change and reentry into the
3 multi-dose vial, leaving it for reuse on another patient, are
4 being reported at least half of the time by professionals in
5 hospital settings. So it's about what you thought; correct?

6 A I said it could be either.

7 Q Right.

8 A That's what I said. It could be either.

9 Q Now, it identifies mistaken beliefs that
10 account for this failure of appreciation of the risks, and I
11 want to go through a couple of them. There are a number of
12 mistaken beliefs about the risks associated with syringe reuse
13 and aseptic technique when handling injectable medications
14 during preparation and administration that likely contribute
15 to many of the outbreaks of healthcare associated viral
16 infections such as hepatitis B and C. For example, there is a
17 belief that contamination is limited to the needle portion
18 when a syringe and needle are used together as a unit. Has
19 that been your experience that there is this mistaken, this
20 misapprehension out there?

21 A Yes, which means there's something wrong with
22 our education, medical education system.

23 Q Okay. And there is also an incorrect belief
24 that the syringe does not become contaminated if the plunger
25 is only pushed to inject, and not pulled to aspirate or

1 withdraw. What's aspirate mean?

2 A Withdraw.

3 Q Oh, okay. Okay. So they're -- they're --
4 this is an ongoing misperception or myth --

5 A Or ignorance. I mean, I really don't know
6 what to say that -- I don't know what to call it, but I will
7 tell you that I -- yes, I agree that they say -- they will say
8 that. And they will say, well, there's no blood in the
9 tubing. Well, you know, the germ theory of disease was
10 discovered by someone who was trying to explain that just
11 because you couldn't see it didn't mean it wasn't there. And
12 it's -- I honestly do not know why they believe this. They
13 really should know better.

14 Q Despite the availability of guidance on best
15 practices from CDC and other groups, it remains a lack of
16 awareness and implementation of these recommendations by many
17 clinicians. Agree with that?

18 A Yes. I don't think the -- yes.

19 Q Hold that thought. Have you seen M-1?

20 A Not recently.

21 Q Okay. You've seen it before?

22 A In different formats.

23 Q Okay. And is that -- well, you tell me what
24 that -- that's dealing with the persistent myths and what the
25 truths are to try to address the people who still aren't

1 onboard.

2 A That's correct. It's part of the campaign,
3 the one and only campaign.

4 Q Yeah, that's --

5 A One needle --

6 Q -- the name on it.

7 A -- one syringe, only one time.

8 Q Okay. Thank you very much.

9 MR. WRIGHT: I have no further questions.

10 THE COURT: Mr. Santacroce.

11 MR. SANTACROCE: May I proceed?

12 THE COURT: You may.

13 CROSS-EXAMINATION

14 BY MR. SANTACROCE:

15 Q Good afternoon, Doctor. I represent Mr. Lakeman
16 back there, and I'm going to ask you a few questions and try
17 to clarify some of your direct testimony. But before I do
18 that, I'm trying to understand exactly what the purpose of
19 your testimony is here today as you understand it. We've had
20 three epidemiologists testify in this case. All of them have
21 participated physically in the investigation of this outbreak.
22 And as I understand it, you haven't done that; correct?

23 A That's correct.

24 Q So what did you understand the purpose of your
25 testimony to be here today?

1 A I'm one of the world's experts on the
2 epidemiology of hepatitis C, and in particular it's
3 transmission patterns and in particular in healthcare
4 settings. And my understanding was to speak to those issues
5 as they relate to this particular outbreak.

6 Q And is this part of the consulting business
7 that you said you have?

8 A You might -- a business? It's like -- yes, I
9 suppose, except that I agreed to do this in 2008.

10 Q Okay. So while you were still employed at the
11 University of Texas?

12 A Yes, I was contacted by the sheriff's office

13 Q Clark County?

14 A Uh-huh. Yes.

15 Q And you were contacted in 2008 by the
16 Metropolitan Police Department?

17 A Yes.

18 Q Who contacted you?

19 A I would like to be able to tell you who it was
20 and, unfortunately, I can't remember his name.

21 Q Okay. And then in 2008 --

22 A Don't tell him.

23 Q I won't tell him. Well, is he sitting here?

24 A I have no idea.

25 Q Did you ever meet with him face to face?

1 A Did I meet -- no, actually, I didn't. Someone
2 else from -- they had a task force, I think, and someone else
3 came to see me at the university. Again, it would have been
4 at least a year later because Hurricane Ike occurred in
5 between.

6 Q Was it after the CDC had conducted their
7 investigation and issued their initial findings?

8 A Presumably.

9 Q Well, they did that in January of 2008. Was
10 your visit --

11 A It would have had to have been after January
12 2008.

13 Q And did they contact you and say, you know, we
14 have this theory. We have this theory as to the mechanism of
15 transmission and want you to validate that theory?

16 A No.

17 Q Okay. What did they want you to do?

18 A They wanted me to provide -- to be an expert,
19 a source of expertise in this area in hepatitis C transmission
20 in this setting.

21 Q So did they contact you throughout their
22 investigation from 2008 forward? Did they contact you --

23 A No, actually, I didn't hear from -- I then
24 talked to the -- Mr. Staudaher, who explained, you know, that
25 sort of what the -- my guidelines should be in terms of other

1 people calling me to discuss the case. The only thing I knew
2 about it were the things that I directly read. Actually, they
3 didn't tell me anything. They did not approach me with any
4 particular -- any particulars, the police.

5 Q Okay. Well, I'm still unclear as to what you
6 were to do for them. They contact you and they tell you we
7 want you to be an expert in this area because --

8 A You are an expert.

9 Q -- you're renowned for that. What did they
10 want you to be an expert to do? Did they give you anything
11 written, instructions, or here's a theory?

12 A No. They wanted me, I think, as an outside
13 observer and whose expertise is specifically in this area, and
14 I'm very experienced, to provide either -- to provide
15 information or --

16 Q Okay. And we don't --

17 A -- on this outbreak.

18 Q And what information did you provide to them.

19 A I provide to them directly?

20 Q Yes.

21 A The articles.

22 Q Okay. Well, the article I have -- one of the
23 articles I have from you was downloaded three days ago. So, I
24 mean, when did you provide it to them. When I --

25 A Three days ago.

1 Q -- mean them, I mean --

2 A Those articles.

3 Q -- Metropolitan Police Department.

4 A Then there were -- did I send that -- you have
5 to understand that our -- actually, there could have been
6 several years that went by between my first contact with Mr.
7 Staudaher and my next contact. I knew that until I was told
8 differently that there was the possibility that I would be an
9 expert witness for this case.

10 Q Okay.

11 A But it, obviously, went on quite awhile and I
12 just went on about my business.

13 Q How many contacts did you have with either the
14 District Attorney's office or the Metropolitan Police
15 Department either telephonically, emails, or person to person?

16 A A handful.

17 Q A handful? Six? Five? Six.

18 A Want me to look? I can look on my phone and
19 see how many emails I have. There are not many.

20 Q Okay. So a few?

21 A Well, that's a handful to me.

22 Q Depends on which hand your using.

23 A I know. I know, but really it's -- there
24 weren't that many. In fact, there weren't that many. They
25 provided me with, you know, the final reports, which one of --

1 which are all public anyway. And --

2 Q When did you get those reports?

3 A Well, I already had them, but the District
4 Attorney's office provided them to me in the last few months.
5 I want to say maybe -- well, earlier this year. Okay. I'm
6 sorry, I just --

7 Q So earlier this year you get the trip report
8 from the CDC from the District Attorney's office.

9 A From their office. I already had everything.

10 Q And then you get from their office what else?

11 A The Southern Nevada County -- the district
12 report.

13 Q Okay.

14 A And -- and 18 exhibits or 25 exhibits, or
15 whatever all the exhibits were that had been filed at that
16 time.

17 Q Did you get the report, statement of
18 deficiencies from the BLC, the Bureau of Licensing and
19 Certification?

20 A I remember it being mentioned, I mean, in my
21 reading. But I don't -- if it was an exhibit, then I got it.
22 If it isn't -- wasn't, then I didn't.

23 Q Well, I'm asking you what your recollection --

24 A I know. Well --

25 Q -- of what you received.

1 A -- I don't remember seeing the report and -- I
2 don't remember seeing the report.

3 Q Okay. You need to let me finish my question
4 before --

5 A Sorry.

6 Q -- answer, okay? Because --

7 A Yes, I --

8 Q -- we're recording.

9 A -- apologize. I apologize.

10 Q You're doing it again. We're recording this,
11 okay. And the record has to be very clear. Okay. Was --
12 were you being compensated for this by the District Attorney's
13 office or Metro or citizens of Clark County?

14 A Since I no longer work for the government, I
15 do have -- I am going to be compensated, but I haven't been
16 compensated as yet. I haven't even submitted a voucher.

17 Q Okay. But you're getting compensated for your
18 testimony here today?

19 A Yes.

20 Q And for any work you did previously on the
21 case?

22 A For the number of hours that I did to review
23 the documents, yes.

24 Q And -- and what is your compensation that
25 you're receiving? How much is it?

1 A For today, I don't know. But for -- you can
2 see I'm a real business person. My hourly rate for reviewing
3 documents or writing reports is \$450 an hour.

4 Q And what is your fee for testifying in court?

5 A This is the first time I've done it as a
6 private citizen, so to speak, and so I have no idea.

7 Q Okay.

8 A Well, I shouldn't say I have no idea, but --

9 Q Well, what's the idea you have?

10 A Well, let me put it to you this way, okay.
11 Well, we have -- we didn't agree on anything. To be quite
12 honest, I still think of myself as a public service.

13 Q Well, let's surprise them right now and tell
14 them --

15 A Well, what I'm going to --

16 Q -- how much.

17 A -- let me tell you that I looked up what other
18 -- what physicians do who have to take off, you know, and it's
19 -- it's so far above what I would even consider that -- you
20 know, they charge 5,000, \$6,000 a day for testimony. And if
21 it's out of town it's more. We're not even --

22 Q Are you from out of town or do you live here
23 now?

24 A I'm from out of town.

25 Q Well, where -- where do you reside?

1 A I reside in Galveston, Texas.

2 Q So you were flown in here today for your
3 testimony?

4 A I flew in last night.

5 Q Well, it's safe to say you're not going to be
6 charging less than \$450 an hour for testifying here today;
7 right?

8 A Yes, I am, probably.

9 Q Oh, you are?

10 A Well, I would do it as a lump sum. I didn't
11 count the number of hours, you know, in the day. I'm not
12 going to charge them by hour since I left home. I just can't.

13 Q I might get --

14 A I'm just not --

15 Q -- into contract negotiations --

16 A -- that way.

17 Q -- after this career is over.

18 A I told you. It's not a business. It's just,
19 you know --

20 Q Okay.

21 A It's something that I do when I believe in
22 something.

23 Q All right. So let's get back to what you --
24 you were supposed to do here. You reviewed certain documents
25 from the CDC, from the Health District, and from someplace

1 else. I don't know where else, but some articles or
2 something?

3 A Well, I -- in the course of my career, I've
4 read or reviewed almost all of the articles that are currently
5 in the literature since I've written reviews and editorials
6 and --

7 Q And so now you have -- at some point you have
8 the Southern Nevada Health District Report and you have the
9 CDC trip report?

10 A And their publication in -- and their
11 publication in the journal.

12 Q And then from that, you read all of that, and
13 you came up with an opinion, or you validated their opinion,
14 one or the other. Which was it?

15 A I don't know. I -- I -- it was already -- I
16 guess I validated their opinion.

17 Q Okay. Now, did you review or look at anything
18 else other than what you've told us here today?

19 A You mean other than the literature, the
20 publications and the literature and the major reports from the
21 CDC and the Health District --

22 Q Right.

23 A -- and the exhibits that were on file, which,
24 you know, were line listings of specimens and patients and
25 things. I don't think so --

1 Q Okay.

2 A -- to the best of my recollection.

3 Q And your opinion was basically supporting the
4 CDC's opinion that the mechanism of transmission in this
5 particular case was the unsafe injection practices at the
6 clinic; is that correct?

7 A Yes, that's correct.

8 Q And what methodology did you employ to come up
9 with that opinion?

10 A I reviewed the methodology for both the
11 epidemiologic investigation, the -- as well as the laboratory,
12 as well as the virus sequencing performed in the laboratory,
13 and then for which I had the results to determine if I agreed
14 with the methods that were used and the conclusions that were
15 drawn from those methods.

16 Q Okay. Were you aware when the CDC conducted
17 their investigation that they were not sure as to which
18 patient was in which room at which time?

19 A I was -- I am aware from reading the reports
20 that it was -- that the records were very inaccurate.

21 Q Okay. How many --

22 A That's all I can --

23 Q How many procedure rooms were at Shadow Lane
24 on July 25, 2007?

25 A Two. I don't know.

1 Q Is that a guess?

2 A Yes, that's a guess.

3 Q How many procedure rooms were at Shadow Lane
4 on September 21, 2007?

5 A I know that they did 65 procedures.

6 Q And the question I asked you was how many --

7 A I'm sorry.

8 Q -- procedure rooms.

9 A I don't know.

10 Q Okay.

11 A Or don't recollect.

12 Q Okay. So my question was were you aware that
13 the CDC did not know which rooms the patients were in and at
14 what times when they conducted their investigations?

15 A No.

16 Q You were not aware of that?

17 A Well, no, not specifically at the time they
18 conducted their investigation, no.

19 Q Were you aware that they didn't know that
20 information when they issued their initial findings?

21 A No. What I was --

22 Q That's -- that's all I need to know. Were you
23 sent copy of Exhibit -- State's Exhibit 156 and 157 as part of
24 your examination?

25 A Yes.

1 Q So you looked at these?

2 A Yes.

3 Q And when did you receive these documents?

4 A In the last couple weeks, sometime in the last
5 couple of weeks.

6 Q Okay.

7 A Like three weeks ago, maybe, four weeks ago.

8 Q When did you reach your conclusion or concur
9 with the CDC's finding?

10 A After reading the reports. It had nothing to
11 do with this.

12 Q It had nothing to do with this. So you
13 reached your conclusions before you saw these two exhibits?

14 A That's right because I reached my conclusions
15 based on the epidemiological investigation.

16 Q Were you aware that the CDC did not interview
17 the RN that administered the heplock on September 21, 2007?

18 A I don't know.

19 Q Were you aware of the cleaning practices for
20 the endoscopes and the biopsy forceps for September 21, 2007?

21 A I read the methods that were used in -- in the
22 reports, they were quite detailed, for the scopes. The biopsy
23 forceps were apparently -- they talked about some reuse of
24 disposables, I guess, that -- a practice that had been
25 stopped. But regardless, there was the investigation. The

1 results of the investigation indicated that there was no
2 association between getting infected and those pieces of
3 equipment.

4 Q Okay. Tell me what you understood the
5 cleaning procedures to be for the endoscopes.

6 A It was a very long -- it was a very long and
7 detailed explanation that involves the cleaning of the scope,
8 the rinsing of the scope. Manual cleaning is extremely
9 important. You have to get all of the organic debris that
10 might be in there out before the disinfectant can work.
11 Because organic matter like blood and things can prevent the
12 disinfectant from getting to the actual scope or germs that
13 might be left there, something that a lot of people don't
14 appreciate. And then they had a -- they have a machine that
15 then reprocesses the -- these scopes for high level
16 disinfection.

17 Q What's the difference between disinfection and
18 sterilization?

19 A High level disinfection actually kills
20 everything but bacterial spores. Sterilization also kills
21 bacterial spores.

22 Q And how was the clinic cleaning bite blocks
23 and biopsy forceps on September 21, 2007?

24 A The biopsy forceps, I'm not sure. The
25 cleaning blocks -- I mean, I'm sorry, the bite blocks I'd have

1 to look at the report. I just -- again, while I was aware
2 when I was reading these reports, it's the epidemiological
3 methodology they use to look at exposures associated with
4 infections that I was -- that I'm focused on and whether or
5 not they considered sufficient -- you know, they considered
6 the issues of importance in that -- in the setting. That's
7 what I was looking at. I'm an epidemiologist. That's what my
8 expertise is in this disease area.

9 Q Well, Doctors Langley and Schaefer testified
10 that prior to coming to Las Vegas they had a theory or
11 hypothesis that the infection was transmitted through unsafe
12 injection practices.

13 MR. STAUDAHER: Objection. Mischaracterizes their
14 statements, Your Honor.

15 BY MR. SANTACROCE:

16 Q But they didn't rule out of other mechanisms.

17 THE COURT: And that's -- that's overruled. And, of
18 course, I've told the ladies and gentlemen of the jury if
19 anyone, you know, prefaces a question with a statement of what
20 the testimony was and that's not your recollection of what the
21 testimony was, it's your collective recollection that's
22 important, not something the lawyers may say or something that
23 I may say as to what the testimony was.

24 BY MR. SANTACROCE:

25 Q So they looked at other mechanisms of

1 transmission.

2 A That's correct.

3 Q Okay. One of those mechanisms was scopes;
4 correct?

5 A Yes.

6 Q And you -- you ruled out that theory because
7 they ruled it out; correct?

8 A I ruled out the theory by looking at the data
9 they generated to show that there was no association.

10 Q Okay. What data did they generate?

11 A There's -- they showed the frequency with
12 which, you know, the -- the use of the scopes, you know,
13 depending on whether you got an upper GI or a colonoscopy,
14 they looked at the frequency of the specific procedures and
15 those people who got infected versus those people who didn't.
16 That's -- that's how you --

17 Q I'm talking about the cleaning of the scopes.

18 A Hold on. You asked me how I drew that
19 conclusion.

20 Q Right.

21 A Okay. That, in addition -- that was most
22 important. But also I thought that regardless of a few
23 deficiencies cited as like the detergent used --

24 Q And you thought those deficiencies were minor?

25 A Actually, from the point of view of

1 blood-borne virus transmission, yes.

2 THE COURT: Mr. Santacroce, we're going to need to
3 take a break now --

4 MR. SANTACROCE: Okay.

5 THE COURT: -- so I'm going to interrupt you.

6 Ladies and gentlemen, we're going to take a brief
7 recess. During the brief recess you're reminded that you're
8 not to discuss the case or anything relating to the case with
9 each other or with anyone else. You're not to read, watch, or
10 listen to any reports of or commentaries on this case, any
11 person or subject matter relating to the case. Don't do any
12 independent research. And please do not form or express an
13 opinion on the trial.

14 Notepads in your chairs and follow the bailiff
15 through the rear door.

16 (Jury recessed at 2:37 p.m.)

17 THE COURT: What do we have to look forward to for
18 the rest of the day?

19 MS. WECKERLY: Well, we have Dr. Lewis and then we
20 have the --

21 THE COURT: And that's Ms. Grueskin's physician;
22 correct?

23 MS. WECKERLY: That's correct.

24 THE COURT: So we have to do him today, which I'm
25 good with.

1 MS. WECKERLY: Okay. And then we have an insurance
2 person, and then --

3 THE COURT: Well, Ms. Stanish says she has all the
4 records, so that should go smoothly.

5 MS. WECKERLY: She's good with this one.

6 THE COURT: Yeah, so that should go smoothly.

7 MS. WECKERLY: And then -- well, we have -- we have
8 -- I mean, one thing we could do is we have Bob as the
9 witness, but I have a doctor for tomorrow, so I can --

10 THE COURT: Is that Romie?

11 MS. WECKERLY: No, Jurani.

12 THE COURT: That's his name Romie Jurani.

13 MS. WECKERLY: I thought it was Patero.

14 THE COURT: Well, I think it's his nickname.

15 MS. WECKERLY: Oh, okay. Maybe.

16 (Off-record colloquy.)

17 THE COURT: In any event. Does that mean we're
18 done?

19 MS. WECKERLY: You mean for tomorrow, then?

20 THE COURT: Right.

21 MS. WECKERLY: Well, with Dr. Olson, and then part
22 two of the other --

23 THE COURT: Right. And then that's it?

24 MS. WECKERLY: That's it.

25 THE COURT: So you're not calling Dr. Jurani at all?

1 MS. WECKERLY: No, because he doesn't really --

2 THE COURT: Okay.

3 MS. WECKERLY: I mean, he doesn't say anything that
4 -- that I don't think we've covered.

5 THE COURT: Okay. All right.

6 MS. WECKERLY: And another GI tech. Just kidding.

7 (Court recessed at 2:39 p.m., until 2:55 p.m.)

8 (In the presence of the jury.)

9 THE COURT: All right. Court is now back in
10 session.

11 And, Mr. Santacroce, you may resume your
12 cross-examination.

13 MR. SANTACROCE: Thank you.

14 BY MR. SANTACROCE:

15 Q You were talking about what you described as
16 insignificant lapses in the cleaning of the scopes. Were you
17 aware that the BLC actually observed the cleaning of the
18 scopes, ma'am?

19 A I know that the cleaning of the scopes was
20 observed.

21 Q Do you know that the BLC was part of the
22 investigatory team, along with Southern Nevada Health District
23 and the CDC?

24 MR. STAUDAHER: Objection --

25 THE WITNESS: Yes.

1 MR. STAUDAHER: -- Your Honor. That's not actually
2 correct. They weren't part of the investigatory team. They
3 investigated separately.

4 THE COURT: Well, okay. They -- they were involved
5 in investigating. Is that your understanding?

6 THE WITNESS: Yes.

7 THE COURT: Okay.

8 THE WITNESS: Well, they were present when groups
9 were represented.

10 THE COURT: Okay.

11 BY MR. SANTACROCE:

12 Q And you understand that they issued a summary
13 statement of deficiencies; correct?

14 A I saw the statement of such, yes.

15 Q Okay. Well, I'm going to show that to you now
16 as Exhibit 80 E-3. This is their statement for the Shadow
17 Lane clinic. And it notes that on January -- I'm not sure if
18 it's a 6 or an 8, 2008. The GI technician was asked to
19 describe the measured amount of EmPower with what amount of
20 water. The GI tech stated add two to three pumps, not sure of
21 the capacity of the basin, I do not have an answer to that.
22 Were you aware the GI tech didn't even know how much
23 sterilizing fluid to use, the ratio between the water and the
24 sterilizing fluid?

25 A No.

1 Q Were you aware as to how many scopes were to
2 be cleaned before the solution was changed?

3 A The -- my understanding -- I actually saw it
4 in the protocol, but I can't tell you what it is now, but it
5 was my understanding that the machine, given this is a
6 relatively automated system, indicates when it needs to be
7 changed.

8 Q Well, that's the third or fourth step in the
9 process.

10 A Uh-huh.

11 Q There's processes before that. Are you aware
12 of those processes?

13 A The specifics of each step?

14 Q Uh-huh.

15 A No, I could not repeat them to you.

16 Q Well, you are aware that scopes are a
17 potential mechanism for transmission of the hep C virus;
18 correct?

19 A No.

20 Q You're not aware of that?

21 A No. However, I would consider them in any
22 investigation I did, but there has never been an instance in
23 which that has occurred, in which it has been shown to occur
24 despite the misleading titles of some articles.

25 Q Are you anticipating where I'm going?

1 A No, I don't know how I could possibly
2 anticipate such a thing.

3 Q I don't think I asked a question about that,
4 but okay. Are you -- you're aware of the article posted in
5 the New England Journal of Medicine on patient -- patient
6 transmission of hepatitis C virus during colonoscopies;
7 correct?

8 A Yes, I am.

9 Q Why don't you tell us the background of that
10 case?

11 A Well, it was the first one ever published,
12 which is why it was in the New England Journal, considered one
13 of the top medical journals in the world. But on closer
14 reading of the article, you'll find that the investigators --
15 and by the way this --

16 Q Ma'am, I asked you to tell me the
17 background --

18 A I can't.

19 Q -- of the article.

20 A I'd have to look at the article again.

21 Q Okay. Well, let me show it to you.

22 MR. STAUDAHER: Your Honor, I think she was
23 answering his question. He said background of the article.

24 MR. SANTACROCE: She was trying to dispute --

25 THE COURT: Well, okay --

1 MR. SANTACROCE: -- the validity of the article.

2 THE WITNESS: No, I am not.

3 THE COURT: Okay. All right. She is going to look
4 at --

5 THE WITNESS: Sorry.

6 THE COURT: That's okay.

7 She's going to look at the article, and then Mr.
8 Santacroce will ask the questions, and the witness, as she did
9 on the prior question, if she can't ask the question as
10 phrased, she's obviously more than able to say I can't answer
11 this question.

12 THE WITNESS: I'm sorry. Okay.

13 THE COURT: All right.

14 BY MR. SANTACROCE:

15 Q Have you read the background information?

16 A I don't know what background -- what you refer
17 to as background information. My --

18 Q Well, let me --

19 A The importance --

20 Q Let me explain what I mean if you don't know.
21 Can you tell me how many patients were involved?

22 A No, I don't remember.

23 Q Okay. Well, I just showed it to you, but I'll
24 show it to you again.

25 A I didn't have a chance to actually look at the

1 page.

2 Q Okay. Well, take all the time you need. Read
3 this part here.

4 A Yes.

5 Q Okay. Now, just to be clear, this is an
6 article you downloaded three days ago; right?

7 A No, I've had it in my files forever. It just
8 so happens I might have downloaded a new copy of it, but --

9 Q What does it say on the bottom.

10 A Okay. Sorry. I'm distinguishing between
11 having downloaded a copy because my files -- and what I have
12 in my files. So, yes, I downloaded it to send three days ago,
13 but it was already in my files. It's been in my files since
14 it was published.

15 Q When you downloaded it three days ago, did you
16 read it?

17 A No, because I had already read it and I knew
18 what it said.

19 Q Okay. Well, after having reviewed it now, how
20 many patients were involved?

21 A Two.

22 Q And a source patient; correct?

23 A Presumably. I didn't get that far.

24 Q Okay. Well, it says Patient 2 contracted
25 hepatitis C from a source patient in this particular study;

1 correct? In fact, they were a husband and wife who underwent
2 endoscopic procedures; correct?

3 A If that's what it says.

4 Q Well, ma'am --

5 A I didn't have a chance. I didn't read it in
6 that detail. I was looking at the paragraph that you pointed
7 out. There were the two patients, the procedures, and they
8 were talking about how the endoscopes were disinfected,
9 cleaned and disinfected. That was what I was reading. I
10 don't know -- I didn't see husband and wife. I didn't see --
11 I just don't remember. But what I know about the results of
12 the investigation lead me to a different interpretation.

13 Q Well, why were they discussing the cleaning of
14 the endoscopes?

15 A Just because -- because it's considered as a
16 potential.

17 Q In fact, it was the leading likely cause of
18 transmission of hepatitis C in this study.

19 A Only according to those investigators, but not
20 according -- not in my opinion.

21 Q Are you saying these investigators weren't
22 competent?

23 A I'm saying -- no, you said that. I did not
24 say that.

25 Q Well, you said only according to these

1 investigators.

2 A As I explained, if you look at the discussion
3 you will see that the investigators themselves admit they
4 could not distinguish whether transmission occurred by the --
5 through the actual scope or through injection practices,
6 unsafe injection practices used to administer anesthesia. It
7 says that in the discussion. They didn't rule out or rule in
8 either one because they couldn't do an analysis, an
9 epidemiologic analysis. All they did was genetic sequencing
10 to determine that the patients had the same virus as the
11 source, and this is where they found it in the -- in the -- in
12 that setting.

13 And I will tell you that when we went to New York in
14 2001, the New York Times, before we even arrived had already,
15 of course, heard about it. And the first thing they -- they
16 interviewed somebody, an expert, whatever, and whose first
17 comment was they're not disinfecting the scopes properly, it's
18 the scopes, it's the scopes. I heard that for a year before
19 we were convinced, you know. So there actually is no
20 documentation that the scopes are directly associated with
21 infection. It has occurred in that setting, but that does not
22 in any way -- as the authors themselves admit, they can't
23 distinguish between the two. They just buried it in the
24 discussion.

25 Q Well, I don't read it that way. It says we

1 suggest that during disinfection of the colonoscope after the
2 procedure on the patients, we describe two recommendations on
3 the endoscopic disinfection made by the American Society for
4 Gastrointestinal Endoscopy and the British Society of
5 Gastroenterology and the Working Party of the World Congress
6 of Gastroenterology were not followed. From our investigation
7 it appeared that the biopsy suction channel was never cleaned
8 with a brush, and that the accessories that breached the
9 mucosa, such as biopsy forceps and dia -- diather -- how do
10 you pronounce that? Diathermic?

11 MR. STAUDAHER: Diathermic.

12 MR. SANTACROCE: Thank you, Mr. Staudaher, my
13 resident medical expert.

14 BY MR. SANTACROCE:

15 Q The loop were not autoclaved after each use.

16 A Autoclaved? They're never --

17 Q Now, it says --

18 A -- autoclaved.

19 Q -- to me here, from our investigation that the
20 scopes, the improper cleaning of the scopes, the failure to
21 autoclave the reusable biopsy forceps were absolutely causally
22 connected to the hepatitis C infection. You disagree with
23 that?

24 A Yes, I do.

25 Q And you disagree with the authors of this

1 article?

2 A No. Read the discussion.

3 Q I have read --

4 A I'm sorry.

5 Q -- the discussion.

6 A It's a very misleading -- it's mis -- they say
7 that, but they can't show an association between that --
8 between that and the infections.

9 Q So you say that there's a failure in their
10 methodology?

11 A Well, they didn't have enough patients to show
12 an association.

13 Q Okay.

14 A They had to consider -- you need to let me
15 finish. They had to consider --

16 Q I didn't say anything that I know of.

17 A They had to consider all types of exposures,
18 regardless of what the preexisting -- preexisting conceptions
19 might be going in. And they don't mention it there, but when
20 you then read the discussion, they come right out and say they
21 couldn't distinguish between that and unsafe injection
22 practices.

23 Q And this was an article published in the
24 highly acclaimed, as you say, New England Journal of Medicine,
25 and yet their investigation was flawed?

1 A I think they over -- they over -- I think
2 their conclusions were not supported by the data in what you
3 read. However, when you read the discussion, it is very --
4 they completely change their -- their perspective and say
5 directly they could not distinguish between the role of what
6 the scope might -- a poorly disinfected scope and the -- or
7 unsafe injection practices.

8 Q What they say is they could not prove that the
9 procedure was the cause.

10 A Okay.

11 Q Okay.

12 A Uh-huh.

13 Q But they spent a lot of time discussing the
14 scope cleaning. And they actually said, as we've already
15 read, that from their investigation that these scopes were not
16 cleaned properly, nor were the biopsy forceps cleaned
17 properly, and that these were potential causes for the
18 transmission of the disease, which you flatly and
19 categorically deny that hepatitis C can be transmitted through
20 the scopes.

21 A I didn't say that.

22 Q Okay. What did you say?

23 A I said it hasn't happened -- it hasn't been
24 shown to happen yet. It hasn't been shown to happen. And if
25 you would give me a copy of the entire article, I would then

1 go on to read the part where they withdraw a little from their
2 strong position about the scope.

3 Q Okay. Well, I'm sure Mr. Staudaher will give
4 that to you. We've had other experts, other hepatitis C
5 experts in this courtroom testify. Now, granted, they weren't
6 world renowned, they were only local Las Vegas doctors, but
7 they've testified that hepatitis C can be transmitted through
8 reuse of dirty scopes. Do you disagree with that?

9 A It could happen. I suppose any germ could be
10 -- could be transmitted through if it's contaminating a piece
11 of equipment that's used on another patient. So, yes, it's
12 possible, it just hasn't been shown to happen yet.

13 Q Were you aware that some GI techs and nurses
14 testified that after the scopes were cleaned and hung to dry
15 that they observed fecal matter coming from the supposedly
16 clean scopes?

17 A No.

18 Q Were you aware that the clinic was reusing
19 biopsy forceps?

20 A I was aware. It was in the report. It stated
21 that they were reusing them.

22 Q Were you aware if the clinic had an autoclave
23 system or not?

24 A A sterilization system? I don't know. I
25 don't remember.

1 Q Well, according to the New England Journal of
2 Medicine article it says that those biopsy forceps were to be
3 autoclaved.

4 A Okay. Uh-huh. Well, that's -- I don't know
5 what to say. I mean, if you're using disposables, then, no,
6 they're aren't autoclaved.

7 Q I'm talking about reusable ones.

8 A Well, I understand it was --

9 MR. STAUDAHER: Objection. There is no evidence of
10 reusable forceps at the clinic at that time.

11 THE COURT: Well, maybe you should ask ones that
12 were reused. Is that really where -- what you're getting at,
13 Mr. Santacroce?

14 MR. SANTACROCE: I'm going to find it here, Your
15 Honor, if you can give me a second.

16 BY MR. SANTACROCE:

17 Q Again, referring to 80 E-3. This is the BLC
18 report. It said on 1/6/08 the director of nursing indicated
19 that staff had been instructed -- that's the wrong one.
20 Sorry. One 1/16/08 the administrative staff indicated that
21 the facility used disposable biopsy instruments, the policy
22 and procedures had not been updated to reflect the current
23 practice. In other words, at this particular time in January
24 they had stopped using reusable biopsy forceps and went to
25 disposable ones. Now, my question to you is were you aware

1 that during the infection dates, September 21st or July 25th
2 that reusable biopsy forceps were being reused.

3 A Forceps intended to be reused after either
4 high -- after sterilization is what you're saying were being
5 reused? Is that what you're saying?

6 Q I'm saying -- I didn't say anything about the
7 sterilization.

8 A Well, you're saying --

9 Q I said reused.

10 A Well, then I don't -- but I have to know
11 whether they --

12 Q I didn't say they were reusable. I said they
13 were being reused.

14 A No, you said reusable biopsy forceps --

15 Q Okay.

16 A -- were being reused.

17 Q Okay. Biopsy forceps were being reused. Were
18 you aware of that when you --

19 A I saw it stated --

20 Q -- came to your conclusion?

21 A -- in the report. I don't know whether it was
22 occurring on those days. Now, if they -- yes.

23 Q Were you --

24 A So I saw it in the report.

25 Q Were you aware as to how those biopsy forceps

1 were being cleaned?

2 A I don't remember what it said in the report,
3 but I do know that the investigation looked at that closely.

4 Q How do you know that?

5 A Because there are data to show that people who
6 didn't get infected had the same frequency of biopsies, if not
7 higher, than patients who did get infected.

8 Q Well, let's -- let's talk about that for a
9 minute. Showing you Exhibit 157. You said you saw this chart
10 but you didn't rely on this chart to make your conclusions.

11 A I actually -- no. This chart has nothing --
12 was generated after the investigation and it's a nice -- it's
13 a good way to look at some things and not others, so --

14 Q Well, let's look at this. You see this guy on
15 the blue line, Ziyad Sharrieff?

16 A Uh-huh.

17 Q Source patient for July 25, 2007. Do you see
18 that?

19 A Uh-huh. Yes.

20 Q Do you then there was one, two, three, four --
21 three patients, and then Michael Washington gets infected
22 genetically linked to Ziyad Sharrieff. Do you see that?

23 A Yes.

24 Q Were you aware that both Mr. Sharrieff and
25 Michael Washington had biopsies on that day?

1 A It was in the report.

2 Q And so you were aware of that?

3 A Yes.

4 Q Okay. Were you --

5 A It said so in the report. I was aware of it.

6 Q And do you know if the biopsy forceps used on
7 Mr. Sharrieff and Mr. Washington were ever cleaned?

8 A I'm not aware of what the -- what the biopsy
9 used on the -- what happened to the biopsy forceps used on the
10 source patient and the infected patient, no.

11 Q And my question before was whether or not you
12 knew the clinic had an autoclave system.

13 A I don't know.

14 Q And you are aware that according the article
15 you provided that biopsy -- reusable biopsy equipment needed
16 to be autoclaved; correct?

17 A The article has nothing to do with my
18 knowledge of what needs to be autoclaved and what doesn't.

19 Q Well, do you think that biopsy forceps need to
20 be autoclaved --

21 A Biopsy --

22 Q -- if they're going to be reused?

23 A Anything --

24 THE COURT: What you mean is your knowledge is
25 independent of what you read in the article, is that what you

1 mean?

2 THE WITNESS: That's correct.

3 THE COURT: Okay.

4 THE WITNESS: If someone is going to stick a needle
5 in your liver to biopsy it, for example, you certainly want it
6 to be sterile.

7 BY MR. SANTACROCE:

8 Q Am I talking about that, or am I talking about
9 biopsy forceps for endoscopic procedures?

10 A It doesn't matter. It's still --

11 Q Okay.

12 A -- something that's going to enter your body.

13 Q How do they need to be cleaned?

14 MR. STAUDAHER: Your Honor, I'm going to object to
15 at least the characterization that they were at least reusable
16 at that time. I don't know that there's any evidence to that
17 effect.

18 MR. SANTACROCE: Well, the jury can --

19 MR. STAUDAHER: I just want to be sure that this
20 witness has at least the proper information before she makes
21 any kind of a conclusion.

22 MR. SANTACROCE: He can object ten times about that,
23 Your Honor, but you've already instructed the jury.

24 THE COURT: Okay. Just ask your question.

25 BY MR. SANTACROCE:

1 Q How are reusable biopsy forceps cleaned?

2 A Assuming that they're made of the proper
3 material they would undergo sterilization.

4 Q And sterilization can only be achieved through
5 an autoclave system; correct?

6 A Of some type, yes. There are other systems,
7 but yes.

8 Q And it's distinguished between high level
9 disinfectant and sterilization; correct?

10 A In terms of the -- yes, there is a difference.

11 Q And the autoclave system is a sterilization
12 method and technique?

13 A Yes, it is.

14 Q And according to your article, not yours, but
15 the one you provided from the New England Journal of Medicine
16 that those items needed to be autoclaved in order to be
17 reused.

18 A The article -- that's what that article said.

19 Q Okay.

20 A Technology may have changed. Do you know why
21 scopes are not -- do you know why the scopes are -- undergo
22 high level disinfection rather than sterilization?

23 Q Ma'am, I've never even seen a scope
24 personally, except for the one when I had my procedure done,
25 and I didn't see that either.

1 THE WITNESS: The front page, first --

2 THE COURT: -- has the abstract?

3 THE WITNESS: -- page of the article, which is page
4 163 of this journal. And I was reading from -- not -- I was
5 reading from the last sentence of the results.

6 MR. SANTACROCE: And, again, the article? The
7 article name?

8 THE COURT: The name of the article.

9 THE WITNESS: Multiple clusters of hepatitis virus
10 infections associated with anesthesia for outpatient endoscopy
11 procedures.

12 MR. SANTACROCE: Thank you.

13 BY MR. STAUDAHER:

14 Q But in this particular case, the same type of
15 sort of reuse is what we're talking about in --

16 A Yes. The only difference is it was
17 needleless.

18 Q So a vent spike or something was used?

19 A Yes.

20 Q Why is that not protective to have a spike
21 versus a needle going into the bottle?

22 A It's for protection -- these are -- have been
23 put -- these are a variety of measures or technological
24 advances have been developed and employed in healthcare
25 settings to protect healthcare workers from accidental needle

1 sticks. So the less needles they handle, the less likely they
2 themselves will get stuck with a contaminated needle. A lot
3 of this resulted from HIV in the '80s, so -- concerns about
4 transmission of HIV to healthcare workers in the '80s. So
5 there have been a lot of these sort of technological advances
6 in equipment use in order to reduce the amount of needle use
7 by the healthcare worker. But it had to do with protection of
8 the healthcare worker.

9 Q So the -- no difference in risk for vent spike
10 versus needle?

11 A No. No.

12 Q If it's used in that way that was described?

13 A No. Presumably -- no.

14 THE COURT: Mr. Staudaher, I'm going to stop you.
15 Some of the jurors need a break, so we're going to take our
16 morning recess.

17 Ladies and gentlemen, we'll take about ten minutes
18 for our morning recess. During the recess you're reminded
19 that you're not to discuss the case or anything relating to
20 the case with each other or with anyone else. You're not to
21 read, watch, or listen to any reports of or commentaries on
22 this case, any person or subject matter relating to the case.
23 Don't do any independent research, and please do not form or
24 express an opinion on the trial. Notepads in your chairs and
25 follow the bailiff through the rear door.

1 (Jury recessed at 10:29 a.m.)

2 THE COURT: I'll see counsel at the bench.

3 (Off-record bench conference.)

4 THE COURT: Ma'am, before we let you take a break
5 and we take our little break, out of the presence of the jury,
6 Mr. Wright needs to ask you some questions regarding the basis
7 of your opinions. Okay?

8 THE WITNESS: Okay.

9 THE COURT: All right. Mr. Wright, go ahead.

10 VOIR DIRE EXAMINATION

11 BY MR. WRIGHT:

12 Q Ma'am, have you read the Southern Nevada
13 Health District report on this matter?

14 A Yes.

15 Q Okay. And the CDC trip report?

16 A Yes.

17 Q Okay. Any other reports on this one?

18 A There was a peer reviewed article published
19 from the CDC in collaboration with the county health
20 department.

21 Q Okay. Other than that?

22 A No.

23 Q Okay. And you're aware of the notifications,
24 patient notifications that took place in this case?

25 A Yes.

1 Q Okay. And it basically went back four years
2 and all patients who had been there who may have been exposed
3 to this ongoing practice were sent letters and test -- and
4 tested. And then there were results laid out, not in CDC's
5 reports because this took place --

6 A Uh-huh.

7 Q -- after they had been here, after their trip
8 report, but in Southern Nevada Health District's report. And
9 do you, in reaching your -- the firmness of your convictions,
10 let me put it that way, you've made a determination as to
11 likely cause of transmission in this case; correct?

12 A Yes.

13 Q And that's the combination of unsafe injection
14 practices and multi-patient use of propofol vial; correct?

15 A Yes.

16 Q Okay. Does -- does the later testing -- the
17 -- the later patient notification and the results of that
18 enter into your determinations?

19 A No.

20 Q Okay. Why do they do that if it has no basis
21 whatsoever on --

22 A For the --

23 Q I mean, the correctness of my conclusion.
24 Because I noticed in your New York case, in various cases like
25 in the New York case when an anesthesiologist -- I think it

1 was the second one readily admitted to his behavior. And then
2 letters were sent out, a couple thousand of them, and then
3 other patients were found to -- to have been infected.

4 A Can I also tell you that in the first outbreak
5 in New York -- New York has had actually quite a few -- and
6 they also -- when they realized how long the practice had been
7 going on with the one anesthesiologist, they also sent many,
8 you know, patients over several years letters of notification
9 to get tested.

10 Q Okay.

11 A Okay. Why do they do that?

12 Q Right. And -- and it seems to me, I'm not an
13 epidemiologist, but it seems to me if certain conduct is going
14 on and I believe it caused on two days these events occurred,
15 okay, the transmission of hepatitis C and that the conduct has
16 been ongoing for, say, a year, then I would look to the other
17 363 days of the year expecting to find other cases the same,
18 other clusters, whatever you want to call it. Because if
19 those were the two things on those two days that caused the
20 transmission and the precise same thing was happening every
21 other day of the year, it would seem to me I would find that
22 on the other days of the year. And then that would confirm
23 for me, bingo, I found the right thing and I -- what am I
24 missing epidemiologically in my analysis?

25 A Well, the fact that they had sufficient

1 numbers of cases actually on one of those days to draw an
2 epidemiological conclusion even separate from the laboratory
3 sequencing, on the July date they only had one new case and
4 the one source patient. And the only way to prove that that
5 was the -- that they were related was by viral sequencing. I
6 mean, if you only have two people -- okay. So wait, I'm
7 getting there.

8 Q Okay.

9 A However, the purpose of the notification was
10 knowing that this practice was going on for a long time and
11 that many patients might have been exposed, it was the ethical
12 -- the obligation of the health department to notify these
13 individuals that they may have been infected and they should
14 get tested.

15 Q I -- I got that. I --

16 A Okay. So for their own -- for their own
17 purpose, the resources -- to be quite honest, the resources
18 involved and then taking all of those patients and doing the
19 same kinds of studies that were done on those two days was
20 probably not available.

21 Q Okay. And I'm not --

22 A And that's true for most of the large
23 notifications that are done. If you're not -- you know, in
24 this -- in many instances now, even without evidence of
25 transmission, if a hospital or a healthcare facility notices

1 -- finds that a practice is -- some practice has not been done
2 correctly, they will send notifications, even though there's
3 been no evidence of infection.

4 THE COURT: So in other words, the point of sending
5 the notification had nothing to do with confirming their
6 hypothesis or their theory, but it was to give patients notice
7 so that they could be tested and get treatment or modify their
8 behavior --

9 THE WITNESS: That's correct.

10 THE COURT: -- or whatever they were going to do.
11 Is that --

12 THE WITNESS: That's correct.

13 THE COURT: Is that a summation?

14 THE WITNESS: Very good.

15 THE COURT: Okay. Thank you.

16 THE WITNESS: Yes.

17 THE COURT: Is that fair?

18 THE WITNESS: That's exactly correct.

19 BY MR. WRIGHT:

20 Q Okay. The problem with that is there's
21 testimony to the contrary in depositions. Not -- not yours or
22 anything, but of -- of the Health District and what they
23 expected to find. I mean, I'm not faulting anyone --

24 A No, no, no, no, no.

25 Q -- for notification whether you found it or

1 not. My -- what I still don't have an answer to is if I'm the
2 epidemiologist and I say here's two days out of a year in
3 which hepatitis C was spread by this method of transmission
4 and then I look and say -- and that identical conduct occurred
5 on the other 363 -- 62 days, whatever, of the year, I would
6 expect to see other -- the same conduct. In other words, I'd
7 expect to see --

8 A I understand, the same set of circumstances.
9 You would expect --

10 Q Right.

11 A But that -- in order to -- it may have been
12 the initial intent to do that, but given the frequency of
13 positives, hepatitis C positives in the general adult
14 population, particularly in that age range getting, you know,
15 GI studies, you're going to find a lot of positives. And I
16 think it might -- and I -- now I'm speculating that while the
17 original intent might have been to identify other clusters,
18 the number that they came up with made it impossible for them
19 to actually do that kind of investigation because, remember,
20 you have to find the source patient, a source patient, you
21 have to determine what the differences in -- they would have
22 had to go through everything that they did for those two days
23 just for -- for all those other positives.

24 And actually in New York, the first outbreak I
25 investigated, that we investigated in 2001, they did the same

1 thing, and they went back four years. And they found a lot of
2 positives for both B and C, but they could -- you know, I
3 think they identified a cluster, maybe, but they couldn't do
4 the same kind of analysis. But that's not the purpose of the
5 investigation. The purpose of the investigation is to
6 identify what happened, how it happened, and if it's -- it
7 shouldn't happen, prevent it from happening in the future.

8 Q I -- I --

9 A Yeah, so --

10 Q I follow all that.

11 A Right.

12 Q I just still -- I told you --

13 A The purpose of -- the real --

14 Q -- I'm not an epidemiologist --

15 A Right. But that --

16 Q -- but it seems to me if -- if it happened
17 this way and this is my conduct and then I did the identical
18 thing --

19 A Yeah.

20 Q -- 100 times --

21 A Uh-huh.

22 Q -- and it's convinced because I did it this
23 way it caused it to happen --

24 A Uh-huh.

25 Q -- then on the other 99 days I would expect to

1 see it again if that was truly the cause.

2 A You wouldn't necessarily see it every day.

3 You have to have someone --

4 THE COURT: You have to have --

5 THE WITNESS: -- who is infected --

6 THE COURT: -- hepatitis to start --

7 THE WITNESS: -- as a source.

8 BY MR. WRIGHT:

9 Q Well, right. I'm saying --

10 A Okay. So -- yes, but how would you show that
11 and how -- what amount of resources should the health
12 department when they have many other things that they have to
13 consider, dedicate to this? This is not for, no offense,
14 legal reasons. This is for public health. So to protect the
15 public they have done their due diligence by identifying the
16 potential source, who was at risk, and notifying them --

17 Q I understand.

18 A -- to get tested. And that was the -- that's
19 really the overall purpose.

20 Q This is a criminal case.

21 THE COURT: I think we're getting --

22 BY MR. WRIGHT:

23 Q And I understand --

24 A I know that, but I'm not --

25 Q Let me ask --

1 MR. WRIGHT: Pardon?

2 MR. STAUDAHER: Your Honor, I think --

3 THE COURT: Mr. Staudaher is objecting. I think
4 we're getting beyond --

5 MR. WRIGHT: No, I --

6 THE COURT: -- the focus.

7 MR. WRIGHT: Just one wrap up question.

8 THE COURT: Okay. One more question.

9 MR. STAUDAHER: He can do this on cross-examination.

10 THE COURT: Well, no, there was --

11 MR. WRIGHT: I can't do it on cross.

12 THE COURT: Wait a minute.

13 THE MARSHAL: Counsel, enough.

14 THE COURT: There was a purpose --

15 MR. WRIGHT: I --

16 THE COURT: Excuse me. There was a purpose for
17 allowing this questioning to go on and it was a limited
18 purpose and I think we're getting beyond the purpose. And so,
19 Mr. Wright, you say you have one more question.

20 MR. WRIGHT: Yes.

21 THE COURT: You can ask your final question. Again,
22 because the questioning was dedicated to a particular issue --

23 MR. WRIGHT: I understand.

24 THE COURT: -- and I think we're getting beyond
25 that. And so ask your final question and then we're going to

1 take a little break.

2 BY MR. WRIGHT:

3 Q As I understand it, if it was conclusively
4 shown that over the four years all 63,000 persons were tested,
5 okay, every one of them was tested and there wasn't any hep C,
6 it turns out it was below the threshold level that would have
7 been expected, okay, if I could show that no one in four years
8 got hep C at that clinic it would make no difference to you in
9 reaching your determination that for those two days the method
10 of transmission was what you found; correct?

11 A That's correct.

12 Q Okay.

13 A But unlikely.

14 THE COURT: Okay. Well --

15 THE WITNESS: Unlikely that that would be the case.

16 THE COURT: All right. If you need to take a break,
17 ma'am, just exit --

18 THE WITNESS: I'm okay.

19 THE COURT: -- through those --

20 THE WITNESS: Do you want me to just --

21 THE COURT: You can sit there if you want to.

22 THE WITNESS: Fine. I'm fine.

23 THE COURT: We're going to take a break.

24 (Court recessed at 10:42 a.m., until 10:46 a.m.)

25 (Outside the presence of the jury.)

1 THE COURT: Yes?

2 MR. WRIGHT: I just want -- I just wanted to tell
3 the witness that that exchange was outside of the jury's
4 presence. So when I examine you in the courtroom --

5 THE COURT: And ask the same things again --

6 MR. WRIGHT: -- we don't act like they've heard it.

7 THE COURT: -- don't --

8 THE WITNESS: Don't sound as if why are you asking
9 me the same --

10 THE COURT: Yeah.

11 MR. WRIGHT: Right. We don't discuss it.

12 THE COURT: Sure. Yeah, so obviously don't say --
13 don't say as I just told you five minutes ago --

14 THE WITNESS: Yeah. Okay.

15 THE COURT: -- blah blah blah.

16 THE WITNESS: No, I appreciate -- I appreciate that.
17 Really, I have to be reminded. I don't do this as a routine.

18 (Off-record colloquy.)

19 MS. STANISH: Judge, I'm on the phone with Nia
20 Killebrew --

21 THE COURT: Okay.

22 MS. STANISH: -- and she's out and about. And I
23 thought if we could just put her on speaker phone if you could
24 make the order to her to reveal Mr. Meana's --

25 THE COURT: Okay.

1 MS. STANISH: You ready, Nia, or are you in the
2 check out?

3 THE COURT: What, is she like at Vons or something?

4 MS. STANISH: Yeah, that's fine. Can we just --
5 just to put on the record --

6 THE COURT: She can call in. I mean --

7 MS. STANISH: Let's see if this works. Nia, can you
8 hear me?

9 MS. KILLEBREW: I can.

10 THE COURT: Can you hear me? This is Judge Adair.

11 MS. KILLEBREW: I can, Judge. How are you?

12 THE COURT: Good, thanks. Basically, I need to
13 direct you to disclose to all of us the amount that the Meana
14 family received in settlement of the various claims and
15 lawsuits they may have filed. So if you could do that.
16 Hello?

17 MS. KILLEBREW: I can do that. I don't have the
18 amount that I can tell you right now. I can email it or have
19 someone bring it in an envelope to the Court today.

20 THE COURT: Okay.

21 MS. KILLEBREW: The only thing that I need, you
22 know, is some minute order or some kind of documentation on
23 the record that you're ordering me to do so --

24 THE COURT: Right.

25 MS. KILLEBREW: --- so my client's --

1 THE COURT: -- Ms. Husted is making that --

2 MS. KILLEBREW: [Inaudible].

3 THE COURT: Ms. Husted is making that part of the
4 minutes right now. And you don't need to, you know --

5 MS. KILLEBREW: Okay.

6 THE COURT: -- rush it over today, as long as we get
7 it, you know, by an email or something like that. We don't
8 have to put that on the record today. So, you know, don't
9 worry about sending over a runner or rushing back to your
10 office or anything like that. You know, just sometime today
11 or tomorrow morning if you get that over to the lawyers, that
12 would be great.

13 MS. KILLEBREW: Okay. I'm out of town, but would it
14 be easier for me to just -- I mean, my office is right across
15 the street -- to have a runner bring it over in an envelope to
16 your -- to your chambers?

17 THE COURT: Sure. That --

18 MS. KILLEBREW: Or would you rather have me disclose
19 it to counsel?

20 THE COURT: Sure. That's fine.

21 MS. KILLEBREW: Okay.

22 THE COURT: All right.

23 MS. KILLEBREW: I'll just do that.

24 THE COURT: Okay.

25 MS. KILLEBREW: Not a problem.

1 THE COURT: Okay. Great. Thank you.

2 MS. KILLEBREW: Thank you so much.

3 THE COURT: Okay.

4 MS. KILLEBREW: Bye, everyone.

5 THE COURT: Bye.

6 MS. STANISH: Bye.

7 THE COURT: Okay. We can bring the jury back.

8 (In the presence of the jury.)

9 THE COURT: All right. Court is now back in
10 session.

11 And, Mr. Staudaher, you may resume your direct
12 examination.

13 MR. STAUDAHER: Thank you, Your Honor.

14 DIRECT EXAMINATION (Continued)

15 BY MR. STAUDAHER:

16 Q With regard to your review of the records in
17 this particular case, we're talking about the Health District
18 report. What else did you review?

19 A The trip report from the CDC, which is their
20 initial follow up report right after they return from the
21 investigation, and then their publication in a peer reviewed
22 journal of their -- of the final analysis of the CDC's
23 investigation portion.

24 Q So the -- in the chronology of things that you
25 looked at, did you look at them in a particular order, did one

1 build on itself, that kind of thing, or did it matter? Was
2 the trip report first and then the article, or vice versa?

3 A Oh, definitely. The trip report definitely
4 because that comes out right after they return from their
5 investigation, like within a short period of time.

6 Q Is it typical to have an outbreak
7 investigation published in a peer review journal after such an
8 outbreak?

9 A Yes.

10 Q So the trip report is -- how would
11 characterize that report?

12 A Well, it's publicly available, but it is -- it
13 is part of CDC's procedure that you summarize, even though
14 they might be preliminary, the results of your investigation
15 immediately upon return so that that's communicated back to
16 the inviting state and they have everything that you have at
17 that moment.

18 Q Is it fair to say that are there sometimes
19 errors in those initial reports?

20 A Yes, probably. Yes.

21 Q When it gets to the stage where you actually
22 publish the paper, though, in the peer review journal, does
23 that go through some sort of vetting process with other
24 investigators? I mean, how is the journal sent out before
25 it's actually published?

1 A The draft or the manuscript, which is what we
2 call the prepublication report is sent out to the co-authors
3 on the -- on -- on the paper to read and make any suggested
4 revisions. It doesn't necessarily mean that all errors, if
5 there were errors, would be caught at that time, but hopefully
6 everything that's in the -- in the manuscript is accurate as
7 far as the co-authors know. In addition, when it gets
8 submitted to a journal for peer review, which is a separate
9 process, it is reviewed by individuals who were totally not
10 related in any way to the -- whatever the study was that's
11 being reviewed. So the journal sends it to its own peer
12 reviewers to decide whether it's of importance and worthy of
13 publication in the journal.

14 Q And once it finally gets published, it's been
15 through that whole process; is that correct?

16 A Yes, including, I should say, clearance at the
17 CDC level.

18 Q So in this particular case you looked at those
19 particular parts of the -- that sort of detailed the
20 investigation; is that correct?

21 A Yes.

22 Q Now, we've talked about some of your kind of
23 conclusions about scopes and the -- or the biopsy forceps,
24 things like that up to this point.

25 A Yes.

1 Q In general, looking at the results in this
2 particular case, did you come to a conclusion as to how you
3 believe the transmission occurred through the records that you
4 reviewed?

5 A Yes.

6 Q And what was that?

7 A My conclusion is that the unsafe injection
8 practices used routinely in this clinic resulted in
9 contamination of medication vials, in this case propofol, with
10 hepatitis C virus that was then transmitted to other patients.

11 Q Okay. Anything in the reports related to that
12 that called into question that analysis or that conclusion?
13 Any results that you saw? Anything in there?

14 A I don't know. I'm thinking.

15 Q -- in there?

16 A I just want to make -- no.

17 Q Have you ever heard of the term serial
18 contamination?

19 A Yes.

20 Q Do you know -- can you tell us what that is,
21 first of all?

22 A Basically you have a source and it's
23 transmitted down the line. I mean, you know, it's transmitted
24 to each subsequent individual who is exposed.

25 Q Have you seen this actually in your own

1 investigations?

2 A Yes, I have.

3 Q Have you -- I mean, is this something that has
4 been around for awhile?

5 A The idea of it, yes, and having seen it in the
6 context of hepatitis B virus because it's so infectious and so
7 much more easily transmitted that we've seen it in a variety
8 -- and we've been able to test for it for a much longer period
9 of time and we've seen that in a variety of settings and done
10 experimental studies to show that it can happen, but it
11 doesn't have to.

12 Q Okay. What do you mean it doesn't have to?

13 A When you refer -- I'm assuming when you mean
14 serial transmission that every single individual after the
15 source gets infected?

16 Q No, not necessarily.

17 A Oh, okay.

18 Q And let's talk about that. Serial
19 contamination meaning just people downstream of the source
20 patient --

21 A Right.

22 Q -- are contaminated serially.

23 A Yes.

24 Q And do you know how that could happen in a
25 situation like that?

1 A Well, if you have a common source of virus
2 like a multi-dose vial or several contaminated vials of
3 medication, then people who are exposed to that vial of
4 medication downstream, so to speak, from its point of
5 contamination will be exposed and potentially infected.

6 Q Is there a dilution effect that involves that
7 sort of serial contamination that might have a play here?

8 A Yes, there is because, you know, there's a
9 certain amount of virus that is in the contaminant, and as the
10 vial gets used up, presumably the level of contamination will
11 go down or you really don't have any idea which dose is going
12 to contain virus and which isn't.

13 Q Now, in this particular case there were two
14 specific days; correct? We're talking about a July date, July
15 25th and a September 21st date. Your -- go ahead. Did you
16 want to say something?

17 A May I correct what I just said? It just
18 occurred to me the question you're asking. I didn't answer
19 the question you were asking about how the serial
20 contamination might occur, whether or not you would get --
21 whether it would be different the further downstream. If you
22 were -- if the source was in the same -- if you only had one
23 source of virus, then presumably as the -- as the vial gets
24 used up you'll have less contamination and lower infection
25 rates the further out you go.

1 However, if it's from different vials, if multiple
2 -- if you have multiple sources of potential contamination,
3 then that might be difficult to see. In an experimental
4 setting, however, that's exactly what happens is you --
5 because you have -- as you go along, downstream you have less
6 and less, your infection rates start to drop.

7 Q So at some point you wouldn't expect there to
8 be infection rate with a common initially contaminated source,
9 or -- or can you --

10 A Presumably, but not always.

11 Q Now, on the two days in question that we're
12 talking about here, and you've reviewed the information
13 pertaining to those; is that correct?

14 A Yes.

15 Q You said that you believe -- if I -- I'm not
16 trying to reiterate, but is it the same conclusion for both
17 days?

18 A Yes.

19 Q And what do you base your conclusions off of?

20 A The only -- first of all, the only significant
21 result that the CDC could find was that all of the patients
22 who became infected received procedures on the same day as a
23 chronic -- you know, as the source patient. And all of their
24 procedures occurred after the source patient. In the
25 September -- on the September day they have a few infections

1 that can actually look at it in an analysis using numbers and
2 statistical techniques. On the July day, there is only one
3 infection downstream from the source patient. So the only way
4 to link those is by genetic sequencing.

5 However, the fact that the only -- the only
6 technique or procedure that could be implicated, that they
7 could identify as being inappropriate and not according to
8 good aseptic technique was how the multi-dose vial -- how the
9 anesthesia was delivered, essentially, and to multiple
10 patients. And so since that had been occurring all along,
11 there was no reason to believe that wasn't the source in July
12 as it was in September.

13 Q Now, the source in July, let's talk about that
14 day just for a second. You said there was just one infected
15 patient from the source patient on that day. You said the
16 only way that there could be a link is through genetic
17 sequencing --

18 A Right.

19 Q -- correct?

20 A Yes.

21 Q Was that -- was that done in this case?

22 A Yes, it was, and they were -- they were
23 genetically related.

24 Q And are you -- I mean, you've -- I assume
25 since you've been at CDC you've seen that kind of analysis

1 done in the past, is that right, where they do linking?

2 A Yes.

3 Q Is there any issue with regard to the methods
4 or procedure that you saw employed in this particular study
5 for that work, for the sequencing work that called into
6 question the results?

7 A No, it only gets better as time goes by.

8 Q Okay. Now, on the 25th date, the July 25th
9 date, were you aware based on the records that the CRNA
10 involved on that day was the one who administered the heplock
11 and administered the medication?

12 A Yes.

13 Q Is there -- although the infected patient on
14 that day did not fall under the same category, it was a nurse
15 that put in the heplock initially --

16 A Yes.

17 Q -- at least according to the records, is there
18 any issue there with regard to, you know, potential error in
19 what the transmission was or the source of the transmission
20 based on that information?

21 A I don't -- I don't think so. The reason being
22 that the procedures that the nurses use to put in the heparin
23 locks were correct, and they were observed to be correct, they
24 routinely were correct, and so there is no reason to believe
25 that the placement of the heplocks were related. They

1 certainly didn't find that in September, and when they
2 investigators were onsite observing the staff, one of the
3 CRNAs continued to administer anesthesia in the same way, in
4 an unsafe way by using -- you know, reusing a syringe on a
5 single patient and then using that vial on multiple patients.

6 Q Were you aware that a communication was made
7 to a second CRNA about that same practice?

8 A Yes.

9 Q And you were aware of the results of that, the
10 admission of the reuse there?

11 A Yes.

12 Q Those two things combined, those are
13 different, if I understand you, that in that New York 2001
14 study where you didn't have any observed mechanism by which
15 you could see or determine transmission?

16 A Until -- that's correct, until we looked at
17 the purchase records.

18 Q So that's what led you to your conclusions?

19 A To confront the person who had been denying
20 the unsafe practices, yes.

21 MR. STAUDAHNER: I pass the witness, Your Honor.

22 THE COURT: All right. Cross.

23 CROSS-EXAMINATION

24 BY MR. WRIGHT:

25 Q Good morning. My name is Richard Wright. I

1 represent Dr. Desai. You did not participate -- let's see,
2 you left CDC in 2006.

3 A Yes.

4 Q And so you had no participation in this
5 investigation in Las Vegas in January?

6 A Other than talking to Brian Labus over the
7 phone

8 Q Okay.

9 A Over the telephone.

10 Q Okay. And the -- when did you talk to him?

11 A It was in the middle of the investigation,
12 just before they -- just before they went public to -- did the
13 public notification.

14 Q Okay. So that would be -- I mean, we know
15 from dealing with all the dates here in the courtroom it went
16 public February 27. It went public and notifications went out
17 to patients February 27, 2008. So prior to then; correct?

18 A Yeah, like the day before.

19 Q Okay. And you -- you had received -- were you
20 contacted by lawyers from the clinic to consult with them? I
21 read that.

22 A Let me think a minute, only because I do get
23 contacted a bit. Yes, I think so. Yes.

24 Q I -- I read somewhere of efforts to reach out
25 to you by civil litigator -- civil lawyers for the clinic at

1 the time seeking to use your expertise --

2 A You're absolutely --

3 Q -- and consult.

4 A Thank you. You actually brought it back.

5 Yes, that's correct. And, in fact, because I knew nothing
6 about the outbreak at the time, it was early on, they did --
7 they were referred by a colleague and I turned them down when
8 I -- when they described the situation. And then I
9 immediately called my contacts at CDC to see what was going on
10 because it sounded, you know -- sorry, from an
11 epidemiologist's point of view, it was quite exciting.

12 Q I -- I read --

13 A I'm sorry.

14 Q I read the articles you forwarded. Okay? All
15 of these articles and the Morbidity -- what's that thing
16 called?

17 A Morbidity and Mortality Weekly Report. It's
18 CDC's public health notification of important events.

19 Q It sounds like a Halloween magazine. But it
20 is really dry reading.

21 A To you.

22 Q Correct.

23 A The rest of us can't wait to get our hands on
24 it, and it's embargoed, too.

25 Q The -- I mean, this is esoteric stuff we're

1 dealing with. The -- I read your article about, and I had
2 nightmares, about the testing the chimpanzee dried monkey
3 blood to see how long the virus lives in dry chimpanzee monkey
4 blood. And the results were how long does the hepatitis C
5 virus live outside, like when it's -- some blood is left on an
6 instrument. What's the results?

7 A The results were that the -- the only way you
8 can demonstrate infectively is with an animal model because
9 you really can't do it in -- in the laboratory, so -- and only
10 non-human primates. So the results were that we had three
11 time points to look at, 16 hours, four days, and seven days.
12 And only the 16-hour sample was infectious. So we know that
13 it persists for at least 16 hours outside the human body. It
14 could be dried on a surface, not visible to the human eye, and
15 still cause infection.

16 Q Okay. And the three-day old -- three-day old
17 blood, using my --

18 A Four-day.

19 Q -- layman's terminology --

20 A It's okay.

21 Q Four-day?

22 A Four days.

23 Q Four days the -- it was no longer infectious,
24 the virus had died.

25 A Right.

1 Q And the same with the seven-day?

2 A That's correct.

3 Q And -- and that's -- learning from your
4 article, that's different than the hepatitis B, where that --
5 it -- the hepatitis B virus survives when exposed to the
6 environment for --

7 A It was only looked at for seven days, okay,
8 because of the limitations of doing these kinds of studies.
9 So its infectivity was demonstrated seven days, but it's a
10 very hardy virus. It's easy to kill, you know, if you use
11 disinfectants on it, bleach does a great job, but it survives
12 a long time. And when people ask -- actually ask our opinion,
13 if they call and say, you know, I've had this thing with blood
14 on it for two years, should I consider it infectious with B?
15 We would probably say, yes, you should just consider it
16 infectious. They've actually found evidence of the virus, not
17 necessarily its infectivity, seven years after it was dried.
18 But unknowing -- you know, we don't know if it's infectious.

19 Q Okay.

20 A Hepatitis C clearly does not survive that long
21 because you have to combine your experimental work with
22 reality and what you see in terms of transmission patterns.
23 And it was clear from transmission patterns that hepatitis C
24 was not like HIV, which does, once it leaves human body, it --
25 it's no longer infectious. But because of its transmission

1 patterns, we suspected it had to live for some period of time
2 outside the body, and that's why we did the experimental
3 study.

4 Q Okay. As -- as a hepatitis expert, I contract
5 hepatitis C today, and the odds are like seven out of ten
6 times I will have no symptoms, asymptomatic. Is that what
7 it's called? Is that right?

8 A Yes.

9 Q Okay.

10 A Right.

11 Q Like three out of ten times I will get the
12 classic symptoms that we've heard about testified here,
13 jaundice --

14 A It'll send you to the doctor.

15 Q Right. Okay. And so I may not -- I may not
16 know I even have it --

17 A Yes.

18 Q -- seven out of ten times.

19 A That is correct.

20 Q And the -- how -- how quickly -- and I guess
21 once I'm past six months and I'm most -- once I'm past six
22 months, I just acquire it today, six months from now, assuming
23 I knew I acquired it, six months from now it's quite clear I'm
24 not going to get the classic symptoms; is that right?

25 A That's correct. I mean, the classic symptoms

1 -- the incubation period is short. It can be as short as 14
2 days, supposedly as long as six months. But likely within two
3 to three months of exposure, if you haven't become symptomatic
4 you're not going to be for the first phase of infection, the
5 new phase of infection.

6 Q Okay. So once -- and then the -- we've heard
7 testimony here in the courtroom, I'm past six months so it's
8 what we've called -- we're calling chronic hepatitis C. And
9 chances are I will end up dying of old age and not hepatitis
10 C.

11 A From an odds point of view, absolutely.

12 Q From a what?

13 A From an odds -- look where we are. From an
14 odds point of view, yes.

15 Q Okay.

16 A Likely you will.

17 Q Okay.

18 A It depends on a variety of factors.

19 Q Okay.

20 A Whether you drink, you know, do other things
21 that might harm your liver that all of that potentiates.

22 Q Okay.

23 A You know, it puts different risks on it, but,
24 yes, that's correct.

25 Q Okay. And if I contract it today, the -- like

1 what do -- what do the studies show or what's your analysis of
2 how quickly I may develop cirrhosis of the liver from
3 hepatitis C?

4 A Presuming you're over 40?

5 Q That I am.

6 A Age --

7 Q And drink.

8 A Age -- well, if you had hepatitis C your
9 doctor would tell you not to drink at all, but -- except maybe
10 champagne at your daughter's wedding. But depending on your
11 age and a variety of other factors, you're male so it
12 increases your risk, as well, and that you can't do anything
13 about. So all other factors being equal, you could develop
14 cirrhosis in 5 years, 2 years, 20 years, or 40 years.

15 Q You just don't know.

16 A No. I mean, there's an average.

17 Q What's the average?

18 A 20, 30. 20 we'll say. And that most of those
19 -- that -- that's -- also includes a range of -- you know,
20 averages always have ranges. So that's the average, but it
21 can be much shorter, and I've observed that directly.

22 Q Okay.

23 A In my follow up studies that I conducted at
24 CDC. So -- but it has usually -- often, in moist people it
25 has a long what we call latent period where nothing happens

1 and you don't know you have it until you have that yearly
2 physical. The doctor finds you have liver -- elevated
3 abnormal liver enzymes, meaning your liver is inflamed. They
4 test you for hepatitis C, and you just found out you have it.

5 Q Okay. And if I have it and I didn't know I
6 had it, I had a blood test and the doctor says you've got
7 hepatitis C, and I don't have any symptoms at all from it,
8 didn't even know I had it, I could still undergo the
9 treatments we've heard about here in the courtroom, which is a
10 48-week interferon and ribafarbon (sic) or something.

11 A Ribavirin, yeah.

12 Q Okay. I -- I could do that even if I had
13 chronic and no symptoms?

14 A Actually, that makes you a better candidate
15 for --

16 Q Okay.

17 A -- resolving your infection. However, there
18 are guidelines for treating people and the guidelines have to
19 do with the severity of your liver disease, which may not be
20 manifest or clear based on your lack of symptoms. So they do
21 laboratory testing, possibly imaging studies, possibly a liver
22 biopsy to determine the stage of your liver disease. And
23 people with mild disease may not have been treated in the
24 past. They may be more likely to be treated now because some
25 of the drugs -- because the treatment is more effective and

1 can be shorter. But in general you have to sort of show that
2 you're progressing in your liver disease to be treated. On
3 the other hand, some physicians treat everybody.

4 Q Okay. Have you heard of Dr. Richard Perrillo,
5 a neuropsychologist?

6 A I know a Robert Perrillo who is a
7 hepatologist.

8 Q Nope, this is Richard Perrillo.

9 A And he's a what, neuroscientist?

10 Q Neuropsychologist.

11 A Neuropsychologist, no.

12 Q Okay. He testified here in the courtroom
13 about hepatitis being neuroviral and attacking the brain and
14 causing -- hepatitis C causing dementia which he distinguished
15 from brain fog.

16 A You mean like the rest of us have.

17 MR. SANTACROCE: I'm sorry. I didn't hear you.

18 THE WITNESS: It wasn't a scientific comment. Can I
19 take it back?

20 MR. SANTACROCE: No.

21 THE COURT: No.

22 THE WITNESS: Like the rest of us have.

23 THE COURT: Oh, okay.

24 BY MR. WRIGHT:

25 Q He testified that he reached this conclusion

1 of hepatitis C causing dementia, as well as the treatment
2 causing dementia. And he based it upon he had seen 19
3 patients with hepatitis C and they had dementia. Do you --
4 are you familiar with any -- any of his work or studies or
5 does any of that ring a bell with you?

6 A No.

7 Q Okay. The --

8 A But I can comment.

9 Q Give me your comment.

10 A Okay. This is a common misconception,
11 particularly by physician researchers. I don't know if he's a
12 physician, but they look at cases only and they don't end up
13 doing a study. They look at case reports or just people with
14 the disease and they see that they all have this in common,
15 whatever it might be, in this case hepatitis C and dementia,
16 and they come to a conclusion about the cause or some
17 association. But you can't. Case -- case reports can be very
18 useful because they can -- you know, they can show that
19 further study might be necessary in that area, but they can't
20 -- you can't draw any conclusions from cases, just looking at
21 cases.

22 Q And that's the difference between association
23 and cause and effect.

24 A No.

25 Q No?

1 A Association --

2 Q Well, let me -- let me ask it this way. I
3 mean, the way it was explained to me the -- why an association
4 doesn't prove cause and effect, let me put it that way. I was
5 told in the late 1940s before there was a polio vaccine, that
6 there was an anti-polio diet put out by the government that
7 you should not eat ice cream or soft drinks because everyone
8 that had polio had been eating a lot of ice cream when they
9 caught polio. They were eating a lot of ice cream and soft
10 drinks. And so ultimately it turned out that polio was
11 transmitted in the summer when it was hot, and so the -- they
12 had misinterpreted. There is merely an association. Everyone
13 caught polio when -- when it was hot and that's when you eat
14 ice cream and drink soft drinks.

15 A Actually, I'm sorry if I interrupt. That is
16 not an association. That's actually -- it's called an
17 ecological fallacy in scientific terms and from an
18 epidemiological point of view. I'm sorry. That's exactly
19 what it is. It's like there are more telephone poles in -- or
20 people -- there's a higher risk of getting -- or a higher rate
21 of cardiovascular disease in places that have more telephone
22 poles. Why is that? That is not an association. It's an
23 ecological fallacy.

24 People who have -- who don't live in -- well, when
25 this was used as an example, telephones were not exactly as

1 common as they are now, and in urban areas where people had
2 less exercise and ate -- and had worse diets had more
3 cardiovascular disease than in rural areas where they worked
4 out, worked on the farms or whatever, and had fewer telephone
5 poles. It's an ecological -- it's a misinterpretation.

6 THE COURT: So it would be a coincidence that has --

7 THE WITNESS: It's a coincidence.

8 THE COURT: -- no bearing on actually the cause of
9 disease or the symptoms of --

10 THE WITNESS: That's right.

11 THE COURT: -- the disease or anything like that.
12 Okay.

13 THE WITNESS: And as a scientist an association has
14 the same implication as a cause and effect if you use it -- if
15 you use it in the same way. Like something is associated with
16 infection, a particular event or -- means in epidemiological
17 terms that there is some kind of cause and effect.

18 So when you do studies that can't establish a cause
19 and effect, what we do is say we found a characteristic
20 related or associated with positivity, testing positive, which
21 is a little -- it may be -- it may be a very obscure kind of
22 -- but it's very important in our line of work to be very
23 clear about what we consider studies that can demonstrate real
24 associations with getting infected or getting a disease and
25 those that are just a characteristic of populations, for

1 example, with the disease. I know it sounds esoteric, but
2 it's important.

3 BY MR. WRIGHT:

4 Q And some -- some of the statistical -- do you
5 -- do you all compute it like statistically, the probability
6 that it was this or that?

7 A Yes, after having done an appropriate study.
8 So the study methods have to be just as appropriate as the
9 analysis. And bad data in, bad data out. You know, good data
10 in, hopefully your results are valid. But there have been --
11 there's a lot published, not necessarily in hepatitis C,
12 that's not valid.

13 Q Okay. The -- Brian Labus stated in -- in his
14 -- in the report that the likelihood of getting hepatitis C --

15 THE COURT: Keep your voice up.

16 BY MR. WRIGHT:

17 Q The likelihood of getting hepatitis C for a
18 patient who went to the clinic on September 21, 2007, was 38
19 million times the likelihood of a person who didn't go to the
20 clinic on September 21, 2007. Okay?

21 A Uh-huh.

22 Q What does that show?

23 A I've read the sentence, too. I don't know --

24 Q I mean, I presume --

25 A -- what calculation --

1 Q -- it's true.

2 A I agree. I -- no, I read the sentence, too.
3 I don't know what calculation he was making or the report was
4 making, what calculation that was based on.

5 Q Okay.

6 A And it wasn't explained.

7 Q It -- it is fair to say that you -- you simply
8 read the reports and you concur with the conclusion of CDC?

9 A Yes.

10 Q Okay. And their conclusion was that the most
11 likely cause was the combination of unsafe injection practices
12 with the multi-patient use of propofol vials?

13 A Right, which is also considered under the
14 overall phrase of unsafe injections.

15 Q Oh, okay. That -- that -- somehow I was
16 viewing an unsafe injection as the actual --

17 A No, it also involves the reuse of a vial for a
18 multiple -- or the reuse of the vial for multiple patients.

19 Q Okay. And the --

20 THE COURT: Keep your voice up.

21 BY MR. WRIGHT:

22 Q Your -- on that New York, your first case of
23 New York 2001, was that your first colon --

24 A My first -- the first investigation of an
25 outbreak of hepatitis C in a GI practice.

1 Q Okay.

2 A Private GI practice, yes.

3 Q Okay. And that -- and was that an
4 anesthesiologist?

5 A Who was reusing syringes and needles. Reusing
6 needles and syringes and on the same vial and going back into
7 a multi-dose vial, actually.

8 Q Okay. And was he -- was it a he, the
9 anesthesiologist?

10 A It was.

11 Q Okay. Was he using -- reusing needles and
12 syringes between patients or simply to re-dose a single
13 patient?

14 A Simply to -- to re-dose. He was discarding
15 between patients.

16 Q Okay. The -- and --- and he had denied it?

17 A Yes.

18 Q Okay. And then ultimately admitted to it?

19 A Yes.

20 Q Okay. And the Oklahoma case you talked about,
21 the one you talked about here, that was a reuse of syringes --
22 reuse of needle and syringes on multiple patients?

23 A That was taking one syringe, filling it with
24 enough medication for ten patients, and going from bed to bed
25 administering the medication.

1 Q That's what I'd call serial.

2 A Yes, that's serial.

3 Q Okay. And so that -- you all call that overt
4 syringe -- needle and syringe reuse? I saw that in one of
5 these articles.

6 A Oh, you mean like direct versus indirect
7 contamination?

8 Q Right.

9 A Yeah, that would be direct contamination of
10 the syringe as opposed to indirect. Indirect being through --
11 through the vehicle of a multi-dose, like contaminating the
12 medication vial. Right.

13 Q Okay. And you -- you were asked about serial
14 contamination. And what does that mean to you?

15 A It means that a line of people, so to speak,
16 or patients, have received -- have been exposed serially.

17 Q Okay.

18 A You know, in --

19 Q I got it. And the --

20 A -- a sequence of some time.

21 Q Okay. And I think it was your New York
22 investigation there was a multi-dose common vial and that
23 appears to have been contaminated with hep C by a source
24 patient, and then that -- that one vial was used over three
25 days and that one vial, which was contaminated, thereafter

1 transmitted hepatitis C to other patients getting out of that
2 same vial, is that fair?

3 A That's correct. Although, there were some
4 patients in sequence who did not become infected.

5 Q Okay. And the -- here, and I'm unsure if it's
6 that clear in the Southern Nevada Health District report, but
7 Brian Labus testified that he had two theories by which the
8 transmission, talking about September 21st, could have
9 occurred where it went from room to room because there were
10 two different procedure rooms.

11 And he said it could have been a single --
12 theoretically it could have been a single 50 cc contaminated
13 vial, one vial of propofol contaminated because if you add it
14 up, all of the dosage for all of the infected patients and you
15 just gave them each like their first dose out of the one vial,
16 there was enough total that it could have all happened through
17 one vial. That was one theory he testified to. Second theory
18 dealt with contaminating multiple vials because the -- and
19 having open multiple vials at the same time. And he called
20 that serial contamination of vials. Okay?

21 A Uh-huh.

22 Q Okay. Have -- have you, in the cases you have
23 seen and studied, have you come across serial -- using that
24 definition of serial contamination of vials? Did any of your
25 cases involve that?

1 A I'm thinking.

2 Q Take your time.

3 A I don't think so. I don't remember that being
4 the case, but the practices at this clinic of having multiple
5 vials open at the same time in the same procedure room and
6 some of the -- and their techniques in general were pretty,
7 well, unfortunate. And so, you know, there is really no
8 reason to have multiple vials open at the same time,
9 particularly if you don't have more than one anesthesia person
10 in the room at the same time. So -- but my understanding is
11 that they did. And --

12 Q Okay. Well, where do you get that
13 understanding?

14 A From the report of the observation --

15 Q Okay.

16 A -- of what they were doing at the time the
17 investigators were there.

18 Q Okay. Well, that was Linda Hubbard. I mean,
19 you don't know that, but Linda Hubbard was not there on
20 September 21st or July 25th. And she --

21 MR. STAUDAHER: Objection. Mischaracterizes the
22 evidence. She was present on July 25th.

23 THE COURT: I'm sorry?

24 MR. STAUDAHER: July 25th.

25 MR. WRIGHT: Okay.

1 THE COURT: All right. So --

2 MR. WRIGHT: Okay. I didn't remember her being
3 there. I'll accept that --

4 THE COURT: And the jury --

5 MR. WRIGHT: -- clarification.

6 THE COURT: -- will recall --

7 MR. WRIGHT: Okay.

8 THE COURT: -- what it recalls. And that's what
9 it's important, what the jury remembers.

10 BY MR. WRIGHT:

11 Q Okay. Linda Hubbard wasn't involved with the
12 source patient or infected patient on July 25th, and Linda
13 Hubbard was not involved on September 21st. Other CRNAs did
14 not testify to you opening multiple vials. They -- they have
15 testified to pre-loading, for lack of a better word. I mean,
16 in the morning drawing up out of one 50 cc, filling five
17 syringes, and other than that simply using a vial until it's
18 empty. Multi-patient, I'm not arguing that, but if you take
19 that open vials out of the equation on September 21st, meaning
20 having more than one vial open at the same time sitting there,
21 do you follow this serial contamination of the vials theory?

22 A I don't think I understand the question --

23 Q Okay.

24 A -- actually.

25 Q Okay.

1 A If you don't have more than one vial, then --

2 Q Open.

3 A Open? Well, you can serially -- you can
4 contaminate it if you open another vial and use a contaminated
5 syringe. Or if you use a new syringe, withdraw some -- some,
6 you know, whatever is left in the contaminated vial into a
7 syringe, and then go into a new vial to get a little more.

8 Q Okay. The --

9 A But, you know, these are all hypotheticals,
10 and my understanding was that, you know, the vials, multiple
11 vials were open at the same time. I mean, there's no reason
12 why either of those scenarios couldn't have happened. I don't
13 know if they did. They also --

14 Q Right.

15 A They may carry, you know, their own -- I mean,
16 it's common in some settings. I'm not saying this one. But,
17 you know, you put what you drew up in your pocket when you
18 change rooms.

19 Q Okay.

20 A Or a vial, you stick the vial in your pocket
21 that you're using and you change rooms and you then use that
22 vial as opposed to whatever is in that room available.

23 Q The CDC trip report noted that there was no --
24 based upon observations and interviews, they didn't haul
25 propofol room to room.

1 A That's true. However, that may not be the
2 case.

3 Q Right. We're -- we're --

4 A I'm just saying a --

5 Q Right. I mean --

6 A It's possible.

7 Q It maybe had --

8 A I don't know.

9 Q Okay.

10 A I don't even know if they had pockets.

11 Q I don't either. We've heard about tackle
12 boxes, but not pockets.

13 A Fanny packs I've seen now, you know.

14 Q So you were -- you're aware of no published
15 articles or cases involving serial contamination of vials, and
16 the evidence in this case --

17 A In which -- what are you -- tell me again your
18 definition of serial contamination of vials?

19 Q Having multiple vials get contaminated by all
20 with the virus of the original source patient, and that's how
21 it moves from room to room into later in the day.

22 A I don't --

23 MR. STAUDAHNER: Objection, Your Honor. That
24 mischaracterizes --

25 THE WITNESS: Yeah.

1 MR. STAUDAHER: -- Brian Labus's testimony.
2 THE WITNESS: It's --
3 MR. STAUDAHER: -- about that.
4 THE WITNESS: It's not serial contamination of vials
5 in my mind.
6 BY MR. WRIGHT:
7 Q Okay. The -- the evidence in this case has
8 been that Brian Labus in March 2009, before -- still having
9 not written his report in December 2009, contacted CDC to ask
10 them if there was any case or any published literature that
11 could document serial contamination of vials as he presumes
12 happened in Las Vegas. And the response was --
13 MR. STAUDAHER: Objection, Your Honor. Hearsay.
14 THE COURT: Well, overruled. She's testifying as an
15 expert.
16 Mr. Wright.
17 MR. STAUDAHER: So hearsay is allowed?
18 THE COURT: Well, Mr. Staudaher, that's enough. I
19 said she could answer the question.
20 Mr. Wright, state your question and be mindful to
21 speak into the microphone --
22 MR. WRIGHT: Okay.
23 THE COURT: -- because you start off strong, and
24 then you start drifting away and we -- we're having trouble
25 hearing you.

1 BY MR. WRIGHT:

2 Q Brian Labus contacted CDC in March 2009 asking
3 if they had any articles or cases in the published literature
4 that document serial contamination of vials as we presume
5 happened in Las Vegas. And the CDC responded that they didn't
6 have any such thing other than one pooling incident, and the
7 CDC stated that they thought there was enough information from
8 your investigation that this is clearly a plausible
9 explanation.

10 THE COURT: Is there a question?

11 BY MR. WRIGHT:

12 Q Does -- would you concur with that response
13 from CDC?

14 A What I would concur is that they were using
15 practices that would -- could result in contamination of
16 medication vials with a blood-borne virus, and that that virus
17 could serve as a source for transmission to multiple patients.

18 Q Okay.

19 A So why couldn't -- I'm -- I still don't
20 understand exactly what definition we're using for serial
21 contamination.

22 Q We -- these are -- this is Brian Labus's --

23 A I know. But I -- I don't know what he meant,
24 either, so --

25 Q I don't either.

1 A Well --

2 Q Six years later.

3 A I -- you know, there -- I don't really know
4 what you're asking. I don't see why multiple vials, if
5 they're out, couldn't have become contaminated if they use the
6 same -- either pooled them into a contaminated syringe or --
7 or used -- reused a syringe on a different vial that was open.

8 Q Okay.

9 A But I don't know what you -- that's the --

10 Q What I'm asking, and I'll ask it again.

11 A Okay.

12 Q Their response was there is no case like it,
13 and there is nothing in the published literature regarding his
14 presumed contamination of vials by serial contamination. Do
15 you agree with that?

16 A I agree with I can't think of a published
17 study involving a specific contamination of different vials --

18 Q Okay.

19 A -- in the same place. However, I can say that
20 we have had an out -- we -- that there have been serial
21 transmission from a common source to multiple patients
22 downstream.

23 Q Right.

24 A But I can't -- I don't know why -- I don't --
25 or -- or contamination of medication vials from blood

1 splatter, which would have contaminated multiple medication
2 vials, even if they weren't being reused.

3 THE COURT: Would the contamination of, say,
4 multiple vials all have had to come from the source patient,
5 meaning the source patient --

6 THE WITNESS: Yes.

7 THE COURT: -- contaminated all the vials --

8 THE WITNESS: Given the --

9 THE COURT: -- as opposed to --

10 THE WITNESS: -- incubation period --

11 THE COURT: -- patient to patient to vial to patient
12 to vial to patient? Do you understand my question?

13 THE WITNESS: Say it again.

14 THE COURT: Would the single source patient have had
15 to contaminate all of the vials in your theory?

16 THE WITNESS: No.

17 THE COURT: Okay.

18 THE WITNESS: One vial could have contaminated
19 another.

20 THE COURT: Okay. As long as you're using the same
21 syringe from -- or mixing the two vials together.

22 THE WITNESS: With the same way that you breached
23 the sterility of the product --

24 THE COURT: Okay.

25 THE WITNESS: -- by using something for one patient

1 on another, yes. So one vial could have served as a source
2 for another vial.

3 THE COURT: If you mix the dosage or the syringes.

4 THE WITNESS: Right.

5 THE COURT: Okay. I get it.

6 BY MR. WRIGHT:

7 Q So a fellow named Priti with CDC --

8 A A woman.

9 Q Oh. I'm sorry. A young lady named
10 P-R-I-T-I --

11 A Patel.

12 Q Okay. Responded that there are no articles or
13 cases like it, but you're theory seems to be a plausible
14 explanation.

15 A It could happen. I don't really see --

16 Q Okay. I'm just --

17 A -- whether it's -- you know, it could.

18 Q Okay.

19 A Given how --

20 Q And that's a plausible explanation as to
21 what --

22 A It's a plausible scenario for contamination.

23 Q Okay.

24 A Is the best --

25 Q And plausible means?

1 A It could happen.

2 Q It could happen. Okay. Now, on -- on 7/25,
3 July 25 -- I don't understand why we don't look at the two
4 events separately like what happened on July 25th and what
5 happened on September 21st.

6 A Is there a question? Are you asking me?

7 Q Yeah, why -- why -- if September 21st hadn't
8 even occurred and we're just investigating July 25th where
9 there was a source patient, there's genetic connection
10 sequencing, in other words the victim, the infected patient
11 received the hepatitis of the source patient; correct?

12 A Yes.

13 Q And the -- we conclude that it must have been
14 unsafe injection practice.

15 A Okay. So you're asking me how we -- well,
16 first of all, they did the same kind of investigation that
17 they tested patients to see if there were any other infections
18 around the same time. So they conducted the same kind of
19 investigation separately. I mean, clearly, two different time
20 points. And -- but they didn't -- they only had the one
21 infection, which from an epidemiological point of view, you
22 wouldn't have been able to, quote, associate it with the
23 source patient unless you did genetic sequencing.

24 Q Okay. But then it happened that it was
25 connected.

1 A Yes.

2 Q Okay.

3 A So how could that happen? Well, there has to
4 be some break in technique for a blood-borne virus to go from
5 one patient to another. And having been able to associate the
6 -- or having observed the unsafe injection practices which
7 were ongoing at this clinic, it would stand to reason that the
8 July 25th incident had the same -- was likely to have been
9 caused by the same mechanism as the September incident --

10 Q Okay.

11 A -- transmission episodes.

12 Q But it -- it could have happened that way.

13 A Yes. You can't prove it, but, yes --

14 Q Okay.

15 A -- it makes perfect sense. And from a public
16 health point of view, that's what -- it's important to know
17 what it is that needs to be changed or communicated to prevent
18 it from happening in the future. That's the purpose of the
19 investigation.

20 Q Okay. And it -- and it's not a -- have you
21 ever participated in a criminal investigation?

22 A No.

23 Q Okay. And you all -- you all, meaning you
24 healthcare epidemiologists, CDC, are going in and you want to
25 as quickly and thoroughly as possible find out what is

1 occurring so that you can both stop it, correct it, and notify
2 anyone who is potentially at risk; correct?

3 A That's correct.

4 Q And are -- are you aware that Brian Labus --
5 you testified on direct about the importance, especially with
6 the new investigators, the newbies who were out there in
7 field, don't jump to conclusions, don't -- don't zero in on
8 one cause, or likely cause, and stop. You have to do
9 everything; correct?

10 A Yes.

11 Q Brian Labus has testified that the
12 investigation started at the clinic on Wednesday, the 9th of
13 January, late in the afternoon, and the next day on Thursday
14 they did chart review, they meaning CDC and Brian Labus and
15 BLC and all these team members.

16 A Uh-huh.

17 Q And the next day on Friday they knew of the
18 propofol multi-patient use and observed reuse of syringe on
19 patient to redose, and by Friday evening, two days into the
20 investigation, he had determined the likely cause. Does that
21 make sense?

22 A That's the question, does it make sense, or
23 did it --

24 Q Yes.

25 A -- is it -- could it have -- did it happen

1 that way? I can't --

2 Q Okay.

3 A I don't know. Since, I can see that that's
4 happening -- that happening, especially given the history of
5 consistency of these outbreaks being due to the same cause
6 over and over and over again. However, the CDC did do a
7 complete analysis of all the other kinds of exposures that
8 could have occurred regardless of what his conclusion was on
9 Friday afternoon.

10 Q Okay. His -- I mean, he testified that he had
11 determined that --

12 A I can't -- I can tell you that in their
13 publication they presented the data showing the other types of
14 exposures that they looked at and ruled out because there was
15 no association between those other exposures and getting --
16 and acquiring hepatitis C.

17 Q Okay. Now, the -- the unsafe practices that
18 keep going on and on and on in the literature and in real life
19 practice, here the evidence has been that the -- the -- on
20 Wednesday afternoon when the -- Mr. Labus and Dr. Fischer and
21 Dr. Schaefer went in, the clinic told them they are multi --
22 they are injecting with multi-dose propofol, multi-dose vials,
23 whatever the terminology was, multi-dose --

24 A Single-dose vials used on multiple patients --

25 Q Correct.

1 A -- is actually what they were.

2 Q And is -- is what they acknowledged and
3 exactly what their practice was. And this -- and the evidence
4 has been here in this courtroom that that was a common
5 practice throughout this community in outpatient settings.

6 MR. STAUDAHER: Objection, Your Honor. I don't
7 believe that's the testimony or evidence as it is right now.

8 THE COURT: Don't spin the evidence, Mr. --

9 MR. WRIGHT: I'm not spinning the evidence.

10 THE COURT: Mr. Wright.

11 And, ladies and gentlemen, once again, it's your
12 recollection of what the testimony was and how you interpret
13 that in terms of, you know, common --

14 MR. WRIGHT: Okay.

15 THE COURT: -- uncommon. It's up to you. Again,
16 I'll remind you.

17 That's what I meant, Mr. Wright.

18 BY MR. WRIGHT:

19 Q Keith Mathahs is a CRNA, okay, who was
20 observed, and he testified here in this courtroom that it was
21 the same practice at Sunrise, it was the same practice at
22 Southwest, it was the same practice everywhere he was
23 involved.

24 MR. STAUDAHER: What practice are you referring to
25 specifically? That's the point that I'm --

1 MR. WRIGHT: Multi --

2 THE COURT: Can you be more specific in your
3 questioning, Mr. Wright.

4 MR. WRIGHT: It was specific before he said --

5 THE COURT: All right. Well --

6 MR. WRIGHT: -- it wasn't --

7 THE COURT: -- Mr. Wright --

8 MR. WRIGHT: -- the evidence.

9 THE COURT: -- state your question again.

10 BY MR. WRIGHT:

11 Q We are talking about using a single-dose
12 propofol vial on multiple patients, acting like it's a
13 multi-dose vial rather than single-dose vial.

14 A The problem, if you just look at it that way,
15 is bacterial contamination and has nothing to do with serial
16 virus contamination.

17 Q Okay.

18 A Because a single-dose vial, something labeled
19 for single-dose has a very short period in which it can be
20 opened and used. It has no bacteria static preservative in it
21 to prevent contamination and when it's -- after it's been
22 opened. So it's bacterial contamination that is intended, a
23 multi-dose vial that's -- excuse me, a vial that's labeled as
24 multi-dose versus single-dose. And I think -- and the package
25 insert is very clear about this for propofol. But not every

1 outbreak has involved propofol, and some have involved vials
2 that are labeled for multi-use. The issue here is the
3 re-dosing with the same syringe.

4 Q I'm going to get to that.

5 A Well, yes, but --

6 Q Okay. Well, I just --

7 A Okay.

8 Q No --

9 A Okay.

10 Q We'll get -- we'll get where you want to go.

11 A But it isn't -- it isn't necessarily the -- I
12 mean --

13 Q Well, I'm --

14 A Well, that might not --

15 Q You're not going where I'm going.

16 A Well, okay.

17 Q I'll drive, and then you can get what you
18 want. And if you think I'm asking unfair questions or
19 something, I'm -- I'm trying to focus in on this why this lack
20 of recognition, this lack of understanding, this lack of
21 awareness in the community of the danger involved in using
22 like a 50 cc propofol vial as multi-dose. Okay? I mean, do
23 you understand that just -- the things just keep going on
24 despite your -- all -- all the best efforts to say don't do
25 it? Do you agree with that?

1 A What I -- you're not in isolation. Well, you
2 shouldn't use a single-use vial unless you use all of it at
3 once. You shouldn't use it for, you know -- you shouldn't
4 have it open for more than the time. It has nothing to do
5 with -- I mean, it has very little to do with the fact that
6 it's labeled for single-use in terms of virus transmission.

7 Q Is that --

8 A Then it has --

9 Q -- part of --

10 A -- more to do --

11 Q -- the confusion?

12 A Well, you can't take it -- in my opinion it's
13 not -- you can't take that as an isolated event, reusing the
14 vial.

15 Q I'm not isolating it.

16 MR. STAUDAHNER: Your Honor, I'm going to object to
17 letting -- I would like him to let her finish her answer
18 before he --

19 THE COURT: Were you -- okay.

20 Were you finished with your answer, ma'am?

21 THE WITNESS: Yes, that I can't -- that his -- the
22 question is not answerable in that way.

23 BY MR. WRIGHT:

24 Q Okay. As part of --

25 A It has no significance.

1 Q Okay. The significance I'm asking is -- is
2 why do these -- we've had a CRNA in this courtroom, Mr.
3 Sagendorf, who is presently a CRNA practicing in California
4 for two large outpatient clinics and he testifies right here
5 within the past month that they still use propofol as --
6 single-use on the label, they use it as multi-dose in their
7 clinics. They use it for multiple patients.

8 A Uh-huh.

9 Q Okay. And I --

10 A I'm not shocked.

11 Q You're not shocked. I'm not shocked either.

12 And -- and we understand best practices. We've heard all
13 about best practices. And all I'm focusing on, we'll get to
14 the needles in due course, but the -- somehow, and this may be
15 the confusion between the multi-dose and single-use has to do
16 with the preservatives and how long it can last once it's
17 open; is that fair?

18 A Yes.

19 Q Okay. Because, I mean, you talk to
20 practitioners and they say I'm using it quickly. Once I open
21 propofol, it -- it says right in there if you read everything
22 that it's good for six hours. And if I am using it all within
23 that time frame, there is no harm in me using it all up. Do
24 you understand what I'm saying?

25 A Yes, I understand perfectly.

1 Q And they -- and if you read the propofol
2 vial --

3 MR. WRIGHT: Where is our propofol vial? It's an
4 exhibit.

5 BY MR. WRIGHT:

6 Q We've had witnesses testify that it's safe to
7 use it if once you open it, if you use it all within six
8 hours. And none of that -- none of it -- if you can --

9 A See it?

10 Q See it. None of that is explained on that
11 label. Is it?

12 A I have to read the label.

13 Q Okay.

14 A However, anyone who uses a drug, any drug,
15 should be -- a professional who uses a drug, any drug, should
16 be fully familiar with that drug.

17 Q Agreed.

18 A Okay. So --

19 Q Best practices. I agree.

20 A Now, the other issue is I think in my opinion
21 there is confusion regarding multi-use and single-use vials
22 and how they contributed. This outbreak could have just as
23 easily occurred with a multi-dose, a vial that was labeled for
24 multi-use. Because the issue wasn't so much that it was a
25 single use vial. It's that they contaminated the vial and

1 then used it on multiple patients. And that could just as
2 easily have occurred with a vial that's labeled for multi-use.
3 Okay.

4 Q Okay. I agree. But why -- why do we have --
5 we had another CRNA testify in here named McDowell. McDowell,
6 I don't remember his first name. But he wanted to argue with
7 the investigators --

8 A I bet he did.

9 Q -- when they told him you use that 20 cc, and
10 then you throw it out and you can't use it on another patient.
11 And he literally argued that as long as I am using aseptic
12 technique and I use a new needle, new syringe every time I
13 enter that vial, there is no way on Earth you can ever show me
14 I will contaminate a patient. And he wants to argue with them
15 to -- to use the vial up and not throw any away. And so why
16 doesn't it sink in?

17 A I have no idea why it doesn't sink it.

18 Q Okay. But --

19 A I have no knowledge or data --

20 Q Okay.

21 A -- to tell you why it doesn't sink in.

22 Q Who in CDC --

23 A It says single patient infusion vial. That's
24 what it says.

25 Q I found it on there, but I needed a magnifying

1 glass.

2 A I can't believe I can read it myself.

3 Q I can't either. But --

4 A It does say it. And the package insert is --
5 it says it in big letters.

6 Q But no package inserts come with this.

7 A No.

8 Q They come in flats of 20 with no --

9 A However, if you were a physician or a nurse
10 and you were using this routinely on patients, you would
11 hopefully have looked it up in the PDR and know everything
12 about it.

13 Q I don't disagree with best practices.

14 A I'm just saying. However, the issue here, in
15 my opinion, is not the fact that this says it's for single
16 patient infusion. It's the fact that they contaminated it.

17 Q We're going to get to the --

18 A But, you see, it's irrelevant
19 epidemiologically --

20 Q Epidemiologically, but --

21 A -- and scientifically.

22 Q -- this is a criminal case --

23 A I know --

24 Q -- okay --

25 A -- but I'm science.

1 Q -- and people's knowledge matters. It matters
2 whether they are mistaken in their judgment or are they
3 consciously, knowingly doing something they're not allowed to
4 do. So I understand epidemiologically it may not matter,
5 but --

6 A Well, then that wouldn't -- that also would
7 not -- if they didn't know that they were doing something
8 wrong, then it would apply to whether it was -- they were --
9 it wouldn't matter if it was single-use or multi-use, they
10 would still be contaminating the vial.

11 Q Right. Because I may think I am engaging in
12 proper practices. Let's move on to your favorite, the
13 contamination. Okay. Needle and syringe usage. What was
14 observed here? Keith Mathahs is the fellow who -- who is in
15 the report who was observed by Dr. Fischer. In the clinic, in
16 front of the CDC inspector with her little -- I don't want to
17 call it her badge, her little plastic badge on, knowing there
18 is a hepatitis outbreak, she is observing his practice.

19 And this CRNA takes a new propofol vial, I'm
20 presuming he wiped the top off, you know, with the alcohol,
21 all of the aseptic stuff, inject the patient, procedure is
22 ongoing, patient needs another dose. He takes the same needle
23 and syringe, holds it up, takes off the needle, puts it in the
24 Sharps container right in front of the CDC inspector, gets out
25 a brand new sterile needle, puts it on, and redraws out of the

1 same propofol vial.

2 A Uh-huh.

3 Q Procedure ends, Dr. Fischer steps in,
4 interviews Keith Mathahs, and her testimony is he was not
5 aware that his practice was risky or dangerous. And he
6 believed that he was being aseptic by changing the needle.
7 Okay. Why does -- where -- why does he think something like
8 that?

9 MR. STAUDAHER: Objection. Speculation, Your Honor.

10 THE COURT: Yeah, that's sustained. You need to
11 phrase that --

12 MR. WRIGHT: Okay.

13 THE COURT: -- a different way. If there's anything
14 in the --

15 BY MR. WRIGHT:

16 Q Why do those instances like him -- I mean,
17 have you seen a situation like that during your investigations
18 where the person just wasn't cognizant, aware, understanding
19 of the improper behavior the person was engaging in?

20 A Yes. Not this specifically, but other
21 investigations --

22 Q Okay.

23 A -- involving unsafe practices, we'll say.

24 Q Okay. And you're dealing with Keith Mathahs,
25 got out of CRNA school before Dr. Fischer was born in the late

1 '60s. Okay.

2 A But not before I was born or graduated. And I
3 can tell you that his -- his original nursing degree is based
4 on a practice taught to him in nursing school, and that
5 practice routinely involves -- or the curriculum routinely
6 involves aseptic technique for -- for giving injections, for
7 preparing and administering injectables.

8 Q Right. But those techniques have evolved.

9 A No.

10 Q Well, in the late '90s, in these articles I've
11 read, in the late '90s, 1990s, you still had between 20 and 35
12 percent of the practitioners believing you could multi-use a
13 needles and syringe on multiple patients if you change the
14 needle.

15 A I know. It's unbelievable, isn't it?

16 Q Right. And -- and what were the standards
17 then?

18 A The standards have been the same all this
19 time. I cannot -- the standards -- aseptic technique is not
20 something that has evolved over time. Although, obviously,
21 disinfection and sterilization techniques have changed, the
22 term and what it implies, asepsis, you know --

23 Q Clean.

24 A -- has not changed. Okay. So the fact that
25 they believe that by changing the needle they are maintaining

1 a sterile connection, I don't under -- I have no idea why they
2 believe that.

3 Q Well, who in the CDC -- I mean, you keep
4 putting out -- I'm talking not you --

5 A It's okay.

6 Q -- but the CDC --

7 A I'm used to it.

8 Q -- puts out these common myths, puts out
9 posters on misperceptions, and -- and keeps trying to drive
10 this in to the practitioners, and it still persists. And so
11 who is studying the why it doesn't trickle in to the
12 perception of the practitioners? I mean, something is wrong
13 in the teaching, something is wrong in the delivery of the
14 message. I mean, I can't believe that like -- I'll show you a
15 study where 28 percent of the --

16 A I saw the --

17 Q -- practitioners --

18 A -- same study --

19 Q -- still believed it was okay to reuse needle
20 and syringe on -- on the same patient. All I'm doing is
21 reusing needle and syringe on same patient, and then threw it
22 away. 28 percent of the practitioners.

23 A Actually, you can do that. You can reuse a
24 needle and syringe on the same patient.

25 Q Not CDC. We heard best practices was you go

1 in, you use it once, once, once, and it's gone. That's what
2 we heard here from Dr. Fischer and -- and Dr. Schaefer.

3 A Once only.

4 Q Okay.

5 A It all -- it's a package. It's not -- you're
6 isolating the events. They're referring to a package. They
7 are trying to drive home a point or a practice and they're
8 trying to make it simplistic. And, you know, I'm -- what we
9 used to say, and still do, is you have two choices. You can
10 either keep your -- if you want to use a multiple-dose vial on
11 multiple -- on more than one patient, or a single-use vial,
12 whatever, you better keep it separate from the treatment area
13 so that people cannot go back into it with a used syringe or
14 needle. You keep it separate in a centralized medication
15 area. What, they're going to walk out of the room to get
16 another dose? I don't think so. So -- or you don't reuse.
17 That's the bottom line and has been for -- since the --
18 well --

19 Q Okay.

20 A -- since I came to CDC. So we've been pushing
21 this home and dialysis centers forever. And the only -- that
22 is one area where I do know, or I can speculate, rather, why
23 staff are not carrying out appropriate infection control
24 practices that have been recommended since the 1970s.

25 Because there -- the cohort of personnel who were

1 there in the '70s, '60s and '70s and early '80s who saw all
2 these transmission episodes that are now being -- that were
3 then prevented by good infection control practices, as well as
4 a little vaccine, have never seen an outbreak because they
5 were prevented. So they don't understand the need for some of
6 these recommendations that are made for that specific setting,
7 okay, which are very -- much more extreme than for other
8 settings.

9 And that was the only -- I mean, they just are --
10 it's like parents who don't want to vaccinate their children
11 against childhood diseases. They have never seen a case of
12 polio or a case of measles and don't know how severe it can
13 be. And, therefore, they would -- you know, they can't
14 appreciate what vaccines to, you know, for the population.
15 It's somewhat of a familiarity. On the other hand, would you
16 operate with an unsterile -- well, yes, actually, I've seen
17 that, too.

18 Q Okay. Well, I get --

19 A I've seen that, too.

20 Q I understand.

21 A Where a surgeon thinks that if he washes it in
22 the sink, his instrument, with soap and water, he can use it
23 on the next patient because it's his instrument and he's very
24 attached to it, he/she. So I -- it's -- I can't explain why
25 it doesn't get through.

1 Q But -- but -- maybe I'm Pollyanna-ish, but I
2 just don't think 28 percent of the healthcare providers in
3 this one study appreciated the risk. I mean, I misstated
4 that. 28 percent of them, I think, misapprehended,
5 misunderstood the behavior they were engaging in, as opposed
6 to 28 percent of them were just saying hell with it, I don't
7 care if I'm going to harm someone.

8 A That I can't say. I have -- I don't know the
9 rationale for reusing. I just know that they did. When they
10 surveyed outpatient surgical centers, 28 percent were reusing.

11 Q It was shocking.

12 THE COURT: Can I see counsel at the bench.

13 (Off-record bench conference.)

14 THE COURT: Ma'am, we're not going to finish with
15 your testimony at a reasonable time before lunch.

16 So, ladies and gentlemen, we'll just go ahead and
17 take our lunch break now. We'll be in recess for the lunch
18 break until 1:30.

19 During the lunch recess you're reminded that you're
20 not to discuss the case or anything relating to the case with
21 each other or with anyone else. You're not to read, watch, or
22 listen to any reports of or commentaries on this case, any
23 person or subject matter relating to the case. Do not do any
24 independent research by way of the Internet or any other
25 medium. And please do not form or express an opinion on the

1 trial.

2 Notepads in your chairs, and follow the bailiff
3 through the rear door.

4 (Court recessed at 12:22 p.m., until 1:34 p.m.)

5 (In the presence of the jury.)

6 THE COURT: All right. Court is now back in
7 session. And, Mr. Wright, you may resume your
8 cross-examination.

9 MR. WRIGHT: Thank you.

10 BY MR. WRIGHT:

11 Q Doctor, one of the articles you forwarded,
12 U.S. Outbreak Investigations Highlight the Need for Safe
13 Injection Practices and Basic Infection Control. In -- in
14 talking about the practitioners continuing to utilize
15 single-dose vials as multi-dose vials despite best practices
16 recommendations, what -- I'm going to read you a portion of
17 this article and then ask you if you agree with it. Okay?

18 Transmission potential is magnified when facilities
19 use vials or bags of medication and infusates that contain
20 quantities in excess of those needed for -- for routine single
21 patient use. Although these medications are often labeled as
22 single use, i.e., single dose, the large volume in the
23 container may lead to the perception that they are suitable
24 for multi patient use. Do you agree with that?

25 A Yes.

1 Q Okay. And that -- that was a long -- I'm not
2 sure of the infusates and all of the words there, but when it
3 comes in a big package, like 50 cc and it's utilized in an
4 outpatient setting where you normally use 10 to 20 ccs for a
5 procedure, having that big vial invites the belief that you
6 can use it for more than one patient; is that fair?

7 A The belief? I don't know if I agree with
8 that, or rather misperception.

9 Q Okay. The misperception that it can. And in
10 this case, the evidence that has been introduced thus far was
11 that 20 cc vials of propofol were initially being purchased,
12 and then the purchase person, a fellow named Jeffery Krueger,
13 the charge nurse, talked to a Baxter representative who said,
14 hey, we have 50s, do you want some of those. Okay? And 50s
15 were then introduced to the clinic. Had -- had that not
16 happened and they just kept with 20s, that would have
17 decreased the opportunity for something like this to happen?

18 A If 20 milliliter vials were used up on a
19 single patient, then the opportunity for contamination of the
20 vial for the next patient would not be there.

21 Q Okay. And I think, as you made clear this
22 morning, if I just stuck to using one vial per patient and
23 throwing it away, or if I just stuck to using one needle and
24 one syringe one time, either of those -- this -- this type of
25 transmission wouldn't occur; correct?

1 A Likely not.

2 Q Okay.

3 A Correct.

4 Q Okay. Most likely this -- this type --

5 A Yes.

6 Q -- of transmission. And you, I think, agreed

7 that using the same needle and syringe to redose the same

8 patient for propofol would be okay as long as that propofol

9 vial is then thrown out?

10 A That's correct.

11 Q Okay. Now, is part of the confusion that

12 continues to manifest itself by lack of following best

13 practices in the practitioners, is part of the confusion due

14 to the varying definitions of single patient use, single use

15 and single-dose vials?

16 A No.

17 Q No?

18 A I don't believe so.

19 Q Okay.

20 A In my opinion it's not the vial that's the

21 problem. The vial -- we're human. Sometimes we actually make

22 policies because we're human. And so we might go a little

23 further with our policy in order to prevent human error, okay,

24 from affecting a particular procedure --

25 Q Okay.

1 A -- knowing that we're human. So it isn't the
2 fact that the vial -- this would still have happened even if
3 the vial was labeled multi-use given their other practices.

4 Q Correct.

5 A Okay.

6 Q I mean, but -- I'm with that. The -- I mean,
7 because if you had simply tossed the vials at the end of each
8 use for a patient, no problem. If I had reused syringes on
9 every patient and tossed the vials, no problem; right?

10 A That's correct.

11 Q And if -- if I use the vials as a multi-dose
12 vial, despite what it says on it, and I used a new needle and
13 syringe every single time I entered it, every single time I
14 dosed a patient, no problem; correct?

15 A As long as there wasn't blood splatter, yes.

16 Q Right. I'm just giving it a -- okay.

17 A Yeah. All things being equal, yes.

18 Q Okay. And the -- my -- I'm -- I'm more
19 confused about the interchangeability of calling a vial single
20 dose, single use, and single patient use. Okay?

21 A Uh-huh.

22 Q And maybe I'm too literal and I'm not a
23 healthcare practitioner, but I -- I read something and I see
24 distinctions between a dose and a patient use. Do you?

25 A No.

1 Q Okay. Well, see, I do. When I think of
2 something as a single dose, to be used once, that means I take
3 it -- I take out a dose, I throw it away, and I use it. And
4 if the patient needs another one, I get out another one for
5 another dose. Am I wrong?

6 A You're interpretation, yes, is incorrect.

7 Q Okay. Okay. Because dose and use are
8 synonymous --

9 A In this instance.

10 Q -- in CDC land?

11 A Yeah, in -- no, in medicine In this instance
12 in medicine. Remember, the FDA approved this packaging.

13 Q For good or bad.

14 A I'm just pointing that out. I mean, they
15 approved the wording that is on these kinds of
16 pharmaceuticals. So I'm just telling you what we -- that's --
17 that's the interpretation.

18 Q Okay. Because I'm going to show you an
19 exhibit. But now maybe it'll make sense since a use is the
20 same as a dose. Do you recognize that?

21 A No.

22 Q Okay.

23 A I mean -- I mean, I haven't been on the
24 website recently to look at their recommendations.

25 Q Okay.

1 MS. WECKERLY: I get what you're saying on some of
2 the counts. She just testified the claim would have been less
3 if the units were less. That's true on insurance fraud. I
4 get what the Court's -- I'm not conceding it -- I get what the
5 Court's theory is on the flat rate.

6 THE COURT: Here's the deal, Ms. Weckerly. That's
7 all well and true for some of these where it's a unit by unit.
8 On some of these where it's rounded down and stuff like that,
9 you may have a problem showing it exceeded what they would
10 have been paid. But that's up to the defense to figure it
11 out. I'm not going to sit here with my abacus trying to work
12 all that out. But on some of this, like I said, if it's unit,
13 you know, if you've got a clear 12 units and they're billed 12
14 minutes and that's one unit and they're billing two or three
15 units, amount doesn't matter, it's more. If it's one of these
16 round down, round up, there may be an issue there that it is
17 more. So again, just pointing that out.

18 MR. SANTACROCE: Back to the issue, what are we doing
19 with her testimony?

20 THE COURT: Well, I'm thinking about it. Anything
21 else you want to say?

22 MR. SANTACROCE: No.

23 MS. WECKERLY: Just on an unrelated matter. We need
24 a ruling on the bad acts because otherwise we've got to --

25 THE COURT: Oh, right. There's still the one bad

1 acts out there.

2 MR. STAUDAHER: The one witness, yes.

3 THE COURT: Yeah, the one, the complaints. I mean,
4 here's the thing on that. You know, I think, again, it's --
5 obviously, anything going to the merits of the complaint is
6 hearsay, is completely inadmissible. The only thing is the
7 relevancy of the notice as to the somewhat shoddy procedure.
8 Balancing it, the prejudicial value I think is quite high. I
9 think the probative value is relatively low and is duplicative
10 of everything that we've heard. There's been abundant
11 evidence of Dr. Desai's a cheapskate and they don't want to
12 spend money on supplies and he's indifferent to the concerns
13 of his patient to the point of actually being callous.
14 There's abundant evidence of that.

15 So to me, this goes to all of that type of evidence,
16 not to the real critical issues here which is what did he know
17 about the syringes, what directions did he give on reusing the
18 syringes and was, in fact, that the manner of transmission,
19 particularly as it concerns Mr. Lakeman. That's the critical
20 issue here.

21 In terms of all of the other, the insurance fraud, I
22 think the motivation is greed and the issue of the complaints
23 and the notice has nothing to do with that issue, insurance
24 fraud theft. So it's totally irrelevant there and it's only
25 relevant on the criminal neglect and the issues. I think it's

1 extremely prejudicial and the probative value is duplicative
2 of everything else we've already heard which is somewhat
3 tangential to the real issue here is was the reuse of the
4 syringes encouraged, directed, mandated, something like that.
5 Which could have even been mandated by the shortage of
6 supplies. I mean, it doesn't have to be you do it. If you've
7 got five people and one syringe, you know, you're going to
8 have to reuse them.

9 Doing the weighing analysis, I just don't -- I just
10 don't see that, coupled with the hearsay issue which I think
11 we would have to -- I would try certainly to limit it. But
12 the risk of hearsay coming in, allegations that weren't
13 supported or substantiated, I think is too dangerous. So
14 that's where we are.

15 I'm taking the -- again, typically, you're not going
16 to strike the testimony just because it was weak testimony or
17 it was incomplete testimony or it was inconclusive testimony.
18 As we all know, that's not the typical remedy for the witness.
19 You just argue that later. I recognize Mr. Santacroce,
20 there's a little more prejudice here because the jury, unlike
21 another witness, like a percipient witness of a street crime
22 or something like that, the jury may not understand how to
23 really evaluate that testimony and that's my concern. They're
24 not going to know that there should be backup and how this is
25 all supposed to come in. So I'll consider that further,

1 although I'm unlikely to strike it. But I understand that
2 that's the danger of it, that the jury won't be able to
3 evaluate it because you need some kind of --

4 MR. SANTACROCE: Or evaluate it incorrectly.

5 THE COURT: Well, what I meant was they won't know
6 how to question it or they won't see what's missing. That
7 would be -- anything else?

8 MR. WRIGHT: A separate matter. I'm subpoenaing Nia
9 Killebrew for the amount the Meanas received insurance wise.

10 THE COURT: Okay.

11 MR. WRIGHT: So I'm going to tell her -- I don't know
12 what the amount is. I'm going to ask her if she'll give us
13 the amount if the State won't --

14 THE COURT: Perhaps we could just do that by way of
15 stipulation.

16 MS. WECKERLY: We can do that by stipulation. We can
17 find that out.

18 MR. WRIGHT: I'll find out and she may --

19 THE COURT: Yeah. Why don't we just do a
20 stipulation --

21 MR. WRIGHT: -- need to --

22 THE COURT: -- and stipulate that the Meana family
23 received blah, blah, blah.

24 MS. WECKERLY: I think she's gone Friday anyway, so
25 we could -- we can just find out and stipulate.

1 MR. WRIGHT: Okay.

2 THE COURT: And that could be done at any time.

3 MR. WRIGHT: Okay. Well, I just was going to tell
4 you it's a little bit -- I -- who else is coming in? His
5 wife?

6 MR. STAUDAHER: No.

7 MS. WECKERLY: Oh, no. That's it.

8 THE COURT: That's it.

9 MR. WRIGHT: Oh, okay. Right. I mean, I thought
10 that was it and so that's why I was -- I'll get it from Nia.
11 She may need to come over and get an order that she has to do
12 it.

13 THE COURT: Yeah. She's going to have to get the
14 order that she can disclose it. But then there's no reason to
15 call her as a witness.

16 MS. WECKERLY: Unless you want to.

17 MR. STAUDAHER: We'll stipulate to that.

18 MS. WECKERLY: If you've got a lot of questions.

19 THE COURT: Yeah, I mean, it should be a stipulation.
20 I'm sure she's very busy counting her money at her beach house
21 in Newport, which I think she actually had before all of this.
22 She's been successful for years.

23 MS. WECKERLY: We'll find a way to get the
24 information and then we'll stipulate to have her disclose it
25 to the Court.

1 THE COURT: You know, if she's comfortable with it to
2 save her a trip, I'm happy -- I could do it by way of written
3 order or she could come over and however, either way.

4 MR. STAUDAHER: Could the Court do it telephonically?

5 THE COURT: Sure. If she's willing to accept that,
6 you know, she can call in and I'll just tell her. I mean,
7 we'll do it on the record like with Court Call or something.
8 That would work as well.

9 MR. WRIGHT: Very good.

10 (Court recessed for the evening at 3:08 p.m.)
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25

CERTIFICATION


I CERTIFY THAT THE FOREGOING IS A CORRECT TRANSCRIPT FROM THE AUDIO-VISUAL RECORDING OF THE PROCEEDINGS IN THE ABOVE-ENTITLED MATTER.

AFFIRMATION

I AFFIRM THAT THIS TRANSCRIPT DOES NOT CONTAIN THE SOCIAL SECURITY OR TAX IDENTIFICATION NUMBER OF ANY PERSON OR ENTITY.

**KARR REPORTING, INC.
Aurora, Colorado**


KIMBERLY LAWSON



CLERK OF THE COURT

TRAN

DISTRICT COURT
CLARK COUNTY, NEVADA
* * * * *

THE STATE OF NEVADA,)	
)	
Plaintiff,)	CASE NO. C265107-1,2
)	CASE NO. C283381-1,2
vs.)	DEPT NO. XXI
)	
DIPAK KANTILAL DESAI, RONALD)	
E. LAKEMAN,)	
)	
Defendants.)	TRANSCRIPT OF
)	PROCEEDING

BEFORE THE HONORABLE VALERIE ADAIR, DISTRICT COURT JUDGE

JURY TRIAL - DAY 40

THURSDAY, JUNE 20, 2013

APPEARANCES:

FOR THE STATE:	MICHAEL V. STAUDAHER, ESQ. PAMELA WECKERLY, ESQ. Chief Deputy District Attorneys
FOR DEFENDANT DESAI:	RICHARD A. WRIGHT, ESQ. MARGARET M. STANISH, ESQ.
FOR DEFENDANT LAKEMAN:	FREDERICK A. SANTACROCE, ESQ.
Also Present Telephonically:	NIA KILLEBREW, ESQ.

RECORDED BY JANIE OLSEN COURT RECORDER
TRANSCRIBED BY: KARR Reporting, Inc.

KARR REPORTING, INC.

008114

I N D E X

WITNESSES FOR THE STATE:

MIRIAM J. ALTER

Direct Examination By Mr. Staudaher	5
Voir Dire Examination By Mr. Wright	46
Direct Examination By Mr. Staudaher (Continued)	59
Cross-Examination By Mr. Wright	68
Cross-Examination By Mr. Santacroce	135
Redirect Examination By Mr. Staudaher	182
Recross Examination By Mr. Santacroce	190
Recross Examination By Mr. Wright	195
Further Recross-Examination By Mr. Santacroce	202

DANIEL LEWIS

Direct Examination By Mr. Staudaher	204
Cross-Examination By Ms. Stanish	218
Cross-Examination By Mr. Santacroce	227

YERENY DUENAS

Direct Examination By Ms. Weckerly	229
Cross-Examination By Ms. Stanish	239
Cross-Examination By Mr. Santacroce	241

E X H I B I T S

STATE'S EXHIBITS ADMITTED:

	PAGE
209, 209A, 209B and 209C	232

DEFENDANT'S EXHIBITS ADMITTED:

	PAGE
S-1	120

1 LAS VEGAS, NEVADA, THURSDAY, JUNE 20, 2013, 9:14 A.M.

2 * * * * *

3 (Outside the presence of the jury.)

4 THE COURT: All right. I just wanted to go on the
5 record out of the presence of the jury. We're still waiting
6 for a couple of late arriving jurors.

7 On Mr. Santacrocce's motion to strike the testimony
8 of the last witness, that is denied. While the Court is
9 concerned about the fact the State isn't proving up the
10 numbers, I don't think striking the testimony is the remedy.
11 I think the remedy is for defense to point that out in their
12 argument that the, you know, testimony may be incomplete or
13 inaccurate or confused or whatever it is you want to argue.

14 I don't think the remedy is for the Court to
15 evaluate the testimony and then step in and say because I
16 don't, you know, agree with the way the State presented it
17 that it should be stricken. So that motion is denied, and I
18 would remind the State, who is not listening --

19 MS. WECKERLY: No, I'm listening.

20 THE COURT: -- that, you know, basically you need to
21 confine your arguments to what the testimony actually was, and
22 in your closing arguments to be very mindful of what the
23 testimony was and not deviate from that. So that's all I'll
24 -- my only comment on that. But the motion, the joint motion
25 to strike the testimony is denied.

1 MR. STAUDAHER: And just for the Court, also based
2 on the issue of whether they're -- that document that was
3 attached that she testified to was part of the record. We
4 actually are -- have a photocopy of a .pdf version. We'll
5 have the actual version of a COR production from the company
6 with that document attached as -- as being part of it that we
7 will move to admit to allay that issue.

8 THE COURT: Okay. And then since it's a .pdf
9 version, can you just email that to the other side so they
10 can --

11 MR. STAUDAHER: I think I did already.

12 MS. STANISH: Yeah, we received some --

13 THE COURT: Okay. So you already got that? Okay.

14 MR. STAUDAHER: The actual hard copy is following.
15 It should be here this afternoon --

16 THE COURT: Okay.

17 MR. STAUDAHER: -- or tomorrow. I've got the .pdf
18 now, but I'm -- if -- I'm going to wait to see if we get the
19 actual hard copy by tomorrow to go ahead and -- go ahead and
20 make that as part of the evidence.

21 THE COURT: Okay. And then I think that was the
22 only pending legal issue. Okay. And then as soon as all the
23 jurors get here, we can get started.

24 (Court recessed at 9:17 a.m., until 9:24 a.m.)

25 (In the presence of the jury.)

1 THE COURT: All right. Court is now back in
2 session. The record should reflect the presence of the State
3 through the deputy district attorneys, the presence the
4 defendants and their counsel, the officers of the court, and
5 the ladies and gentlemen of the jury.

6 And the State may call its next witness.

7 MR. STAUDAHER: The State calls Miriam Alter to the
8 stand, Your Honor.

9 THE COURT: All right.

10 MIRIAM J. ALTER, STATE'S WITNESS, SWORN

11 THE CLERK: Thank you. Please be seated. And
12 please state and spell your name.

13 THE WITNESS: Miriam J. Alter; M-I-R-I-A-M, middle
14 initial J, last name Alter, A-L-T-E-R.

15 DIRECT EXAMINATION

16 BY MR. STAUDAHER:

17 Q Dr. Alter, what kind of a doctor are you?

18 A I have a PhD in infectious disease
19 epidemiology.

20 Q And can you give is a little bit about your
21 background and training in that area? Tell us where you went
22 to school, what you've done, that kind of thing.

23 A Okay. Actually, my original degree was
24 Bachelor of Science in nursing from the University of
25 Pennsylvania in 1971. And then went on, actually, to do

1 infection control in hospitals. Went to Johns Hopkins
2 University for my master of public health and PhD in
3 infectious disease epidemiology, and then went to work for the
4 Centers for Disease Control and Prevention in Atlanta, where I
5 worked for 25 years in the division of viral hepatitis. And
6 as an epidemiologist, that meant investigating epidemics,
7 which is, you know, just the term for the -- the formal
8 definition basically.

9 Q Well, let's go -- let's go back to the CDC
10 involvement. So when do you actually go to the CDC?

11 A In 1981.

12 Q And you said you were there for --

13 A 25 years.

14 Q -- 25 years? And it's going to be really hard
15 if we talk over each other, so -- because we have to record
16 this.

17 A Thank you.

18 Q If you let me finish my question, I'll try to
19 let you finish --

20 A No --

21 Q -- your answer.

22 A -- it's okay.

23 Q Okay?

24 A Sorry.

25 Q As we go forward, this time that you said you

1 were in the area of viral hepatitis, did you say?

2 A Yes.

3 Q Was that for the entire 25 years, or --

4 A Yes.

5 Q So you -- I mean, that was your whole area the
6 entire time?

7 A Yes. There are --

8 Q Go ahead.

9 A Yes.

10 Q You started to say there --

11 THE COURT: I'm sorry. Was that yes?

12 THE WITNESS: There are -- it is -- there are five
13 different types of known hepatitis viruses. They're
14 transmitted in different ways, they have different risk
15 factors, so it's like being involved in five different --
16 completely different diseases. And their transmission
17 patterns and their public health interventions are also
18 completely different. And there was technology that evolved
19 during the -- all that time that provided a lot of variation
20 in your day to day activities, so it doesn't -- it wasn't
21 boring at all.

22 BY MR. STAUDAHER:

23 Q You said five different areas within that?
24 Five different viruses; is that right?

25 A Yes.

1 Q Okay. So can you describe for us the
2 differences? And then you said they had different
3 transmission patterns, can you tell us about that?

4 A You're probably familiar with the term
5 hepatitis A, hepatitis B, hepatitis C, you might also have
6 heard of hepatitis D and hepatitis E. And hepatitis is just a
7 non-specific term for inflammation of the liver. And you can
8 have an inflamed liver for many reasons that have nothing to
9 do with infection. You drink too much, you jogged that day, a
10 variety of medications can have a side effect that can infect
11 your liver because your liver detoxifies almost everything
12 that you take into your body. So it's a filter. It's a big
13 filter.

14 And if you have too much of something that is toxic
15 to your body, then the liver can react adversely and it
16 produces chemicals in your blood stream which show that you
17 have liver inflammation or liver disease. And all of these
18 things cause the same symptoms and some of the laboratory test
19 results will be the same. But for infections with these
20 viruses, even though they're all called hepatitis viruses,
21 that's because they all inflame the target organ. Where they
22 go when they first enter the body is to the liver, and that's
23 where they replicate and grow and multiply and then get
24 released into your blood stream. That's it's only
25 commonality.

1 So hepatitis A as you're probably familiar with is
2 very common among young children. It's due to poor hygiene.
3 The route is actually fecal oral, eating contaminated foods,
4 that type of thing, changing diapered children without washing
5 your hands.

6 Q So hepatitis A is not a blood-borne type of --

7 A It can be under very unusual circumstances,
8 but it has a very short period in which the virus is in the
9 blood, so it's unusual. The circumstances under which it's
10 transmitted by blood are unusual and are not part -- are not
11 common -- commonly -- common in the hospital, in the
12 healthcare setting.

13 Q So hepatitis E, if I under -- or, excuse me,
14 A, as I understand it that would be -- the transmission route
15 would be fecal oral from contaminated food and the like, is
16 that fair?

17 A Right. You know, and particularly among
18 contacts in the household where, you know, someone is
19 preparing the meals and, you know, food can get contaminated.

20 Q So what is the next one?

21 A Hepatitis B and hepatitis C are both
22 blood-borne viruses. They're completely different viruses.
23 In fact, all these viruses are completely different. They're
24 only commonality being the term hepatitis. And they're both
25 transmitted by the blood-borne route, which means that virus

1 from the blood of one person goes -- if it gains entrance into
2 the blood stream of another person, it can cause infection.
3 This occurs through breaks in your normal barrier, mucus
4 membrane or skin barriers.

5 So this can happen by, before screening, blood
6 transfusions, injections, contaminated injections both from
7 illegal as well legal drug use, sex are the primary modes of
8 transmission. Now, for hepatitis B, actually, sex is one of
9 the biggest risk factors even though it's a blood-borne virus.
10 And for hepatitis C, direct blood to blood is the most common
11 method, although it is transmitted sexually, as well.

12 Q Is that a lesser component, though, of
13 transmission?

14 A Yes. For C, yes, it is.

15 Q Now, you mentioned the other ones. I think
16 you said D and E, also. What is -- what are they?

17 A Hepatitis D and hepatitis E, again, two
18 entirely different viruses. Hepatitis D is actually -- is --
19 is not as common in the United States, and it's also a
20 blood-borne and sexually transmitted virus. But it's got a
21 problem in its genetic code, and it can only be transmitted
22 along with hepatitis B. So -- but it's not that common. So
23 it has the same transmission modes.

24 Hepatitis E has the same transmission mode as A --
25 see, I told you it was not a boring career -- in that it's

1 transmitted by the fecal oral route. But it's rarely seen in
2 the United States and other western type countries. It's more
3 common in countries that have poor -- really poor sanitation
4 and monsoon rains that then swell the rivers and you've got a
5 lot of refugee camps and the rivers -- the drinking water is
6 downstream from the latrines and you see the point. So they
7 become contaminated and you get large outbreaks.

8 Q I'm going to focus primarily on the hepatitis
9 C aspect of things, maybe B if it -- if it's germane to
10 whatever you need to tell us. But you had mentioned that you
11 did over this 25 year period outbreak investigation; is that
12 -- is that correct?

13 A Yes, that is correct.

14 Q Can you tell us what that means and how you
15 typically go through when you get a call, or how -- how does
16 it happen? How does it work?

17 A Being a federal agency, the Centers for
18 Disease Control and Prevention has to be invited by the state
19 health department to come into the state and investigate
20 whatever it is the state thinks is a problem, unless, of
21 course, those rules are suspended in an emergency. But other
22 than that we usually receive a call from the state or county
23 health department telling us they think they have a problem
24 and they'll describe it to us, and we -- and -- and then after
25 usually a few discussions they will invite us in.

1 And so several -- usually several people from the
2 division that's appropriate for that disease will -- who have
3 been trained in epidemic investigations will go to the state
4 and assist the state and local health departments in the
5 investigation. So you want to confirm that, in fact, they
6 have an outbreak. You want to confirm what the outbreak is
7 due to, in other words you want to confirm the case, the case
8 diagnosis and -- before going any further.

9 Q And before I go any further, I neglected to
10 ask you are you still working at the Center for Disease
11 Control?

12 A No, I am not.

13 Q Where is -- are you still working at all at
14 this point? And when I say that as in an academic or any
15 other setting?

16 A I retired from CDC in 2006 and went to the
17 University of Texas medical branch in Galveston as the Robert
18 E. Shope professorship in infectious disease epidemiology.

19 Q And you were there until what year?

20 A The end of 2011.

21 Q And then did you completely retire, at least
22 from that aspect of your career?

23 A From the -- well, I still teach. I'm an
24 adjunct professor. I teach, I consult, help people with study
25 design and making sure that -- you know, helping them with

1 their methods for researching any kind of disease, which is
2 what epidemiology is. And -- and I also do a little private
3 consulting.

4 Q In this particular instance, I mean, were you
5 asked to consult regarding an outbreak that here occurred
6 locally?

7 A Yes.

8 Q And we'll get to that in a moment, but I want
9 to go back to the -- the beginning, the --

10 A Right.

11 Q -- outbreak investigation that we started
12 with, you know, the process that you go through. You said
13 that one of the things that you do is -- I mean, you being the
14 CDC, and I'm having you wear that hat for the moment, if you
15 would. When you get the information and you decide if you're
16 -- what you're going to do to help the state that's asking for
17 your assistance, you mentioned that you had to do some sort of
18 confirmation or confirmatory testing. Can you describe what
19 that is?

20 A Well, in this particular instance?

21 Q Well --

22 A Or in any --

23 Q -- in general.

24 A -- instance?

25 Q For hepatitis C, let's say.

1 A Actually, in any instance you would want to
2 make sure that the test results were consistent with the
3 diagnosis that you were being told these people had. So you
4 either rely on a formal laboratory report from local health
5 departments, or from the local laboratories, whoever did the
6 testing, as well as usually, if you have time, asking them to
7 send samples to the CDC so the CDC can begin its own testing,
8 just in case additional testing is required.

9 Q So what kind of testing would the CDC do over
10 and above whatever was done locally?

11 A Well, that depends on what was done locally.
12 But for hepatitis C, often the screening antibody test is the
13 only test that can -- may be done initially. And that test
14 needs to be confirmed that it's actually real and not a false
15 positive. And then you want to go on to determine whether or
16 not that person continued to -- had recovered or continued to
17 circulate virus in their blood.

18 Q Do you ever do any kind of genetic sequencing
19 and matching to try and see if you can source the patient, so
20 to speak?

21 A We do, yes. We often are called upon to do
22 genetic sequencing to determine the relatedness of viruses
23 from different patients. Under those circumstances -- under
24 most circumstances we only do that -- see, I still talk like I
25 work at CDC -- we only do that if an investigation is also

1 being carried out.

2 Q Assuming an investigation is being carried
3 out, I know we kind of jumped the gun with that a little bit.

4 A No, that's okay.

5 Q But assuming that has occurred and the testing
6 -- you've confirmed whatever you needed to confirm at that
7 level, now we're onto the genetic sequencing. What kind of
8 information are you trying to get out of that kind of work?

9 A That's really -- you really -- you want to
10 jump that -- because you wouldn't -- you want to jump that

11 far? Q Then let -- then let's back up, then. I don't
12 want to jump that far.

13 A Okay.

14 Q So let's go back to the investigation stage
15 and let's pick up where we left off and you continue on.

16 A Okay. So -- so we arrive, you know, and we
17 look at the information about the cases that they already know
18 about. And then we try and identify additional cases from a
19 variety of sources. In this particular disease, many people
20 don't show any symptoms initially. So it's really hard. So
21 you may not get a lot of clinical case reports, but there may
22 be some that were overlooked. And you -- so you'll do a
23 variety of surveillance over on different day to day basis or
24 by surveying physicians most likely to see people with
25 hepatitis and determine if there are additional individuals.

1 Most importantly, however, you then interview or at
2 least review the records of these patients to determine their
3 characteristics. What is it about them that might be common?
4 Are they -- you know, this is the first thing you want to do.
5 You want to find out everything you can just about the cases
6 you know about because that will allow you to generate
7 hypotheses that you can then test with your studies, with the
8 study you're going to end up performing.

9 Q Okay. So you -- you go through that process.

10 A Right.

11 Q What would be the next logical step, then?

12 A Well, then because of the disease being non --
13 subclinical in a lot of cases, meaning people don't have any
14 symptoms, they -- we would -- if we can focus in, in this
15 instance you can usually -- you can focus in on two days, one
16 a date in September and a date in July.

17 And so you then want to test all the patients who
18 had procedures around that area to see if you can identify
19 additional infections. Which the more cases you have, the
20 more you have to analyze, the more robust, in essence, your
21 analysis is, not with respect to the laboratory sequencing,
22 but with the epidemiological analysis. And I'll explain that.

23 So we would go and focus in on what we think might
24 be the exposure period and what was common to the patients, in
25 this case it was those two days, and attempt to identify the

1 infection status of all the patients before, during, after to
2 see if we could identify additional infections.

3 Q Okay. And once you start going through that
4 process?

5 A After we've done that, and you never get
6 everybody, after you do that then you start looking at the --
7 in this case since the only common factor among the original
8 cases was -- were their procedures at this particular clinic,
9 you're going to look at the clinic and what all of those
10 patients had in common during their procedures while they were
11 at the clinic.

12 And you -- and then you start thinking about, well,
13 what exposures would cause blood-borne transmission?
14 Remember, blood has to get into the blood stream of a
15 susceptible individual. So it has to -- there are only
16 certain ways that can happen. So it has to get through your
17 natural barriers of skin or mucous membrane.

18 And so you start generate -- so you then -- you look
19 at all the clinic's procedures and you observe the procedures
20 that might be an issue or different exposures that might --
21 and you go through everything written, procedures, you
22 interview the staff, you interview the patients, and you
23 observe and you read the -- yeah, and you observe. And then
24 that helps you focus your formal study, which will compare
25 infected patients with uninfected patients to see what was

1 different. And that -- that's the essence of epidemiological
2 methods. And can I give an example that might be --

3 Q Sure.

4 A A new drug, someone is developing a new drug
5 to treat diabetes, let's say. So in order for the drug to be
6 licensed by the FDA, they have to test it to make sure that it
7 works and that it's safe. But let's just go to the work part.
8 In order -- they need to show that if they treat people with
9 diabetes with this drug they get better more often than if
10 they're not treated with that drug, okay. But it's never 100
11 percent. I mean, in other words, no drug is 100 percent
12 effective.

13 So let's say they treat people with a certain type
14 of diabetes with this drug and 60 percent get better. But of
15 the people who weren't treated with the drug, only 10 percent
16 got better. Well, that's a pretty big gap. And, you know,
17 it's a very simple explanation, but you can -- you know,
18 that's in the news all the time about -- nothing is ever 100
19 percent is the point.

20 And so you can see that the drug actually did have
21 an effect, even though -- on people who took it versus people
22 who didn't with the same disease. So that's an example of
23 what you are doing here. You are comparing the types of
24 exposures patients who got infected with had versus patients
25 who didn't get infected. What's different?

1 Q So what kinds of things in a -- and you know
2 the setting that we're talking about.

3 A Yes.

4 Q An endoscopy clinic, outpatient setting,
5 patients having basically two types --

6 A Right.

7 Q -- of procedures.

8 A So obviously you're going to look at the date
9 of the procedure, you're going to look at the timing of the
10 procedure compared with everything you know about the
11 infection status of the patients who had the procedures during
12 the time period of interest. You're going to look at specific
13 procedures such as the type of procedure they had, what scope
14 was used, what the -- what medications they received, how they
15 received them, and the process of giving them the medications.
16 You'll look at the staff members who were assigned to those
17 individuals. You'll look at the timing of the cases relative
18 to the potential source patient because presumably you had to
19 have a source patient, someone who was infected in order to
20 serve as a source for transmission to other patients.

21 Q Along those lines, I mean, do you -- when you
22 look at various things related to -- and let's -- let's talk
23 about an endoscopy clinic type thing, what types of things
24 would you look at as possible modes of transmission in that
25 setting?

1 A Well, the first thing people look at are the
2 scopes themselves to see if they've been properly disinfected
3 between patients. And -- as well as what type of procedure
4 the person had. Because if you have an upper GI versus a
5 lower GI, they're two different scopes. So someone who gets a
6 colonoscopy has a scope that's completely different from
7 someone who gets an upper -- an upper GI. So even if the
8 records were not accurate, you would know that the same scope
9 was not used. Plus, it requires time to perform high-level
10 disinfection on each of the scopes that are used.

11 So basically the first thing you would do besides
12 looking at the procedure for disinfect -- cleaning and
13 disinfection of each scope is what procedures the patients had
14 and compare the frequency, let's say, of colonoscopy in the
15 infected patients versus the frequency with which uninfected
16 patients had that procedure, the frequency of biopsy in the
17 infected patients versus the frequency of biopsy in the
18 control patients, and whatever else is involved, let's say, in
19 -- you know, that might be unique to these procedures.

20 And what you're looking for is a -- well, when I say
21 a statistically -- a statistical, significant -- significant
22 statistical difference between the frequency in the infected
23 and the frequency in the uninfected to point you in the right
24 direction, point you in the direction of where the
25 contamination might have originated.

1 In this situation it was not the scopes because the
2 frequency of procedures, the different procedures were not
3 different between infected patients and uninfected patients.

4 MR. SANTACROCE: Objection as to that conclusion.
5 If she's making a personal opinion, that's fine. But if she's
6 making a definitive statement as to the legal conclusion, I
7 object to that.

8 THE COURT: All right. Well, I think it's clear
9 it's her opinion as to --

10 MR. STAUDAHER: Yes.

11 THE COURT: -- based on reviewing the records.
12 Correct?

13 THE WITNESS: That's correct.

14 THE COURT: Okay.

15 BY MR. STAUDAHER:

16 Q And you're not here to make legal conclusions;
17 correct?

18 A No, I'm here for science --

19 Q So you're just going to --

20 A -- and medicine.

21 Q -- tell us what you know based on your
22 analysis and 25 years of doing this --

23 A Yes.

24 Q -- is that fair? Okay.

25 THE COURT: And, ladies and gentlemen, at the

1 conclusion of the trial when I give all of the instructions,
2 there will be an instruction pertaining to this type of
3 testimony, which will cover not only testimony you've heard
4 from this witness, but, you know, other witnesses that we've
5 heard through the course of the trial. And it will describe
6 -- I'm not going to paraphrase the instruction because I get
7 in trouble for doing that, or could get in trouble.

8 So, Mr. Staudaher, go on.

9 MR. STAUDAHER: Thank you.

10 BY MR. STAUDAHER:

11 Q So at least your opinion based on the issue of
12 the scopes was that it was not the scopes in this case?

13 A From an epidemiological point of view, it was
14 not the scopes.

15 Q Now, there were other areas. You mentioned
16 biopsy forceps, things like that.

17 A There was no difference in the frequency with
18 which the patients who were infected got biopsies compared
19 with patients who were not infected. Now, often an overall
20 comparison like that might not show you -- might not show
21 anything. And based on observations and information that you
22 get while you're there, you might say to yourself, well, I
23 don't know, I don't feel like I've looked at this sufficiently
24 and you might then want to, you know, cut it down into
25 different categories like that morning, that afternoon, or the

1 next day, or by a certain person, you know, to see if these
2 procedures, for example, either the scope or the biopsy had
3 any relationship to the infections on a smaller scale or a
4 different scale just to make sure that you've covered your
5 bases.

6 Q Okay. Did you see anything along those lines
7 that cause you concern?

8 A No.

9 Q So at least from that perspective the same
10 analysis for the scopes and the snares, did that, is it fair
11 to say, eliminated those as --

12 A Yes.

13 Q -- transmission possibilities?

14 A Yes.

15 Q What about the issue of cleaning? What if it
16 was not what was believed to be the case?

17 A Well, despite -- even though they did cite
18 some -- some small, minor deficiencies, their high-level --
19 their cleaning and disinfection of the scopes was according --
20 was very strictly followed.

21 Q So --

22 MR. SANTACROCE: I'm sorry. I didn't hear that.
23 Very strictly what?

24 THE WITNESS: Followed.

25 MR. SANTACROCE: Followed.

1 BY MR. STAUDAHER:

2 Q According to the records and so forth that you
3 reviewed; right?

4 A Yes.

5 Q What if that had not been the case? What if
6 the scope cleaning had been less than, well --

7 A Optimal?

8 Q Optimal. That's a good word.

9 A Well, one, you would have made them change,
10 and, two, you would have -- you're looking at it, but still
11 you'd have to consider the epidemiological -- see, to me,
12 that's very -- epidemiology is a very powerful tool all by
13 itself. And if it's done right, when you can make that
14 comparison of patient, the frequency of a procedure in -- in
15 the infected patients versus those who didn't get infected and
16 you see absolutely no difference, then even though
17 disinfection may not have been ideal, you've got to look
18 elsewhere. You have to look elsewhere for other types of
19 exposures. And, in fact, I don't think we've ever had an
20 actual outbreak related to -- of a blood-borne virus related
21 to the scope itself.

22 Q Let me talk to you about the --

23 A At least hepatitis C anyway.

24 Q Since you've done this for -- for quite some
25 time, are you familiar with the literature in the area?

1 A Yes.

2 Q And when I say that, I mean records of and
3 reports of infections across the United States.

4 A Yes.

5 Q For many years?

6 A Yes.

7 Q Have you actually been involved in outbreak
8 investigations pertaining to endoscopy type clinics or centers
9 or transmissions in that setting?

10 A Yes.

11 Q Have you done a number of them in that regard?

12 A Yes.

13 Q Now, as far as the investigation, I mean, I
14 imagine that over the 25 years that you were there that your
15 role at least in the process maybe changed a little bit,
16 supervisor, actually in the trenches, that kind of thing, is
17 that fair?

18 A That's fair.

19 Q Did you actually go out and do investigative
20 work at some stage of your career?

21 A Yes. Early in my career, which is true for
22 everybody at CDC, you get to go out and actually do the
23 investigations. And as you remain at CDC and keep getting
24 promoted, then you're in a supervisory capacity and on the
25 phone usually every day with your what we call epidemic

1 intelligence service officers who are sent out, you know, who
2 are the ones you're supervising who are actually onsite doing
3 the investigations.

4 Q So what is the purpose of that interaction
5 that you have with the people that were actually in the field
6 once you're in that role as a supervisor?

7 A Well, presumably we know more than they do
8 because they're young and we're not, and we have a lot of
9 experience. And so we're making sure that they are getting
10 all the information they should be getting, they're drawing
11 the proper conclusions, they're doing the types of comparisons
12 that they need to do, that they've covered all the bases that
13 they need to cover at each step along the way because you
14 don't want to have to go back.

15 Q So if you are -- if you have somebody even
16 that's relatively new in the field, a year or less, whatever,
17 and you're having communication with that person, I mean, how
18 does that -- how does that work? What do they -- what kinds
19 of things do they tell you and then what do you respond as far
20 as follow up?

21 A If they're listening to me or not?

22 Q Well, I mean, is there a way to determine if
23 they listened to you? Do you follow up --

24 A If they're listening to me --

25 Q --and say did --

1 A -- then they --

2 Q -- you do that?

3 A Well, hopefully they're, you know, on the
4 right track. They'll be telling me -- first they're telling
5 me all about the cases, and they're going to be telling me how
6 they're going about identifying the steps that I described
7 earlier. I want to hear that they've done all those --
8 they've gone through all those steps and what the results have
9 been, okay. And so if anywhere along the way I think that
10 they need to delve further, I will tell them to do that.

11 Q And then do you ask them in follow up what was
12 the result of that?

13 A Absolutely. And then as they start to -- when
14 they generate -- for example, then they're going to have to
15 design a question of some type. So they'll send it to us,
16 email is a wonderful thing, and we will look it over and offer
17 suggestions. And probably they've taken some examples of
18 questionnaires used in previous outbreaks with them, as well
19 as publications of previous outbreaks to help them, you know,
20 along the way, and they'll revise it and, you know, use that.
21 And then we'll decide upon it together upon a method of study,
22 how the study will be conducted to determine the source of the
23 outbreak, the extent of the transmission, and what we need to
24 do to prevent it, either prevent it from continuing or prevent
25 it from occurring someplace else.

1 Q Whether you've been in situation where you're
2 a supervisor or actually in the field doing the actual
3 investigative work, do you -- as part of your epidemiologic
4 investigation, do you ever have a situation where you see
5 something that is -- you know, you've got your, I assume, your
6 likely causes, or the possibilities anyway for a situation
7 like we're talking about here, correct, as far as how it would
8 actually occur?

9 A Right.

10 Q If you see one of those things in practice,
11 you're out there and you see them do something like that, do
12 you stop there, or do you continue to look at other things to
13 make sure?

14 A You continue to look at everything that could
15 possibly be a cause. And this actually has been an issue
16 between supervisors and young investigators. Because the
17 young investigator who hasn't completed their training in
18 epidemiology will say, well, it's so obvious, you know, it was
19 this or that. And we'll say, no, you have to do the study.
20 You have to show definitively that it was this or at least,
21 you know -- you have to show that it was likely this versus
22 something else in order for your investigation to be useful.

23 Q Is that invariable in all cases that you go
24 through that process?

25 A Yes.

1 Q Okay. Have you ever been involved in a case
2 where you did not go through that process, you just
3 shortchanged it and --

4 A Not at the CDC, no. Not when the CDC was
5 involved onsite, no,

6 Q Now, as far as the literature that you
7 described or that you said that you have at least been aware
8 of over the years, I mean, are we talking about one, two,
9 three studies? I mean, how many studies are we talking about?

10 A That I'm aware of, hundreds, but that I've
11 been involved in, many. But, you know, since -- especially in
12 the last decade, 10 to 15 years because they've been
13 increasing in -- there's been an increased reporting of these
14 episodes of transmission in outpatient healthcare settings.
15 So it's many. I don't know how many, but many.

16 Q Does that have to do with anything related to
17 whether testing was available back then versus now?

18 A I think -- I think that for hepatitis C it is
19 -- there's an increased awareness, and also I think a health
20 department that identifies a case that tests positive may be
21 -- and the only -- and someone without traditional risk
22 factors might be more likely to call us and say we have this
23 case that might have had a healthcare exposure, but we don't
24 know. Whereas, now that we have the ability to go in and test
25 people so we can determine the extent of the problem as

1 opposed to relying on just clinical symptoms probably makes it
2 more likely that they will report it or recognize it.

3 Q With regard to those studies, have -- and I'm
4 talking about the -- not necessarily just the ones you've been
5 involved with --

6 A Right.

7 Q -- but the hundreds of studies that you've --
8 you've looked at over the years, have a number of those been
9 in areas involving colonoscopy, endoscopy, that kind of thing,
10 in a -- in a setting where those kind of procedures are done?

11 A Yes, a number have been.

12 Q Have you been directly involved in any of
13 those?

14 A Yes, I have. In fact, directly involved in
15 the first one we ever investigated for hepatitis C.

16 Q Can you tell us about that one?

17 A That one occurred in New York City.

18 Q And the year, roughly, if you know?

19 A 2001.

20 Q Okay.

21 A And it was actually interesting because four
22 people developed acute symptoms of hepatitis, symptoms of
23 hepatitis and were actually hospitalized. And they were
24 middle-aged people without traditional risk factors. And it
25 just so happens that the gastroenterologist on call that

1 weekend was their gastroenterologist and he recognized that
2 all four of them had had procedures at his -- in his practice,
3 at his private practice. And so he called the health
4 department and reported it. And that was the initiation of
5 the investigation.

6 And what we found is that these four patients had
7 procedures over a three-day period. It was actually about 48
8 hours, but a span of three days. And so we -- in order to
9 look for more patients in addition to existing data, like
10 surveillance, etcetera, we chose that week before, during, and
11 after those three days to find as many patients as we could
12 and test them to determine if we had any other infections.

13 And to make a long story short, we did find a source
14 patient. Someone known to be chronically infected who had the
15 first procedure of the day on the first of those three days.
16 And we found -- and then we found that all of the patients who
17 became infected, newly infected, followed that patient, but
18 also over a 48-hour period. So they began on different days.
19 They had their procedure on different days, but consecutively.

20 And after an intensive investigation in which we
21 compared all types of exposures, including the scopes and the
22 injection practices, the anesthesiology, the sedatives, we
23 couldn't identify a difference, something that stuck.
24 Everybody -- the procedures and writing were correct, the
25 observation of personnel actually performing procedures was

1 correct. There were some problems with the high-level
2 disinfection, but nothing that would -- everybody had a
3 different procedure, particularly the source patient had a
4 colonoscopy and the next infected patient -- next patient to
5 become infected did not.

6 So, you know, there were a lot of -- they just --
7 there was not commonality. And because everyone gets sedation
8 from, you know, the same sedation, you really can't -- you
9 can't compare them with respect to that. And so on the last
10 day that the team was there it was suggested to them that they
11 might want to look at the purchasing records for needles and
12 syringes for the anesthesiologists. And they did.

13 And they found that while the IV catheters, number
14 of IV catheters coincided with the number of patients who had
15 procedures, not one to one, but close, however, the number of
16 needles ordered compared with the number of procedures didn't
17 even come close. So there were like 600 needles, new, you
18 know, sterile needles ordered that attach to syringes compared
19 with, I don't know, over 2,000 procedures.

20 And since we know that patients got multiple doses
21 of sedation during their procedure, they should have been
22 using a sterile needle, especially because they had multiple
23 dose vials. In this case it was a different type of sedative
24 than the one involved here which actually comes in multiple
25 dose vials, but the anesthesiologist had denied reusing

1 syringes and needles. Well, this suggested that, in fact,
2 that was not true.

3 And when confronted with the purchasing information,
4 the anesthesiologist admitted to reusing syringes and needles
5 on one patient, discarding the syringe and -- and going back
6 into a multi-dose vial with the same needle and syringe that
7 he used to inject that one patient with subsequent dosages --
8 doses of sedative, and then that multi-dose vial was then used
9 for the next patient, with a new sterile syringe and needle.
10 But that vial was now contaminated, presumably contaminated.
11 And it turns out that they had just switched to large vials of
12 this particular sedative.

13 And we were able to show that if -- if a new vial
14 had been opened on the day for the first patient who was the
15 source of the outbreak, it would have let -- given the average
16 dose that the patients received of this particular drug, would
17 have lasted the 48 hours or over the three-day period that the
18 patients became infected. And -- and the procedure was that
19 these vials would be used if they were -- if they were not
20 used up at the end of the day, they were kept for the next
21 day.

22 So it was actually only that way that we were able
23 to determine that in fact there were unsafe injection
24 procedures being used in the clinic that put patients at risk
25 of -- of transmission. It was the only thing we could

1 identify, and, it turns out, is a common problem. Much more
2 common than we'd like to believe.

3 Q So when you looked at that, I mean, that's
4 2001. I mean, that information gets published, I assume?

5 A Yes.

6 Q Okay. So 2001, fast-forward to you and this
7 case today, did you see similarities, striking similarities
8 between the two cases?

9 A This -- these practices of reusing needles and
10 syringes or even just syringes and contaminating vials that
11 are then used on subsequent patients is -- has been the source
12 of many outbreaks, and continue to be primarily, but not
13 exclusively, in outpatient settings.

14 Q So in the studies you've looked at in
15 outpatient settings, just so I'm clear, this issue of
16 contaminated multi-use vial being used on the next patient
17 kind of thing is something that has been reported multiple
18 times --

19 A Right.

20 Q -- before?

21 A Yes, it has.

22 MR. SANTACROCE: I'm going to object. Asked and
23 answered. Your Honor, can we approach?

24 THE COURT: Sure.

25 (Off-record bench conference.)

1 THE COURT: All right. Mr. Staudaher, please
2 proceed.

3 MR. STAUDAHER: Thank you, Your Honor.

4 BY MR. STAUDAHER:

5 Q And I'm not even sure where we left off, but
6 I'll try to pick up. I was -- at one point I was asking you
7 about the various studies related to these types of clinics.
8 Are you with me again?

9 A Yes.

10 Q This type of thing, the 2001 study that you
11 mentioned, as well as your review of this particular case, are
12 there other like outbreaks that have occurred with similar
13 results?

14 A Yes.

15 Q Okay. And in the studies that you have looked
16 at over the years, I think if I -- I just want to make sure
17 the -- the scope issue that you mentioned, has that ever been
18 shown to be a source of transmission in any of those?

19 A No.

20 Q What about some of the other items that were
21 -- that were looked upon by the CDC as possible modes of
22 transmission?

23 A No. The only -- other than an infected
24 healthcare worker who was abusing narcotics and therefore
25 contaminated a multi-dose vial of a narcotic by self injecting

1 and then contaminating the -- you know, using the contaminated
2 needle and syringe so that it was the healthcare worker's
3 virus that was transmitted from patient to patient. Other
4 than that, all of them have been the result of what we now
5 refer to as unsafe injection practices.

6 Q Can you describe for us what you -- what you
7 view as an unsafe injection practice?

8 A Well, anything that enters the body through
9 your normal barrier, skin or mucus membrane, should be
10 sterile. You would expect to go into an operating room and
11 everything that they use would be sterile if it was entering
12 your body, and injections are no different. And so once a
13 needle and syringe have been used to access your blood,
14 whether it be through IV tubing or direct, you know, through a
15 vaccine injection or something, it's now contaminated. It's
16 no longer sterile.

17 So if you reuse it on the same patient with the same
18 medication, that's fine. But if you reuse it and any part of
19 that is used on another patient, you've broken the barrier of
20 sterility and that next patient is exposed to a non-sterile
21 product.

22 Q In the -- in the literature and training and
23 so forth, and I'm talking about primarily here nurses, nurse
24 anesthetists, things like that, are you familiar with the
25 training that those individuals go through on that issue?

1 A Yes.

2 Q Can you tell us about that?

3 A Nursing, when you go to nursing school, no
4 matter what school you go to, they actually have in textbooks
5 and in practice a curriculum that specifically addresses the
6 safe way to provide injections or injectable therapy, whether
7 it be directly, you know, into your -- you know, like by
8 vaccine or through an intravenous setup of some type, and
9 they're very specific about the fact that these practices must
10 be what we say must conform to aseptic technique. Aseptic
11 meaning the lack of any contamination.

12 Q So is it fair to say that in that information
13 that you've reviewed, the textbooks and the like, is that part
14 of the basic training?

15 A Yes, it's part of basic nursing training.

16 Q With regard to that, even though there are
17 outbreaks that have occurred over time, is that information
18 continuing to be disseminated on each one of these outbreaks?

19 A Yes, the information continues to
20 disseminated.

21 Q So not only in training. I mean, I'm talking
22 about the textbook kind of thing.

23 A I must -- I may have misunderstood your
24 question. When you say after the outbreak -- when we do the
25 outbreak investigation, we then disseminate the information

1 that unsafe practices are being used and this is what you
2 should do. But in a continuing medical education you mean?
3 Like yearly --

4 Q Actually, the first part is what I was asking.
5 After an outbreak --

6 A We publicize in various ways what it is that
7 people are doing and what they -- what they're doing wrong and
8 what they should be doing.

9 Q So I want to ask you about another outbreak,
10 if you're familiar with it. In August of 2002 in Oklahoma
11 there was another outbreak of hepatitis C related specifically
12 to actions of a CRNA. Are you familiar with that?

13 A Yes.

14 Q Can you tell us about that?

15 A Is this the pain clinic or the oncology
16 clinic?

17 Q If there's a document that you need to refresh
18 your memory, I can provide it to you.

19 A Just -- yes, would you mind? I'm just like --
20 right now I just --

21 MR. STAUDAHER: May I approach, Your Honor?

22 THE COURT: Sure.

23 MR. STAUDAHER: And, counsel, I'm showing the MMWR,
24 Morbidity and Mortality Weekly Report, September 26, 2003,
25 Volume 52, Number 38.

1 MR. WRIGHT: Thank you.

2 BY MR. STAUDAHER:

3 Q And this is page, I believe, 903 of that.

4 A Okay. It was the pain -- pain clinic.

5 Q If you -- if you need a moment to look at that
6 you can do so and then I'd like to ask you a couple of
7 questions.

8 A Oh, yes.

9 Q Okay. Can you tell me about this?

10 A In this instance the -- this was a pain
11 remediation clinic where people go to get pain meds for
12 chronic pain, like back pain and a variety of other maladies.
13 And the individual providing -- who was providing the pain
14 medication to these patients through a heparin lock, actually,
15 which is -- you've probably already heard that described --
16 with a -- filled a large syringe with the pain medication, and
17 then went from one patient to another with the same syringe
18 and injected them with the appropriate amount.

19 I think the same needle, too. That I'd have to
20 double check; regardless, from one patient to the next using
21 the same syringe which was filled with the pain medication
22 until it was empty. And they could trace the infections that
23 were transmitted by virtue of who was there that day, what bed
24 they occupied, etcetera.

25 Q So another unsafe injection practices

1 outbreak?

2 A Yes.

3 Q And in that same article, I can bring it up to
4 you again if you need to, was there a dissemination of that
5 information through the actual organization of CRNAs at that
6 time?

7 A Yes.

8 Q I mean, nationwide dissemination?

9 A Yes.

10 Q Now, related specifically to some other
11 articles that you may be familiar with, and the next article I
12 want to ask you about is a entitled -- for counsel -- multiple
13 clusters of hepatitis C virus infections associated with
14 anesthesia for outpatient endoscopy procedures. And I think
15 one of the officers is -- excuse me, authors, is a Bruce
16 Gutelius?

17 A Uh-huh.

18 Q I don't know if I pronounced that correctly.
19 Can you tell us what this is about?

20 A A case of acute hepatitis C was identified
21 and, in fact, possibly more than one by the clinician, again,
22 who noticed that the only commonality between the patients was
23 procedures at this particular -- at actually two different
24 gastroenterology practices. And when they did the
25 investigation, actually, the transmission involved both

1 hepatitis B virus as well hepatitis C virus. So they had
2 clusters in each clinic setting with both viruses.

3 And in this instance it was a similar scenario in
4 which a -- they were reusing syringes, but needless. You
5 know, they now have needless devices so that healthcare
6 workers are protected from sticking themselves, essentially,
7 and so you're only using the syringe.

8 And they put a vent -- they put a little spike in
9 the multi-dose vial, although this might have been
10 single-dose, but multi-dose vial and they stick the syringe in
11 and then they pull out the medication and then they -- the IV
12 may also be needless, in which you can inject just directly
13 with the syringe. And the syringe was being reused on the
14 same patient to get additional doses, and even though it was
15 discarded and a new syringe used for the next patient, the
16 vial was already contaminated from the source patient.

17 Q So -- and I've got the article here if you
18 need to look at it. It appears as those propofol was the
19 drug.

20 MR. WRIGHT: Where was that?

21 THE COURT: That is this article here.

22 MR. WRIGHT: Which -- no, I mean, which city?

23 THE WITNESS: New York City.

24 MR. WRIGHT: Okay. A different New York one?

25 THE WITNESS: Pardon?

1 MR. WRIGHT: A different New York one than the first
2 one?

3 THE WITNESS: Yes, but a different one.

4 MR. WRIGHT: Thank you.

5 THE WITNESS: It occurred much more recently.

6 BY MR. STAUDAHER:

7 Q As a matter of fact, the date of this article
8 is -- it looks like it was published in 2010, but it's talking
9 about a report in 2007, March of 2007; is that correct?

10 A Yes.

11 Q And I don't want to -- if you need to look at
12 it --

13 A No, it's -- usually there's quite a lag
14 between.

15 Q Okay. So it's not unusual --

16 A But although, is that the -- no, you're
17 looking at the actual publication. It was probably in an MMWR
18 prior to that.

19 THE COURT: Why don't you show it to her so we can
20 make sure --

21 THE WITNESS: Sorry.

22 THE COURT: -- that --

23 MR. STAUDAHER: It's okay.

24 THE COURT: -- it's correct.

25 THE WITNESS: No, that is -- those are the dates.

1 BY MR. STAUDAHER:

2 Q Okay. Yes.

3 A Yes, those are the dates of publication and
4 when the outbreak occurred.

5 Q March of 2007 outbreak, publication 2010?

6 A Yes, in a peer reviewed journal.

7 Q Will you confirm that -- that it was propofol?

8 A Yes.

9 Q Yes, it was?

10 A Yes, it -- I'm sorry. I tend to be long
11 winded, so I try and be short. Yes, it was a single patient
12 use vial of propofol for multiple patients with reuse of
13 syringes to re-dose patients.

14 Q So, again, some --

15 MR. SANTACROCE: I'm going to -- I need a
16 clarification. If you're reading, I'd like to know what
17 you're reading -- where you're reading from exactly.

18 THE WITNESS: Actually, right now I'm just reading
19 from the abstract, but I just read this article again for the
20 10th time last night.

21 MR. SANTACROCE: Well, it appeared to me you were
22 reading an answer from that document. If that is, in fact,
23 the case I'd like to know which page.

24 THE WITNESS: Okay.

25 THE COURT: Is it the front page that --

IN THE SUPREME COURT OF THE STATE OF NEVADA

Electronically Filed
SEP 02 2014 09:17 a.m.
Tracie K. Lindeman
Clerk of Supreme Court

DIPAK KANTILAL DESAI,)	CASE NO. 64591
)	
Appellant,)	
)	
vs.)	
)	
THE STATE OF NEVADA,)	
)	
Respondent.)	
_____)	

APPELLANT'S APPENDIX VOLUME 35

FRANNY A. FORSMAN, ESQ.
Nevada Bar No. 000014
P.O. Box 43401
Las Vegas, Nevada 89116
(702) 501-8728

RICHARD A. WRIGHT, ESQ.
Nevada Bar No. 000886
WRIGHT, STANISH & WINCKLER
300 S. Fourth Street, Suite 701
Las Vegas, Nevada 89101

Attorneys for Appellant

STEVEN S. OWENS
Chief Deputy District Attorney
Nevada Bar No. 004352
200 Lewis Avenue
Las Vegas, Nevada 89155
(702) 671-2750
Attorney for Respondent

INDEX TO APPENDIX VOLUMES 1 through 41

<u>DOCUMENT</u>	<u>VOL.</u>	<u>PAGE(S)</u>
Indictment	1	000001-000042
Amended Indictment	1	000043-000084
Court Minutes 7/21/10	1	000085
Court Minutes 2/08/11	1	000086
Finding of Competency	1	000087-000090
Recorder's Transcript - Hearing: Video Deposition Tuesday, March 20, 2012	1	000091-000129
Indictment (C-12-283381 - Consolidated Case)	1	000130-000133
Second Amended Indictment	1	000134-000176
Third Amended Indictment	1	000177-000212
Defendant Desai's Motion and Notice of Motion for Competency Evaluation	1	000213-000229
Recorder's Transcript - Hearing Re: Defendant Desai's Motion for Competency Evaluation Status Check: Experts/Trial Readiness (All) Tuesday, January 8, 2013	1	000230-000248
Fourth Amended Indictment	2	000249-000284
Notice of Motion and Motion to Use Reported Testimony	2	000285-000413
Reporter's Transcript Re: Status Check: Experts (All) Thursday, March 7, 2013	2	000414-000440

<u>DOCUMENT</u>	<u>VOL.</u>	<u>PAGE(S)</u>
Defendant Desai's Opposition to State's Motion to Admit Foreign Documents Relating to Rodolfo Meana	2	000441-000445
Order	2	000446-000449
Court Minutes 3/21/13	2	000450
Defendant Desai's Opposition to State's Motion to Use Reported Testimony	2	000451-000454
Court Minutes 3/26/13	2	000455
Independent Medical Evaluation, 4/14/13 Filed Under Seal - Separately	2	000456
Reporter's Transcript - Calendar Call (All) State's Motion to Admit Evidence of Other Crimes Tuesday, April 16, 2013	2	000457-000497
Fifth Amended Indictment	3	000498-000533
Reporter's Transcript - Jury Trial Day 7 Friday, May 3, 2013	3	000534-000622
Reporter's Transcript - Jury Trial Day 8 Monday, May 6, 2013	3 & 4	000623-000773
Reporter's Transcript - Jury Trial Day 9 Tuesday, May 7, 2013	4 & 5	000774-001016
Reporter's Transcript - Jury Trial Day 10 Wednesday, May 8, 2013	5	001017-001237
Reporter's Transcript - Jury Trial Day 11 Thursday, May 9, 2013	6 & 7	001238-001517

<u>DOCUMENT</u>	<u>VOL.</u>	<u>PAGE(S)</u>
Reporter's Transcript - Jury Trial Day 12 Friday, May 10, 2013	7 & 8	001518-001784
Reporter's Transcript - Jury Trial Day 13 Monday, May 13, 2013	8 & 9	001785-002061
Reporter's Transcript - Jury Trial Day 14 Tuesday, May 14, 2013	9 & 10	002062-00
Reporter's Transcript - Jury Trial Day 15 Wednesday, May 15, 2013	10 & 11	002303-002494
Reporter's Transcript - Jury Trial Day 16 Thursday, May 16, 2013	11 & 12	002495-002713
Reporter's Transcript - Jury Trial Day 17 Friday, May 17, 2013	12 & 13	002714-002984
Reporter's Transcript - Jury Trial Day 18 Monday, May 20, 2013	13 & 14	002985-003247
Reporter's Transcript - Jury Trial Day 19 Tuesday, May 21, 2013	14 & 15	003248-3565
Reporter's Transcript - Jury Trial Day 20 Wednesday, May 22, 2013	15 & 16	003566-003823
Reporter's Transcript - Jury Trial Day 21 Thursday, May 23, 2013	16 & 17	003824-004014
Reporter's Transcript - Jury Trial Day 22 Friday, May 24, 2013	17	004015-004185
Reporter's Transcript - Jury Trial Day 23 Tuesday, May 28, 2013	18	004186-004384

<u>DOCUMENT</u>	<u>VOL.</u>	<u>PAGE(S)</u>
Reporter's Transcript - Jury Trial Day 24 Petrocelli Hearing Wednesday, May 29, 2013	19	004385-004510
Reporter's Transcript - Jury Trial Day 24 Afternoon Session Wednesday, May 29, 2013	20	004511-004735
Reporter's Transcript - Jury Trial Day 25 Thursday, May 30, 2013	21	004736-004958
Reporter's Transcript - Jury Trial Day 26 Friday, May 31, 2013	22	004959-005126
Reporter's Transcript - Jury Trial Day 27 Friday, June 3, 2013	22 & 23	005127-005336
State's Exhibit 18 - Meana Death Certificate Admitted 6/3/13	23	005337-005345
Reporter's Transcript - Jury Trial Day 28 Tuesday, June 4, 2013	23 & 24	005346-005611
Reporter's Transcript - Jury Trial Day 29 Wednesday, June 5, 2013	24 & 25	005612-005885
Reporter's Transcript - Jury Trial Day 30 Thursday, June 6, 2013	25 & 26	005886-006148
Reporter's Transcript - Jury Trial Day 31 Friday, June 7, 2013	27 & 28	006149-006430
Reporter's Transcript - Jury Trial Day 32 Monday, June 10, 2013	28	006431-006641
Reporter's Transcript - Jury Trial Day 33 Tuesday, June 11, 2013	29 & 30	006642-006910


<u>DOCUMENT</u>	<u>VOL.</u>	<u>PAGE(S)</u>
Reporter's Transcript - Jury Trial Day 34 Wednesday, June 12, 2013	30 & 31	006911-007143
Reporter's Transcript - Jury Trial Day 35 Thursday, June 13, 2013	31	007144-007382
Reporter's Transcript - Jury Trial Day 36 Friday, June 14, 2013	32	007383-007619
Reporter's Transcript - Jury Trial Day 37 Monday, June 17, 2013	33	007620-007827
State's Exhibit 228 - Table 20-1 - Modes of Transmission and Sources of Infection Considered Admitted 7/17/13	33	007828
Reporter's Transcript - Jury Trial Day 38 Tuesday, June 18, 2013	34	007829-008038
Reporter's Transcript - Jury Trial Day 39 Wednesday, June 19, 2013	35	008039-008113
Reporter's Transcript - Jury Trial Day 40 Thursday, June 20, 2013	35 & 36	008114-008361
Reporter's Transcript - Jury Trial Day 41 Friday, June 21, 2013	36 & 37	008362-008537
Reporter's Transcript - Jury Trial Day 42 Monday, June 24, 2013	37 & 38	008538-008797
Reporter's Transcript - Jury Trial Day 43 Tuesday, June 25, 2013	38	008798-009017
Reporter's Transcript - Jury Trial Day 44 Wednesday, June 26, 2013	39	009018-009220

<u>DOCUMENT</u>	<u>VOL.</u>	<u>PAGE(S)</u>
Reporter's Transcript - Jury Trial Day 45 Wednesday, June 27, 2013	39 & 40	009221-009473
Defendant's Proposed Instruction No. 2	41	009474-009475
Defendant's Proposed Instruction No. 3	41	009476
Defendant's Proposed Instruction No. 4	41	009477
Defendant's Proposed Instruction No. 5	41	009478
Instructions to the Jury	41	009479-009551
Verdict	41	009552-009559
Reporter's Transcript - Sentencing Hearing Thursday, October 24, 2013	41	009560-009583
Judgment of Conviction	41	009584-009589
Amended Judgment of Conviction	41	009590-009595
Notice of Appeal	41	009596-009600

(COPY)

Electronically Filed
03/11/2014 01:20:57 PM

TRAN



CLERK OF THE COURT

DISTRICT COURT
CLARK COUNTY, NEVADA
* * * * *

THE STATE OF NEVADA,)	
)	
Plaintiff,)	CASE NO. C265107-1,2
)	CASE NO. C283381-1,2
vs.)	DEPT NO. XXI
)	
DIPAK KANTILAL DESAI, RONALD)	
E. LAKEMAN,)	
)	
Defendants.)	TRANSCRIPT OF
)	PROCEEDING

BEFORE THE HONORABLE VALERIE ADAIR, DISTRICT COURT JUDGE

JURY TRIAL - DAY 39

WEDNESDAY, JUNE 19, 2013

APPEARANCES:

FOR THE STATE:	MICHAEL V. STAUDAHER, ESQ. PAMELA WECKERLY, ESQ. Chief Deputy District Attorneys
FOR DEFENDANT DESAI:	RICHARD A. WRIGHT, ESQ.
	MARGARET M. STANISH, ESQ.
FOR DEFENDANT LAKEMAN:	FREDERICK A. SANTACROCE, ESQ.

RECORDED BY JANIE OLSEN COURT RECORDER
TRANSCRIBED BY: KARR Reporting, Inc.

KARR REPORTING, INC.

008039

I N D E X

WITNESSES FOR THE STATE:

MARJORIE MEANA-STRONG

Direct Examination By Ms. Weckerly 7

Cross-Examination By Ms. Stanish 16

MAYNARD BAGANG

Direct Examination By Mr. Staudaher 24

Cross-Examination By Ms. Stanish 30

KATIE KALKA - (Resumed)

Direct Examination By Mr. Staudaher (Continued) 39

Cross-Examination By Ms. Stanish 45

Cross-Examination By Mr. Santacroce 54

Redirect Examination By Mr. Staudaher 55

Recross Examination By Ms. Stanish 55

E X H I B I T S

STATE'S EXHIBITS ADMITTED:

PAGE

239 28

240 and 241 45

1 LAS VEGAS, NEVADA, WEDNESDAY, JUNE 19, 2013, 10:31 A.M.

2 * * * * *

3 (Outside the presence of the jury.)

4 THE COURT: You can proceed however you want on
5 cross-examination.

6 MR. WRIGHT: Well, I thought she doesn't know any of
7 this, they kept her in the dark.

8 MR. STAUDAHER: She doesn't know what transpired with
9 them looking at the records or the discussions we had with the
10 lawyers in here related to her. She doesn't have that
11 information. Unless they want to -- we've tried to exclude
12 that information from her, actually.

13 MR. WRIGHT: Well, presumably, since she's the
14 knowledgeable person and knows everything about all the
15 records, she'll know about this other contract, right?

16 MR. STAUDAHER: I don't know -- I can't make a
17 representation of what she knows as far as the two different
18 contracts or not. She has access to the records as part of
19 her job, but they didn't apparently have that contract at the
20 time. That's what she was tasked to go do was to get that
21 record.

22 THE COURT: All right. Going forward this morning,
23 here is what we will do. We'll put on the -- I'm assuming the
24 Meana family witnesses. We'll look at the video. We'll go to
25 lunch. You will provide the documents, State, as soon as you

1 get them to Mr. Wright. If there are questions that need to
2 be asked before we go forward, defense and State can ask them
3 of the witness together in the hallway or in the vestibule or
4 whatever.

5 Mr. Wright, you can cross-examine the last witness
6 however you want to cross-examine her. And if we need to
7 bring her in out of the presence of the jury to sort out this
8 confusion regarding what the lawyers said and what she said,
9 we can do that off the record if you request us to do that, so
10 that you have a better understanding going forward. We don't
11 have to do that. I'm making that option available to you.
12 Certainly, that doesn't aid the Court. I mean, that's just
13 for the benefit of the attorneys.

14 Or if you want to do it more informally, you and Mr.
15 Staudaher or Ms. Weckerly and Mr. Santacroce can just talk to
16 her, as I said, in the hallway or in the vestibule or whatever
17 you want to do. And then if you want to put it on the record
18 with her, we can do that as well.

19 So I see those as the options going forward. Then if
20 there seems to be some other issue, then we'll deal with that
21 when that comes up. But that may be a way of figuring out
22 what this dispute is before you have to blindly rush into
23 cross-examination. I think those options are available to you
24 if you choose to take them.

25 MR. WRIGHT: Okay. I just raised it right now so

1 that she could like -- it seems simple to me that she ought to
2 have all the records, like all of the contracts since she's
3 the records custodian, the person most knowledgeable for the
4 company. So that's what I'm just putting it on notice. She
5 ought to have all of these records instead of just what the
6 District Attorney wants her to have.

7 MR. STAUDAHER: That's -- I think that's a
8 misaccurate statement. It's not what the District Attorney
9 wants her to have. The Court tasked her with getting certain
10 documents. The company got certain documents. I'm going to
11 go out there right now and provide those to her in addition to
12 the ones that everybody has had and that she's testified to.
13 So that's where we're at. That's not something that the State
14 has skewed one way or the other, it's something that I think
15 the Court directed to happen and we're just trying to --

16 THE COURT: Well, directed at the defendant's
17 request. I mean, let's be clear. I'm not dictating what
18 records people bring. Those records were ordered by the Court
19 at the defendant's request.

20 MR. STAUDAHER: Now we're just trying to get those
21 records to the witness.

22 MR. WRIGHT: I thought we were going to get a
23 knowledgeable witness. She testified she wouldn't know how to
24 apply it even if she had the records. That was her testimony.

25 MR. STAUDAHER: She did not have the records to look

1 at to see. If she has the records and now can do what she
2 needs to do with the records as they are. The records are
3 what they are, whatever they say. It has the conversion. If
4 it has the information, it does. If it doesn't, it doesn't.
5 So I just need to get them to her at this point so I can give
6 her a chance to look at them.

7 THE COURT: All right. So, Mr. Staudaher, you're
8 free to go hand her the records. Obviously, not to discuss
9 them. And the bailiff will bring in the jury.

10 (Jury reconvened at 10:38 a.m.)

11 THE COURT: All right. Court is now back in session.
12 The record should reflect the presence of the State through
13 the Deputy District Attorneys, the presence of the defendants
14 and their counsel, the officers of the Court and the ladies
15 and gentlemen of the jury.

16 Ladies and gentlemen, before we proceed with the
17 cross-examination of the last witness from yesterday, the
18 State is going to call some other witnesses and then we'll
19 resume with the last witness sometime later in the day today.

20 State, call your next witness.

21 MS. WECKERLY: Marjorie Meana.

22 MARJORIE MEANA-STRONG, STATE'S WITNESS, SWORN

23 THE CLERK: Please state and spell your name.

24 THE WITNESS: Marjorie Meana-Strong.

25 M-a-r-j-o-r-i-e, M-e-a-n-a, hyphen, S-t-r-o-n-g.

1 THE COURT: Thank you. Ms. Weckerly.

2 DIRECT EXAMINATION

3 BY MS. WECKERLY:

4 Q Ms. Strong, were you living in Las Vegas in
5 2007?

6 A Yes, ma'am.

7 Q Did your parents live in Las Vegas as well?

8 A Yes, ma'am.

9 Q Who is your father?

10 A Rodolfo Turillio Meana.

11 Q And your mom?

12 A Linda Guerrero Meana.

13 Q And during the time period of I guess the summer
14 of 2007, how often would you see your father?

15 A At least three, four times a week. And if we
16 don't see each other, we spoke over the phone every day.

17 Q And I don't want you to tell me what you said,
18 but during that summer of 2007, what were your observations
19 about his physical health at that time?

20 A He was a typical father in his 70s, active. He
21 ran errands with my mom every day. He was driving. He
22 sometimes would hold a part-time job as a security person, but
23 at that time he was already retired. They would do a lot of
24 the retired people's routine. Go to the grocery store, walk
25 around. He would walk a minimum of a mile, mile and a half

1 every day.

2 Q So he was capable of walking at least some
3 distance every day at that time?

4 A Yes.

5 Q And he was able to go places with your mom? He
6 was ambulatory?

7 A Absolutely, yes.

8 Q Without saying what he said, how was he mentally
9 at that time?

10 A He was very alert. He read a lot. He would
11 read the paper every day, listen to the news. He would -- my
12 dad loved to read and he liked knowledge, so he did a lot of
13 fact finding. He used the computer a lot too, so.

14 Q Did he seem at all depressed during that time,
15 that summer, to your knowledge?

16 A No. Not to my observation, no.

17 Q Are you aware -- you're aware that in September,
18 on September the 21st of 2007 your father had a procedure done
19 at the endoscopy center.

20 A Yes. I was very aware because that day my mom
21 does not drive and because the procedure, the doctor told us
22 that the procedure meant he couldn't drive after the
23 procedure, my husband Jeff Strong was the one that drove him
24 that morning. So yes, we were aware.

25 Q Okay. So your husband actually drove him to the

1 procedure at the center?

2 A Yes. He drove my father and my mom was with
3 them and my Uncle June was with them. Then he picked them up
4 too after.

5 Q But if I'm understanding you, you weren't
6 actually there though.

7 A I was not there, I was at work.

8 Q Okay. Sometime after that, did your dad's
9 health change at all?

10 A Yes. A few weeks after that he said he felt
11 like he had a very bad cold. First he thought it was a very
12 bad cold. But the more symptoms he told me, I said dad, to my
13 observation that looks like you may have flu-like symptoms.
14 He had it for a while.

15 Q Let me just interrupt you one second.

16 A Yes, ma'am.

17 Q When you saw your dad during this time period,
18 how would you describe how he was physically?

19 A He slept a lot. He was getting tired a lot. He
20 just kept -- my observation, he just wasn't himself. He was
21 very tired. He wanted to sleep a lot. Usually he would go
22 out after lunch, go somewhere with mom, but he can't go past
23 lunchtime anymore. Then he slept a lot. Then there was at
24 one point where he would go to the bathroom and he said my --

25 Q I don't want you to say what he said, but you

1 described him as being sort of fatigued during that time?

2 A Yes, he's always tired. He couldn't eat a lot.
3 He was actually -- he said I don't -- I saw for a fact that
4 when I would go see him it looked like he lost weight. I
5 mean, I could tell from his face, his body. And my mom even
6 said that he wasn't eating a lot for weeks.

7 Q At some point after that period, were you aware
8 that he had some tests indicating that he was positive for
9 hepatitis C?

10 A Yes, we were aware. A blood work was done
11 because he had to go to the -- I encouraged him to go to the
12 doctor first because of the fatigue and the flu-like symptoms.
13 And then many weeks later was when it was revealed that he
14 tested positive for hepatitis.

15 Q Okay. Now I want to kind of fast forward a
16 little bit. After that diagnosis, did you ever see medication
17 at your parents' house associated with some treatment for your
18 dad?

19 A Yes.

20 Q What did you actually see at the house?

21 A I saw the actual box of the medication and it
22 says interferon. And there was paperwork there that I read
23 regarding the interferon and we needed to have it refrigerated
24 properly in the refrigerator.

25 Q During that time period, what were your

1 observations about your father physically at that time period?

2 A When -- when he had the hepatitis C already, he
3 just started not being himself. He slowly, not just
4 physically -- his physical looks were changing. He started
5 losing weight to when he would have yellowish look on his eyes
6 which we later found out was jaundice. He would have a
7 problem with his bowel movements, between the bowel movements
8 and the urine. The urine would have a yellow substance. But
9 what was hard for the family, especially with mom and my
10 uncle, was that he couldn't drive them anymore. He couldn't
11 walk too much. He was sleeping a lot.

12 He was -- at times he started getting angry for no
13 reason. More like he was sad. He was depressed and we know
14 he was depressed because we would see his mood changes. We
15 would say happy things and take him places. He doesn't want
16 to go, he doesn't want to eat.

17 Q When you say he would get -- when you say he
18 would get angry, was that different than how his general
19 demeanor was before all this happened, before September the
20 21st?

21 A It's very different. My dad is ex-military,
22 very simple, a very peaceful happy man. So he never -- he
23 doesn't really show any anger signs or sad signs on his face,
24 facial expression or deflection on his voice. So there was a
25 remarkable difference. Even my mom noticed it. I would

1 notice it or she would call me in the middle of the night and
2 let me know.

3 Q To your knowledge, did your dad complete the
4 interferon therapy?

5 A No. I know he did not.

6 Q Now --

7 A The --

8 Q Go ahead.

9 A I'm so sorry.

10 Q Do you know -- do you know how long he was on
11 it?

12 A He was just on it about a week, if I'm -- yes,
13 about a week.

14 Q When he went off of it, did his physical health
15 or mental health improve or change at all from your
16 observation?

17 A No, it didn't change at all. And the frequency
18 of his physical and mental deterioration started getting worse
19 from then on.

20 Q Now I want to move to 2012. Okay? During the
21 early part of 2012 was your dad able to walk and drive at that
22 point in time?

23 A December before 2012, even before that, I went
24 to every single doctor's appointment with him, so I was always
25 with him. And we -- I was told he cannot drive anymore

1 because it was explained that his -- as his liver functions
2 deteriorate and he gets what they told me and I've heard,
3 hepatic episodes, ammonia levels go up into his brain and
4 start shutting it down.

5 MR. SANTACROCE: I'm going to object as hearsay.

6 THE COURT: Okay.

7 BY MS. WECKERLY:

8 Q Let me ask you this. During I think you said
9 December of 2011, you were responsible for driving your dad
10 places.

11 A Correct.

12 Q Previously he had been able to drive.

13 A Yes, ma'am.

14 Q Okay. During that time period, was he able to
15 walk around like he had prior to September of 2007?

16 A Yes.

17 Q How far was he able to walk during this later
18 period?

19 A He was a normal dad in his 70s that would walk
20 at least two to three miles.

21 Q I think we're miscommunicating. You described
22 how he could move around and he walked before.

23 A Yes.

24 Q Before the procedure in September 2007. And I'm
25 sorry if I'm not communicating it clearly. In December and

1 January of 2011, 2012, was he able to do that same kind of
2 physical activity like walking around like he had previously?

3 A No, not at all. In fact, I had to help purchase
4 a walker. Already, a few months already before that we had to
5 purchase a wheelchair because he can only walk maybe not even
6 ten minutes and it would be too tiresome for him. So for him
7 to go places he would need to be in a walker or when he's too
8 tired and I would have to assist him in his wheelchair.

9 Q Did you ever witness or did you participate in
10 any other care associated with him during that time period?
11 Like, I don't want to know what he said, but did you have to
12 do anything at home to assist with his physical care?

13 A I did everything.

14 Q What would everything be?

15 A I would make sure and check his, when we're not
16 at the doctor for them to check it, I would check his blood
17 pressure and then check his temperature. There were times in
18 and out of the hospital because he would be on a catheter. So
19 they taught us how to use that. Towards a few weeks before
20 March 27th of 2012, it was 24 round care between my mother and
21 myself. So my sisters came to help. And when we could not,
22 we had to hire a caregiver for the nighttime for about nine
23 hours just to let us rest. He was very bedridden already and
24 he would go in and out of being able to talk to. And he can't
25 bathe himself.

1 Q So he required pretty much round-the-clock care.
2 Is it fair to say that everything had to kind of be done for
3 him during --

4 A Yeah, everything had to be done for him. And
5 what was also consuming was not just taking care of him, he
6 had to be in and out of the doctors a lot. And if he wasn't
7 in and out of the doctors a lot, he was in the hospital for
8 extended periods of time sometimes.

9 Q At some point during 2012, did your father fly
10 to the Philippines?

11 A Yes.

12 Q Were you there? Did you go with him?

13 A We were all with him. All his four daughters,
14 his wife Linda, including myself. There were six of us that
15 flew him on March 27th of 2012.

16 Q And how long did you stay?

17 A We were -- my other sister that lives here and
18 myself were there until the second week of April.

19 Q When you left the Philippines, was your father
20 -- was he still alive?

21 A He was still alive, yes.

22 Q At some point after that, did you become aware
23 that he had died?

24 A Yes.

25 Q How long after you left?

1 A About a couple weeks after I came back -- we
2 came back here to the United States.

3 Q So you were here?

4 A Yes.

5 Q After your father had died, did you, I guess,
6 coordinate or assist the Las Vegas Metropolitan Police
7 Department in being able to observe an autopsy done on your
8 father in the Philippines?

9 A Yes. I had to call them the day that my father
10 died, which was April 27th. Detective -- it's okay to state
11 name?

12 Q It's okay. But a detective --

13 A A detective and the coroner flew.

14 Q And did you go too?

15 A Yes. With my sister and myself, yes.

16 Q So you actually went with the doctor from Clark
17 County and the Metro detective with your sister back to the
18 Philippines to help facilitate this autopsy.

19 A Yes, ma'am.

20 Q Thank you.

21 MS. WECKERLY: I'll pass the witness.

22 THE COURT: All right. Thank you. Cross.

23 CROSS-EXAMINATION

24 BY MS. STANISH:

25 Q Good morning, Ms. Strong.

1 A Good morning.

2 Q I'm Margaret Stanish. I represent Dr. Desai.
3 I first want to start with just seeing if you can help me
4 develop a timeline of what you just described with a little
5 more particularity, if you can. All right?

6 A I will try my best, ma'am.

7 Q I understand. Let's start with the September
8 21st, 2007 visit to the center for the colonoscopy as kind of
9 a starting point. Can you tell me how long after that you
10 noticed your dad having flu-like symptoms?

11 A It was already about fall at that time, so I
12 would say maybe approximately, please don't quote me on it,
13 maybe three or four -- about three weeks, four weeks after
14 that, towards October, end of October.

15 Q And if you know, I understand you encouraged him
16 to go to a doctor. Do you know what doctor he went to?

17 A Well, because of the insurance, he would always
18 go first to his doctor which would be Dr. Jurani. He's a
19 general doctor. It was just a simple ailment, I mean illness,
20 so I told him let's go there and let him see what's wrong,
21 dad.

22 Q Okay. And then, as I understand your testimony,
23 he continued to deteriorate.

24 A Yes, ma'am.

25 Q And you noticed him getting the jaundice and

1 being fatigued, correct?

2 A Yes, ma'am.

3 Q Can you tell me when about that occurred after
4 the September 21st date? How many weeks or months are we
5 talking about?

6 A The frequency of the -- of those things I
7 mentioned became more frequent. I would say maybe within
8 another few weeks after that, maybe two to -- at least two to
9 three weeks after that. But when he would go to the bathroom
10 he actually -- I actually saw it because he told me this is
11 not -- he said I got to show you something.

12 Q Well, what I'm trying to get at is, I'm trying
13 to get your timeline of when he went to different doctors, if
14 you know. So you see that he gets the jaundice.

15 A Yes.

16 Q You notice problems with his urination. What --
17 at that point, do you know who he went and saw?

18 A He went to see Dr. Jurani.

19 Q Again?

20 A After which timeline, ma'am?

21 Q Well, as I understand it, a few weeks after the
22 procedure he has flu-like symptoms.

23 A Yes, ma'am.

24 Q And then a few weeks more he's jaundiced.

25 A Yes.

1 Q And having urination problems. At that point,
2 do you know where he went?

3 A He went to Dr. Jurani, yes.

4 Q Do you know -- you mentioned that you observed
5 him having a box of the interferon medication.

6 A Yes, ma'am.

7 Q Can you kind of put that on a timeline for us?

8 A I would say that would be maybe around March,
9 2009. It's not in '08, so it would be many months after that.

10 Q So -- if I'm understanding the timeline, and I
11 understand you're estimating.

12 A Yes, ma'am.

13 Q I understand that. He's showing the symptoms
14 within a few weeks of going to the clinic. He doesn't start
15 the interferon treatment until March of 2009 or thereabouts?

16 A I mean, it's -- I'm so sorry, it's been a long
17 time ago.

18 Q I understand.

19 A So it was either later of 2008, you know, almost
20 late winter or beginning of 2009. I mean, that -- I remember
21 those dates just because it was wintertime, around wintertime,
22 almost springtime.

23 Q Had you -- I understand at some point in time
24 you were accompanying him to the doctor appointments since he
25 couldn't drive. Were you accompanying him to doctor

1 appointments before he started the interferon treatment?

2 A Before the interferon treatment?

3 Q Right.

4 A Once -- not a lot because he was still able to
5 drive at that time. So Linda, his wife, my mom Linda would
6 always be with him.

7 Q Okay. So prior to the interferon treatment
8 which you think was in March of 2009 or late '08, he was able
9 to get -- he was able to drive still?

10 A Yes, ma'am.

11 Q And am I understanding your testimony that he
12 took the interferon treatment for one week?

13 A That's -- yes. From my -- from me seeing it at
14 the house and asking -- and I literally asked him --

15 Q We can't talk about conversations.

16 A Okay.

17 Q But so I'm looking at -- I understand you saw
18 the package, you read it, you made sure it was in the
19 refrigerator. Do you know if he was taking another medication
20 that was administered by a shot?

21 A No, ma'am.

22 Q You don't know or you're --

23 A I know he did not because I did not see it
24 anymore.

25 Q All right. Were you aware -- do you have

1 firsthand knowledge, if you do, of your dad's other health
2 issues prior to getting the colonoscopy?

3 A Little bit, yes, ma'am.

4 Q Could you tell us what you know?

5 A From knowing -- from being there with them, yes.
6 He has some blood pressure problem and he has ulcers.

7 Q Did he ever have to have surgery on his
8 gallbladder?

9 A Yes. That was a long time ago, but yes. He had
10 gallbladder surgery, yes.

11 Q Do you know how long ago that was?

12 A '90s.

13 Q In the '90s.

14 A Maybe mid 90s.

15 Q All right. Did he have -- did he suffer from
16 prostate cancer?

17 A No, ma'am.

18 Q Did he -- were you aware whether he had any kind
19 of chemotherapy?

20 A No, ma'am.

21 Q You're not aware of whether --

22 A I'm not aware and I know he does not have
23 prostate cancer.

24 Q All right. Do you know if he had any kind of
25 prostate issue?

1 A He had enlarged or benign -- enlarged prostate.

2 Q I see. You don't know whether or not he had to
3 have chemotherapy at all?

4 A No, I know he did not have.

5 Q All right. Am I to understand that one of your
6 sisters resides in the Philippines or two of them?

7 A Yes, ma'am.

8 Q Okay. I understand you traveled to the
9 Philippines. Was it you or your sister who resides in the
10 Philippines that assisted in arranging the autopsy in the
11 Philippines?

12 A Are you talking about the date that my dad
13 passed away now?

14 Q Yeah. I am fast forwarding to --

15 A I'm sorry. I just want to make sure.

16 Q That's all right. I understood that you, at
17 least stateside, coordinated with the metropolitan police to
18 arrange for an autopsy in the Philippines, correct?

19 A Yes, ma'am.

20 Q And what I'm asking is was it you or one of your
21 sister who resides overseas that actually coordinated with the
22 Philippine authorities?

23 A Oh, the Philippine authorities?

24 Q Right.

25 A It wasn't -- it wasn't directly from us.

1 Q Okay.

2 A We authorized it. But then by the time my
3 sister that resides here in the U.S., Marlene and I flew
4 there. Then we were told that they were the ones that's doing
5 the actual autopsy there.

6 Q Okay.

7 A That's -- we were just verbally stated.

8 Q Okay. I just wasn't -- I just wanted to clarify
9 if you had any involvement in coordinating with the Philippine
10 authorities.

11 A No, ma'am. We have to deal with my dad's death.
12 I mean --

13 Q No, I understand. I just meant for purposes of
14 the autopsy. All right. That's all I needed to know. Thank
15 you.

16 MS. STANISH: I have nothing further.

17 THE COURT: Mr. Santacroce.

18 MR. SANTACROCE: I don't have any questions.

19 THE COURT: All right. Thank you. Ms. Weckerly,
20 redirect.

21 MS. WECKERLY: No redirect, Your Honor.

22 THE COURT: Do we have any juror questions for this
23 witness? No juror questions? Ma'am, thank you for your
24 testimony. Please don't discuss your testimony with anyone
25 else who may be a witness in this case. Thank you and you are

1 excused.

2 THE WITNESS: Thank you.

3 THE COURT: The State may call its next witness.

4 MR. STAUDAHER: State calls Maynard Bagang, Your
5 Honor. I may be slaughtering that name.

6 MAYNARD BAGANG, STATE'S WITNESS, SWORN

7 THE CLERK: Please be seated. Please state and spell
8 your name.

9 THE WITNESS: My name is Maynard Bagang,
10 M-a-y-n-a-r-d, B-a-g-a-n-g.

11 THE COURT: Thank you. Mr. Staudaher, go ahead.

12 MR. STAUDAHER: Thank you, Your Honor.

13 DIRECT EXAMINATION

14 BY MR. STAUDAHER:

15 Q Sir, what do you do for a living?

16 A I'm currently employed by the Las Vegas
17 Metropolitan Police Department as a police officer.

18 Q How long have you done that work?

19 A I've been a police officer for approximately
20 nine years now.

21 Q I'm going to take you back in time to 2007,
22 specifically April of 2007. Before I get there, do you have
23 any special language skills?

24 A I speak Tagalog and the local dialect of the
25 Philippines which is Kapampangan, sir.

1 Q Because of those skills, that knowledge of the
2 language of Tagalog you said?

3 A Yes, sir.

4 Q Were you contacted by Detective Whitely from the
5 Las Vegas Metropolitan Police Department to assist in an
6 autopsy that was going to be performed --

7 A That's correct, sir.

8 Q -- in the Philippines?

9 A Yes, sir.

10 Q And specifically on April 27th of 2012, did you
11 become involved?

12 A Yes, sir.

13 Q Can you describe for us how that happened?

14 A I was performing my military duties, because I'm
15 in the Navy Reserve, I was in Coronado, California when I
16 received a phone call from Sergeant Misty Pence from the Las
17 Vegas Metropolitan Police Department informing me that I will
18 be traveling from Las Vegas to the Philippines that same day.
19 She gave me the briefing on what I am supposed to do when I
20 get to the Philippines and at the end of the process, bring
21 back the items that I'm supposed to escort.

22 Q Was the reason that you were sent there because
23 of your language ability?

24 A Yes, sir.

25 Q Did you grow up in the Philippines or how are

1 you associated with that particular country?

2 A I grew up in the Philippines and I went to
3 college in the Philippines, sir.

4 Q So when you get this information, do you come
5 back to Las Vegas?

6 A Yes, sir.

7 Q And then what happens?

8 A Got back in Vegas. I flew out that night, April
9 27th via Korean Airlines. I got to the Philippines April 29th
10 in the morning, it was a Sunday. And that's when I met with
11 the U.S. Embassy representative FBI agent to escort me to my
12 hotel room.

13 THE COURT: Sir, you have sort of a soft voice. Keep
14 your voice up.

15 THE WITNESS: Yes, Your Honor.

16 BY MR. STAUDAHER:

17 Q There's a microphone right in front of you, if
18 you could try to get as close to that as you can.

19 When -- actually, you're traveling. Are you alone or
20 are you with anybody else?

21 A I was with the Nevada coroner, Dr. Olson and
22 also one of the daughters of Rodolfo Meana, Marjorie.

23 Q So all of you are on the same flight?

24 A That's correct, sir.

25 Q When you get to the Philippines, do you

1 coordinate with Dr. Olson?

2 A Yes, sir.

3 Q Are you with Dr. Olson during the time that
4 you're facilitating or at least getting the issues related to
5 the autopsy completed?

6 A Yes, sir.

7 Q Tell us once you get there, that whole process
8 about the autopsy and what you did, if you were there, that
9 kind of thing.

10 A When I got there, first of all, I was introduced
11 by the FBI agent to the Philippine local law enforcement
12 agency, which is the National Bureau of Investigation.
13 Because we're going to need their help to facilitate the
14 autopsy. We're going to need a Philippine coroner. So I
15 briefed the National Bureau of Investigation representative
16 and also the Interpol chief based in Manila requesting the --
17 requesting a Philippine coroner to perform the autopsy. Then
18 that same day, that was Monday, April 30th, they were able to
19 provide the Philippine coroner and we went to the funeral home
20 where I met with the [indiscernible] staff members and also
21 one of the daughters of Rodolfo Meana. That's when I asked
22 them to show me the body so I can identify the body. And then
23 they did show me the body and it was Mr. Meana.

24 MR. STAUDAHER: May I approach, Your Honor?

25 THE COURT: You may.

1 BY MR. STAUDAHER:

2 Q I'm showing you what has been marked as proposed
3 State's 239 and ask if you recognize that item.

4 A Yes, sir, I do.

5 Q And what is it?

6 A This is a driver's license of Rodolfo Meana.

7 Q Is this the same person that you identified when
8 you went to the Philippines?

9 A That's correct, sir.

10 MR. STAUDAHER: At this time I'd move for admission
11 of State's 239, Your Honor.

12 THE COURT: Any objection?

13 MS. STANISH: No, Your Honor.

14 MR. SANTACROCE: No, Your Honor.

15 THE COURT: All right. 239 is admitted.

16 (State's Exhibit 239 admitted.)

17 MR. STAUDAHER: And I know we can't put it on the --

18 THE COURT: Right.

19 MR. STAUDAHER: But I just want to have it as an
20 admitted exhibit --

21 THE COURT: That's fine.

22 MR. STAUDAHER: -- his driver's license photo.

23 BY MR. STAUDAHER:

24 Q So the purpose of you going there, was it in
25 part to identify the right person that was going to have an

1 autopsy performed?

2 A That's correct, sir. My main purpose is to
3 identify the body, facilitate and witness the autopsy and
4 escort Dr. Olson to bring back the samples back here in the
5 United States.

6 Q So when you say witness the autopsy, does that
7 mean you're actually physically there when it's taking place?

8 A Yes, sir, I was.

9 Q Who else is there? I mean, I assume that the
10 Philippine coroner and so forth are actually doing the
11 autopsy. Is that fair?

12 A That's correct, sir.

13 Q You're there. Is Dr. Olson present?

14 A Yes, sir.

15 Q What is her role in this?

16 A Her role was to witness the autopsy and collect
17 the samples, the tissue samples and blood samples.

18 Q Were you there when that occurred?

19 A Yes, sir.

20 Q So once the samples come into the possession of
21 Dr. Olson, are you involved with the -- I mean, the husbandry,
22 the care of those samples in any way before they get back to
23 the United States?

24 A Yes, sir. My job is to escort the doctor. She
25 took custody of the samples and put the samples in a secured

1 safe inside her hotel room.

2 Q And then when you got back to the United States,
3 did she maintain possession of those to the coroner's office?

4 A Yes, sir. The samples were hand carried and we
5 bypassed the airport security from the Philippines all the way
6 to Las Vegas.

7 Q So there was no intervening, where you had to
8 release those samples to somebody else, for example, like
9 customs or so forth?

10 A No, sir. Everything was set up by Homeland
11 Security and we bypassed all security of the airports.

12 Q So when you are present during the autopsy, are
13 you there for the entirety of the autopsy?

14 A Yes, sir.

15 Q So you don't step out for a break or anything
16 during that time?

17 A No, sir.

18 Q After you got back to the United States, did
19 that pretty much complete your role in this case?

20 A That's correct, sir.

21 MR. STAUDAHER: I pass the witness, Your Honor.

22 THE COURT: All right. Thank you. Cross.

23 CROSS-EXAMINATION

24 BY MS. STANISH:

25 Q Good morning.

1 A Good morning, ma'am.

2 Q Officer, how do I say your last name?

3 A Bagang.

4 Q Bagang?

5 A Yes.

6 Q Officer Bagang, just clarify a few points. Is
7 it the case that a law enforcement official in the United
8 States must go through formal diplomatic channels in order to
9 what you described in another country?

10 A That's correct, ma'am.

11 Q So it's not unusual that if a stateside law
12 enforcement officer needed to conduct an investigation or get
13 some information in connection with their case, they would
14 have to go through Interpol, FBI, State Department or whatever
15 U.S. authority is located in another country?

16 A I'm not familiar with the process, but I believe
17 that's what occurred because it was Homeland Security of the
18 Las Vegas Metropolitan Police Department who set up everything
19 for me.

20 Q All right. And as I understand it, when you got
21 there you had to actually do the formal request of the various
22 law enforcement authority to conduct the autopsy?

23 A That's correct, ma'am. Because it is a
24 different country and our coroner is not licensed to perform
25 an autopsy. That's why it had to be done by the Philippine

1 coroner. And we went through the proper channel by going to
2 the Interpol chief based in Manila and also the National
3 Bureau of Investigation.

4 Q And as I understand your testimony, you were the
5 one that had to brief them on the nature of this case?

6 A That's correct, ma'am. Because the National
7 Bureau of Investigation head doctor asked me if I can brief
8 him on what we are planning to do and what's our mission.

9 Q And what did you relate to him? What was your
10 -- the mission that you related to him?

11 A I related to the doctor that we were there to
12 obtain samples from the body of Rodolfo Meana and through
13 their help we're going to need a Philippine coroner and also a
14 consent from the family which was taken by the National Bureau
15 of Investigation from the family.

16 Q And did you provide them with medical records?

17 A No, ma'am.

18 Q Did you bring medical records with you at all?

19 A No, ma'am.

20 Q Did Dr. Olson?

21 A I do not recall that, ma'am.

22 Q Did you, yourself review any medical records?

23 A No, ma'am. And even if they show me medical
24 records, I am not an expert to make any justification on any
25 medical records.

1 Q Fair enough. Fair enough. Did you see Dr.
2 Olson with any medical records relating to Mr. Meana?

3 A I cannot recall, ma'am. She's bringing her
4 personal bag, no.

5 Q Okay. And as I understand it, you witnessed the
6 autopsy.

7 A That's correct.

8 Q Where did that take place?

9 A It was [indiscernible] in Manila.

10 Q Was it a government facility?

11 A No, it's a private funeral home.

12 Q So the autopsy was conducted in a private
13 funeral home?

14 A Yes, ma'am.

15 Q And do you recall, sir, what samples were given
16 to Dr. Olson?

17 A I'm not an expert of -- in that particular
18 matter, so I cannot tell you what body part was given, but I
19 knew there were samples that were taken and given to Dr. Olson
20 and they were put in a specified medical container and sealed.

21 Q Do you know where they were stored while you
22 were in the Philippines?

23 A Yes, ma'am. They were stored in a secured safe
24 by Dr. Olson inside her hotel room.

25 Q Okay. So what, like her hotel room had a safe

1 in it?

2 A Yes, ma'am.

3 Q And so she put the samples in there?

4 A Yes, ma'am.

5 Q How long were -- how long did you -- when did
6 you travel back to the United States with Dr. Olson?

7 A I believe it was approximately May 3rd. It was
8 a Wednesday when we traveled back.

9 Q Did Dr. Olson maintain control -- did you ever
10 receive the samples into evidence or did Dr. Olson take care
11 of that?

12 A Dr. Olson took care of it.

13 Q Do you know how long or can you estimate, if you
14 recall, how long the autopsy took?

15 A Approximately two hours, ma'am.

16 Q And did Dr. Olson, did she just observe it or
17 did she actually participate in anything?

18 A She observed, she didn't participate.

19 MS. STANISH: Court's indulgence.

20 THE COURT: That's fine.

21 MS. STANISH: No further questions. Thank you.

22 THE COURT: All right. Mr. Santacroce, any questions
23 for this witness?

24 MR. SANTACROCE: No, Your Honor.

25 THE COURT: Mr. Staudaher, any redirect?

1 MR. STAUDAHER: No, Your Honor.

2 THE COURT: Do we have any juror questions for this
3 witness? No juror questions? Officer, thank you for your
4 testimony. Please don't discuss your testimony with any other
5 witnesses in this matter.

6 THE WITNESS: Yes, Your Honor.

7 THE COURT: Thank you, sir, and you are excused.

8 THE WITNESS: Thank you, Your Honor.

9 MR. STAUDAHER: Your Honor, if we could take maybe a
10 five-minute break to make sure everything --

11 THE COURT: Okay. To queue up for everything?

12 MR. STAUDAHER: That's correct.

13 THE COURT: All right. Ladies and gentlemen, we'll
14 next be playing a video deposition, so we're going to take a
15 quick break to get everything all set up for that. We'll be
16 in recess until 11:35.

17 During the recess you're reminded you're not to
18 discuss the case or anything relating to the case with each
19 other or with anyone else. You're not to read, watch, listen
20 to reports of or commentaries on this case, any person or
21 subject matter relating to the case. Don't do any independent
22 research and please don't form or express an opinion on the
23 trial. Notepads in your chairs and follow the bailiff through
24 the rear door.

25 (Jury recessed at 11:22 a.m.)

1 THE COURT: Before we take our break, what do we have
2 for today? The Meana deposition.

3 MR. STAUDAHER: And then whatever, as far as the
4 insurance --

5 THE COURT: This gal left and that's it. That's fine
6 because Ms. Mayo, we told her she didn't have to come in. She
7 set up a doctor's appointment so we need to be done by like
8 3:30. So that shouldn't be --

9 MR. STAUDAHER: Oh, I think that should be --

10 THE COURT: Oh, that's great. Okay. So Janie, can
11 we interrupt the Meana deposition in the middle if we need --
12 want to take lunch?

13 MS. WECKERLY: It's, you know, it's really not as
14 long. There's a lot of argument in it.

15 THE COURT: Okay.

16 MR. STAUDAHER: We're trying to cut out as best we
17 can. I talked to counsel about that. We're eliminating all
18 the beginning stuff, all the end stuff and there's a big
19 section in between that where he had to be medicated, I guess.
20 We're eliminating that. So we're going to start off with the
21 questioning of Ms. Weckerly going through questioning with Mr.
22 Wright. Then it stopped, then there was the break and then we
23 pick back up with Mr. Wright's questioning until the Court
24 stops it and that's -- whatever happens in between we can't
25 really take out.

1 THE COURT: Okay. That's fine. And then we'll --

2 MR. WRIGHT: What do you mean in between?

3 MR. STAUDAHER: When you're questioning. During your
4 -- if there was an objection.

5 THE COURT: You know, if somebody came in or said
6 something, then that's going to be on there. Okay. And then
7 we'll take lunch after that and then you guys can get with the
8 witness on the documents.

9 MR. STAUDAHER: Right. I've given them one document.
10 The other one I guess is still on it's way. I haven't
11 checked.

12 THE COURT: And then we'll figure that out and that
13 will be after lunch and then we'll take our recess for the
14 day. Sounds good? Okay.

15 (Court recessed at 11:24 a.m. until 11:36 a.m.)

16 (Outside the presence of the jury.)

17 THE COURT: Bring them in. Are we all queued up?

18 MR. STAUDAHER: We believe so, yes.

19 THE COURT: Okay.

20 MR. STAUDAHER: As soon as we get to the -- just so
21 the Court knows. In order to remove all of this -- the in
22 between medication thing, when we get to the end of this
23 segment there's another segment I have to go to. And I will
24 play the entirety of that segment because we just pick back up
25 with Mr. Wright speaking or asking questions up until the

1 point where the Court starts talking about being done. And
2 then there's some stuff that comes after that, so I'm going to
3 end it at that point. There's nothing -- there's no more
4 questioning that happens after that particular point.

5 (Pause in proceedings)

6 (Jury reconvened at 11:39 a.m.)

7 THE COURT: All right. Court is now back in session.
8 Ladies and gentlemen, in a moment we will be playing for you a
9 video deposition that was taken of Mr. Meana. That is
10 questioning that is done under oath when the trial is actually
11 not in session. We will see, I believe, in the video
12 deposition that the questioning of Mr. Meana was cut short due
13 to concerns that were expressed regarding his physical state.
14 So for that reason, you will see that both the defense side
15 did not have an opportunity to thoroughly question Mr. Meana.
16 The deposition was not concluded, meaning it was not
17 completed. But we are showing you the portion of the
18 deposition that we were able to complete.

19 Having said that, Ms. Olson, will you queue that up.
20 Can everyone see this monitor? Is this is a good location or
21 would it be better if the bailiff moved it more centrally into
22 the courtroom? Yeah, why don't you move it so they're not all
23 -- whatever you do, don't unplug it. Can everyone see that
24 all right? Everyone good. Okay. Very good. Janie.

25 (Rodolfo Meana testimony previously transcribed.)

1 THE COURT: All right. Ladies and gentlemen, that
2 concludes the deposition. Kenny, you can move the screen
3 back. And then I believe next up is the witness from
4 yesterday; is that correct, Mr. Staudaher?

5 MR. STAUDAHER: Yes.

6 THE COURT: So while Kenny's moving the screen back
7 and the easel so the jurors can see, can you just get the next
8 witness?

9 MR. STAUDAHER: Certainly.

10 THE COURT: Help us out here. Ma'am, just come on up
11 here, back to the witness stand, please. Then just go ahead
12 and have a seat. And you are still under oath. Do you
13 understand that?

14 THE WITNESS: Yes.

15 THE COURT: All right. Thank you. Mr. Staudaher,
16 did you have anymore direct examination?

17 MR. STAUDAHER: I just have [indiscernible] document.

18 DIRECT EXAMINATION (Continued)

19 BY MR. STAUDAHER:

20 Q At the end of the testimony last time there were
21 some discussions about a particular document that you had that
22 at least was part of your company as far as what the policy
23 was in place at the time with the endoscopy center. Do you
24 recall that?

25 A Yes.

1 MR. STAUDAHER: May I approach, Your Honor?

2 THE COURT: You may.

3 BY MR. STAUDAHER:

4 Q I'm showing you two documents. One is marked
5 proposed State's 240 and the other one is marked 241. Can you
6 tell us if you've been able to obtain these documents, if
7 you're familiar with them and what they are?

8 A Yes.

9 Q Start with 240.

10 A 240 is the Medical Group Participation Agreement
11 which is the contract between the providers and United
12 Healthcare.

13 Q And what does that mean exactly?

14 A This is a contract which was signed that they
15 will provide care and follow terms of billing and such for --
16 to become a participating provider with the network.

17 Q Now there are two separate contracts. This is
18 the second one; is that correct?

19 A Correct.

20 Q Do you know what the difference is between the
21 two?

22 A The contract that we discussed previously was
23 for the facility itself. This one covers the providers within
24 the facility.

25 Q Okay. So this is the one that was used to -- as

1 a guideline for billing purposes for the providers?

2 A Correct.

3 Q Does that include CRNAs?

4 A Yes.

5 Q Now Exhibit Number, proposed 241, what is that?

6 A This is a Market Standard Specifications. This
7 would be what we would consider the fee schedule.

8 Q So the fee schedule for what, for various
9 procedures and things?

10 A Yes, for various procedures.

11 Q Now I note on that document that at least the
12 procedures themselves have been, looks like redacted out; is
13 that correct?

14 A Correct.

15 Q Is there anything on there related to
16 anesthesia?

17 A Yes.

18 Q And is there anything on there that relates to
19 what the actual unit value reimbursement was for anesthesia at
20 the time?

21 A Yes.

22 Q At this point, there is, and I just want to go
23 through one thing on 240, getting to the back of this
24 document. I believe it is the second page, actually second to
25 the last page, refers to Appendix Three.

1 A Yes.

2 Q Now, there's nothing -- there's just some
3 verbiage there on Appendix Three, but does it refer to yet
4 another document?

5 A It refers to the fee schedule.

6 Q Okay. And then the fee schedule that's 241 is
7 listed as Appendix Three?

8 A Yes.

9 Q Is that the document that it refers to?

10 A Yes.

11 Q Okay. To your knowledge, does this all go
12 together?

13 A Yes.

14 Q For the Endoscopy Center of Southern Nevada?

15 A Yes.

16 MR. STAUDAHNER: At this time I'd move for admission
17 of State's proposed 240 and 241, Your Honor.

18 THE COURT: Any objection?

19 MS. STANISH: May I voir dire, Your Honor?

20 THE COURT: Sure.

21 MS. STANISH: Thank you.

22 BY MS. STANISH:

23 Q After your testimony yesterday, did you have any
24 discussions with anybody regarding these two documents that
25 you just spoke of?

1 A No. I had not seen either one of these
2 documents until I got here this morning.

3 Q And who showed them to you?

4 A They were shown to me by United Healthcare's
5 counsel once we were here in the witness room.

6 Q And then, did you discuss the context --
7 contents of these documents?

8 A No, I just reviewed them.

9 Q Okay. And do you, referring to -- referring to
10 State Exhibit, proposed Exhibit 241, do you see a date on
11 that?

12 A No, I do not.

13 Q In your experience, if you know, do the fee
14 schedules change periodically?

15 A In my experience, yes.

16 Q And can you tell us how often the fee schedules
17 normally change?

18 A I cannot tell you that, no.

19 Q Is it annually?

20 A I do not know.

21 Q You don't know?

22 A No.

23 Q And do you have any way of -- well, let me ask
24 you this. The date on this contract, this provider contract
25 that's marked as proposed Exhibit 240, what's the date of that

1 document?

2 A It says May, 2003.

3 Q And in your experience, do these contracts
4 normally get amended over time?

5 A At times there is a possibility of it being
6 amended.

7 Q As you sit here today as the custodian of
8 record, do you know if this contract that's dated October,
9 2003 -- is that the date you said?

10 A This is October. Down here it says May, 2003,
11 so that must have been when it, when the format was created.

12 Q Oh, I see.

13 A So, I'm sorry. October, 2003.

14 Q So it was signed in October, 2003.

15 A Correct.

16 Q So as you sit here today as custodian of record,
17 do you know if there -- this contract was amended between
18 October, 2003 and July of 2007?

19 A Not that I'm aware of. I do not know.

20 Q What would you do to figure that out?

21 A There would have been another agreement on file
22 which would have then been sent to us if it had been updated.

23 Q Did you personally look for this document?

24 A No, I did not.

25 Q And with respect to the rate schedule, what

1 would you, as custodian of record, have done to determine
2 whether that was the rate schedule in effect in July of 2007?

3 A As custodian of records, I count on our network
4 management to provide me with the accurate documents that I
5 request, as they are requested from me.

6 Q Who's that person?

7 A It varies depending upon who's available to pull
8 the documents.

9 MS. STANISH: Your Honor, may we approach?

10 THE COURT: Sure.

11 (Off-record bench conference.)

12 THE COURT: Mr. Staudaher, you may proceed. Did you
13 have any additional questions regarding that document?

14 MR. STAUDAHER: No, Your Honor.

15 THE COURT: And that's Exhibit Number what?

16 MR. STAUDAHER: Exhibits Number -- actually, I think
17 they're up there. 241 and 240.

18 THE COURT: All right. Those will be admitted.

19 (State's Exhibit 240 and 241 admitted.)

20 THE COURT: Pass the witness? Mr. Staudaher, that
21 concludes your direct?

22 MR. STAUDAHER: Yes, Your Honor.

23 THE COURT: All right. Ms. Stanish.

24 CROSS-EXAMINATION

25 BY MS. STANISH:

1 Q Do you know what the base value -- do you know
2 -- explain to us what formula the insurance company used to
3 calculate the payment to the gastro center for Ms. Aspinwall?

4 A The formula was listed in the reimbursement
5 policy. I do not have the formula memorized.

6 THE COURT: Is that in one of the exhibits that you
7 testified about --

8 THE WITNESS: Yes.

9 THE COURT: -- yesterday?

10 THE WITNESS: Yes.

11 THE COURT: All right.

12 BY MS. STANISH:

13 Q I'm just going to give you all the documents and
14 you can plow through them and find whatever helps you. Okay?
15 You got it?

16 A Yes.

17 Q What is it?

18 A The standard formula for the anesthesia maximum
19 is the base value plus the time increments plus the modifying
20 units times the conversion factor times the modifier
21 percentage.

22 Q All right. And do you know what the base value
23 was assigned to Ms. Aspinwall's case?

24 A The base value was five.

25 Q I want to display this chart which I will note

1 is not handwritten but made with high technology just like the
2 State. I'm hoping that you can help us understand the value
3 of anesthesia services that were provided. I understand you
4 to say that the base value was five, right? And it might be
5 helpful if you could pull out Ms. Aspinwall's 1500 form.

6 A That's what I'm doing right now.

7 Q Now when I ask you these questions, please, if
8 you don't have knowledge on how to do this, tell me because I
9 understand you're a fraud investigator and not a billing
10 expert.

11 A Okay.

12 Q So I want this to be precise, if we can do that.
13 So turning to Ms. Aspinwall's claim, there were no modifying
14 units; is that correct?

15 A Correct.

16 Q So we can just put zero there. So with respect
17 to the amount of time for Ms. Aspinwall, that was how much
18 time? How many units billed?

19 A Three.

20 Q So this is what's actually paid to Ms. -- for
21 Ms. Aspinwall's anesthesia service, correct?

22 A That is what the insurance company paid.

23 Q And you're suggesting that there -- Ms.
24 Aspinwall had another insurance, a secondary insurance policy,
25 correct?

1 A No. What I'm saying is that based on the
2 explanation of benefits, Ms. Aspinwall had a patient
3 responsibility of a certain amount of money.

4 Q All right. Now, can you tell us based on this
5 new document that we got today regarding the conversion rate,
6 on this document what is the conversion rate for anesthesia?

7 A Forty-four dollars.

8 Q And so each unit is \$44?

9 A Correct.

10 Q And as I understand it, if we take \$44 and
11 multiply it by eight units?

12 A Correct.

13 Q We're going to get the gross amount of
14 compensation to the clinic; is that correct?

15 A Correct.

16 Q That amount still has to be reduced somehow
17 based on the member's what?

18 A Member's responsibility.

19 Q Is that the term?

20 THE COURT: Is that like a co-pay?

21 THE WITNESS: Like a co-pay or co-insurance.

22 THE COURT: And us regular folk would call it co-pay.

23 THE WITNESS: Right. Yes.

24 BY MS. STANISH:

25 Q But now, and I want to -- if you would turn to

1 Ms. -- the EOB, the explanation of benefits, doesn't part of
2 the equation also factor in the plan that Ms. Aspinwall's on
3 as far as what percentage the business or the insurance
4 company's going to pay?

5 A Correct.

6 Q So can you explain to me how we get to this
7 figure? I mean, the conversion factor we now know is \$44 if
8 that document you have there was the one that applied during
9 calendar year 2007, correct?

10 A Correct.

11 Q So let's pretend for a moment that that's the
12 case. All right? So we multiply eight by \$44 and we come up
13 with \$252. We don't have any modifier percentage on Ms.
14 Aspinwall?

15 A The modifier percentage was 100 percent.

16 Q Okay. So we don't have to worry about that
17 math, right?

18 A Right.

19 Q We'll leave that blank. Can you tell me how we
20 get to this figure?

21 A According to the explanation of benefits, the
22 allowed amount or the approved amount, the total amount paid
23 -- that was approved to be paid was \$312.40. So there was the
24 provider, participating provider discount was \$247.60.

25 Q So I got this figure of 352. Let me just do

1 this and I'll subtract the 249 and maybe you can -- will that
2 help us?

3 A Actually, what would help us is to subtract the
4 312.40.

5 Q Okay, 312.40 equals \$39.60. What do I do now?

6 A I don't know.

7 Q Yeah, me neither. Who would know in your
8 organization about this?

9 A It would have to be a claims processor that
10 would know why there's a difference.

11 Q And you know what I was hoping we could
12 accomplish and tell me how we have to do this. If we wanted
13 to know what the value of service was that Ms. Aspinwall
14 received and we want to fill in the blanks on this chart,
15 assuming she -- we know what the figure is but we're not quite
16 sure how we got there with respect to a procedure between 31
17 and 32 minutes. But if I wanted to know what the compensation
18 would have been had the anesthesia service lasted 16 to 30
19 minutes, how would we do that?

20 A Well, based on the fee schedule provided here
21 today, it would have been \$44 less.

22 Q So the -- assuming Ms. Aspinwall had anesthesia
23 service that lasted between 16 and 30 minutes, it would be \$44
24 less than the \$249.92?

25 A No. It would be \$44 less than the \$312.40,

1 because the allowed amount.

2 Q Let's try that. The allowed -- tell me what to
3 do.

4 A Okay. The allowed amount was \$314 --

5 Q Let me stop you right there just to go through
6 this. We would be talking about seven base units if the
7 service lasted between 16 and 30 minutes.

8 A Correct.

9 Q And so you're not able to do -- you're not going
10 to multiply that figure, you're just going to somehow work
11 your way backwards?

12 A Well, no. I mean, I'm assuming that this \$44 is
13 correct. If it was one unit less, one unit equals \$44, it
14 would have been \$44 less than the total allowed amount.

15 Q Okay. And you're saying the -- and that amount
16 is the 312.40?

17 A Correct.

18 Q 312.40 minus \$44 equals \$268.40?

19 A Correct. And then the plan would have paid 80
20 percent of that.

21 Q So I have to do more math. I have to multiply
22 this by .80?

23 A Correct.

24 Q So I'm taking 268.40 and multiplying it by .80
25 and I get \$214.76.

1 A And that's what the plan would have paid then.

2 Q \$214.76. And what would you do here if the time
3 frame was between zero and 15?

4 A Again, we would follow the same process.

5 Q Would we be still subtracting \$44 or \$88?

6 A No. What we would do is if you go back to what
7 the allowed amount was on that 214.72.

8 Q Take this and subtract \$44?

9 A No.

10 Q What? What do you want me to do next?

11 A Okay. Take the \$214.72, so that's 80 percent of
12 the allowed amount. We need to get back up to 100 percent of
13 the allowed amount. Okay? So we're going to multiply --

14 Q Are you sure?

15 A Yes.

16 Q Okay. Go ahead. What do you want me to do?

17 A Okay. Let's scratch this for a minute. The
18 easiest way to do this is let's go back to the original. The
19 original allowed amount was \$312.40.

20 Q Okay. The amount approved.

21 A Correct.

22 Q And that amount approved comes from what
23 figures, by the by?

24 A That comes from the claims processor's dealing
25 with the contract and the plan that the member's under. I do

1 not -- don't have specifics.

2 Q Doesn't it also have to factor in all the
3 co-pays and all that?

4 A That's what the 80 percent factors in at the
5 end.

6 Q Does this \$312.40 even have anything to do with
7 the conversion factor of \$44?

8 A I do not know.

9 Q Are you certain what you're explaining to us is
10 accurate then?

11 A What I'm saying is that if the allowed amount or
12 approved amount is \$312.40 and each unit is \$44, we subtracted
13 \$44 for the down step from one unit. Now if you subtract \$88,
14 subtracts two units. And that's going to be the approved
15 amount or the allowed amount. And then the amount the
16 insurance company would pay is 80 percent of that.

17 Q So 80 percent of 224.40 is \$179.52 for
18 anesthesia time between zero and 15 minutes.

19 A That's the way the formulas read.

20 Q All right. Do you know, if you know, does the
21 insurance company as part of the contracting process inspect
22 the facility, the clinic?

23 A I do not know.

24 Q Do you know if it requires certain
25 credentialing?

1 A I do not know.

2 MS. STANISH: Court's indulgence.

3 THE COURT: That's fine.

4 MS. STANISH: No further questions.

5 THE COURT: All right. Mr. Santacroce.

6 CROSS-EXAMINATION

7 BY MR. SANTACROCE:

8 Q Ms. Kalka, who figures out how much is going to
9 be paid on a claim?

10 A That's one with claim processors.

11 Q So tell me how that process works.

12 A I do not know. I don't work in claims
13 processing. I never have.

14 Q Do you know what kind of training these people
15 have?

16 A No, I do not.

17 Q Well, can you tell me two things? How much was
18 paid for Patty Aspinwall's anesthesia service on September
19 21st of 2007?

20 A The insurance company paid the \$249.92.

21 Q And can you tell me who that money was paid to?

22 A It was paid to the Nevada Gastroenterology
23 Center.

24 Q So it wasn't paid to the CRNA, correct?

25 A Correct.

1 MR. SANTACROCE: Nothing further.

2 THE COURT: All right. Mr. Staudaher, redirect.

3 MR. STAUDAHER: Just one series of questions.

4 REDIRECT EXAMINATION

5 BY MR. STAUDAHER:

6 Q Do you know what the term prorated means?

7 A Yes.

8 Q On State's 241, \$44 figure per unit.

9 A Yes.

10 Q See where it says partial units priced on a
11 prorated basis?

12 A Yes.

13 Q Do you know what the prorated basis was for an
14 individual unit within a unit [indiscernible]?

15 A No.

16 Q At least that was part of the fee schedule.

17 A Correct.

18 MR. STAUDAHER: Nothing further.

19 THE COURT: Anything else, Ms. Stanish?

20 RECROSS-EXAMINATION

21 BY MS. STANISH:

22 Q What does that mean, what you just said?

23 A Prorated?

24 Q No. Yeah. Prorated to what?

25 A I don't know what it was prorated to.

1 Q You know the time units that you talked about?

2 A Yes.

3 Q We heard testimony from a billing code expert
4 about the CMS way of measuring time with decimal points. So
5 18 minutes would be different than 12 minutes. Do you know
6 how your insurance company delineated time?

7 A No.

8 Q Time is relative and we don't know what the time
9 is.

10 A I do not know.

11 MS. STANISH: Okay.

12 THE COURT: Mr. Santacroce, anything?

13 MR. SANTACROCE: That wasn't me whistling.

14 THE COURT: Can I blame you anyway?

15 MR. SANTACROCE: Sure. You usually do.

16 THE COURT: I'll see counsel at the bench.

17 (Off-record bench conference.)

18 THE COURT: We have a juror question. A juror would
19 like to know do you know if the fees for 2003 through
20 currently 2013 have changed when it comes to the CRNA charges
21 for anesthesia?

22 THE WITNESS: That I do not know.

23 THE COURT: Okay. So you don't know if there's been
24 a change over time?

25 THE WITNESS: No, I don't.

1 THE COURT: All right. Mr. Staudaher?

2 BY MR. STAUDAHER:

3 Q If the anesthesia units were actually lower than
4 the \$44, would less have been paid on the claim?

5 A Yes.

6 Q Okay.

7 MR. STAUDAHER: Nothing further, Your Honor.

8 THE COURT: Ms. Stanish.

9 MS. STANISH: No further questions.

10 THE COURT: Mr. Santacroce.

11 MR. SANTACROCE: No, Your Honor.

12 THE COURT: Any additional juror questions before we
13 excuse the witness? All right, ma'am. Thank you for your
14 testimony. Please don't discuss your testimony with anyone
15 else who may be a witness in this matter.

16 THE WITNESS: Yes, ma'am.

17 THE COURT: Thank you and you are excused.

18 THE WITNESS: Thank you.

19 THE COURT: All right, ladies and gentlemen, I
20 believe that that's all the State had lined up for us today.
21 We will reconvene tomorrow morning at 9:15.

22 During the evening recess you're reminded that you're
23 not to discuss this case or anything relating to the case with
24 each other or with anyone else. You're not to read, watch,
25 listen to any reports of or commentaries on this case, any

1 person or subject matter relating to the case. Don't do any
2 independent research by way of the Internet or any other
3 medium and please do not form or express an opinion on the
4 trial. Notepads in your chairs and just follow the bailiff
5 through the rear door.

6 (Jury recessed at 2:46 p.m.)

7 MR. SANTACROCE: Your Honor, I'm going to make a
8 motion to strike her testimony. She certainly didn't have
9 information enough for us to cross-examine her on and she had
10 no idea, no experience in billing, processing claims. So for
11 those reasons we're going to move to strike her entire
12 testimony.

13 MS. STANISH: We would join that.

14 MR. STAUDAHER: She testified to what she testified
15 to. The fact that she said she didn't know something doesn't
16 mean that her whole testimony goes away. That was ferreted
17 out on cross-examination. The documents that were provided
18 were provided at the defense request. She certainly testified
19 about the records that were a part of the actual original
20 complaint -- claim that she certainly had knowledge of and
21 testified about. So we believe there's no basis to strike her
22 testimony. The jury can weigh it as they will and they can
23 certainly argue the things that they brought out on
24 cross-examination.

25 THE COURT: Anything else, Mr. Santacroce?

1 MR. SANTACROCE: No, that's all.

2 MR. WRIGHT: Yeah. At the defense request, because
3 the Government never investigated it to begin with. I mean,
4 that's what's so irritating in all this. Yeah, we do things
5 like object to hearsay and want the documents presented that
6 should have been gathered five years ago. And it makes us
7 look obstructionist in front of the jury and like we're trying
8 to hide or confuse things. And it's all because the
9 Government didn't prepare their case. And it is -- remains
10 unprepared. We don't know if the units here are incremental
11 to 31 minutes, 16 minutes. We don't even know if the rates
12 have changed out of this witness. Absent more coming in, I
13 think it should be stricken. It's incomplete and she didn't
14 bring necessary records and the necessary witness to present
15 it properly.

16 THE COURT: Anything else, Mr. Santacroce?

17 MR. SANTACROCE: No, Your Honor.

18 THE COURT: Anything else, Mr. Staudaher?

19 MR. STAUDAHER: Just if the Court entertains that at
20 all, we would like to at least have the opportunity to
21 potentially cure that. I don't think that that's --

22 THE COURT: Yeah. I mean, here's the thing. I mean,
23 generally, of course, you know, if a witness's testimony is
24 incomplete or they didn't have a real basis of knowledge for
25 everything, of course you wouldn't strike their testimony. It

1 would just be well then, the jury can consider that they
2 really didn't know what they were talking about or their
3 testimony was incomplete or something like that.

4 The issue here is a little bit bigger than that
5 because the issue here is, you know, it's the State's burden
6 to prove these things. And what Mr. Wright is really is, you
7 know, a jury doesn't know what they're supposed to be looking
8 for. So a jury doesn't know that there's supposed to be
9 backup documentation for all of these things. I mean,
10 basically, this is a fraud case and it's numbers. Numbers
11 matter. Mr. Wright is saying look, you know, it's their right
12 to demand the backup and the explanation. And when that's not
13 forthcoming or that wasn't part of the State's presentation,
14 then it makes it look like the defense is somehow nitpicking
15 or hiding the ball or trying to confuse the jury or whatever
16 and that that's unfair because that should have been put out
17 on direct and made a part of the case, the State's case in
18 chief.

19 You know, a criminal case is a little different. In
20 a civil case they could, you know, make a Rule 50A motion at
21 the end of the State's case and say the State didn't prove it,
22 they didn't prove the numbers, they didn't prove the loss.
23 You know, a criminal case is different. So really, I think
24 what the issue is is what's the remedy here for this sort of
25 incomplete testimony. Because at the end of the day, I don't

1 know, maybe you guys figured it all out -- I mean, I'm still
2 not sure her calculation -- we never figured out how it got to
3 that number. And then when it says well this is prorated,
4 well to me that suggests now you're prorating based on the
5 increments, meaning like 17 minutes is different than 15
6 minutes and 21 minutes is different than 15 minutes is
7 different than 30 minutes. So what does that even mean?
8 We're left -- I don't know.

9 And I think what they're saying is it's the State's
10 obligation to put that forward. So what's really the remedy
11 in this matter. Like I said, normally, if a witness's
12 testimony is incomplete or incomprehensible or something like
13 that, assuming they've been qualified, that just goes to the
14 weight. And you tell the jury, you know, in argument, that
15 witness wasn't making any sense. But you don't strike it.
16 This is kind of a little bit different because, you know,
17 she's supposed to be here as the person most knowledgeable or
18 whatever, which to me really should have been a billing person
19 to explain all of this.

20 It's not the defense's obligation -- it's not the
21 defense's obligation to try to calculate your damages. When I
22 say damages, to try to calculate the amount of the theft.
23 That's what's happened here. I mean, this is the most bizarre
24 thing. You don't prove up the amount of the theft -- I mean,
25 I get your theory is well, it's any amount because it was a

1 fraudulent charge and therefore, they didn't have to pay
2 anything. But they could argue look, they were entitled to --
3 I'm just going to use easy numbers.

4 The defense would have a right to argue look, we know
5 anesthesia was performed, they're entitled to \$100. By virtue
6 of the fact that they billed for 33 minutes, they got paid
7 \$175. And so the amount of this is \$75. That's the amount
8 they ripped the insurer off for. That's a misdemeanor. I
9 mean, they should be able to argue that. And then if the jury
10 accepts that, then the jury accepts that and you can argue
11 your theory that it's any amount because they made a
12 fraudulent statement in their thing and it should have been
13 zero. I guess that's what your argument is going to be.

14 It's the State's obligation to prove this, not the
15 defense's obligation to try to prove -- I mean, that's the
16 weird situation I think we're in. The defense is trying to
17 prove the amount of the damage which should have been the
18 State's amount -- obligation. And then you can argue it and
19 spin it however you want. That's argument and that's entirely
20 up to you however you would want to spin it. I'm not saying
21 that and they can't tell you how to do it. But I understand
22 that that's your theory --

23 MR. STAUDAHNER: May I weigh in on two points?

24 THE COURT: Okay.

25 MR. STAUDAHNER: First of all, that is one part of our

1 theory. The other part and the statute is on point. Under
2 NRS 205.265, if we can prove that any portion of the amount of
3 money that was taken in this particular case was taken in a
4 death-related manner, fraudulently in this case, we get to
5 count the entire amount. We also get to aggregate under --

6 THE COURT: You can aggregate various patients
7 together. No one has a problem with you doing that.

8 MR. STAUDAHER: But with regard --

9 THE COURT: But then you still, if you're aggregating
10 you still -- and you're trying to get above a threshold,
11 again, numbers matters. What was that statute? I got to look
12 at it.

13 MR. STAUDAHER: NRS 205.265. It's commission or part
14 -- excuse me. Commission or part ownership is no defense to
15 larceny. There's a case on point, it's a 1975 case, Babcock
16 v. State. The cite is 91 Nevada 312. In that case it says
17 that it shall be no defense to a prosecution -- and this was
18 an embezzlement case, but a theft-related case -- that
19 property appropriated was partially the property of the
20 accused and partially the property of another. The accused is
21 still guilty of taking for his own monies that belonging to
22 someone else. His portion is disregarded for this
23 determination.

24 So under NRS 205.265, we get to count the entire
25 amount if we can show that any portion of that is taken. It's

1 the -- this is a case where it's a tip jar, essentially, where
2 the person was entitled to the money --

3 THE COURT: Right. They took the tip jar and it was
4 a tip pooling situation.

5 MR. STAUDAHER: Correct.

6 THE COURT: And they said well, we're entitled to
7 part of the tips. And that's the analogy -- did the defense
8 know that that was the basis of the State's theory of the
9 case?

10 MR. STAUDAHER: That's one.

11 THE COURT: Okay. Well --

12 MR. STAUDAHER: The other one the Court has said,
13 articulated --

14 THE COURT: Well, I'm asking you about the numbers.
15 And then I heard this theory yesterday or the day before, so
16 I'm just saying, is that how I -- I said you spin it however
17 you want. I'm not going to --

18 MR. STAUDAHER: There are two theories, Your Honor.

19 THE COURT: You spin it however you want, but numbers
20 matter. This is a fraud case and however you want to spin it
21 or whatever theory you want or however you want to compare
22 this to the pooling of tips in a jar on a bar, that's fine.
23 But they're still entitled to numbers. Numbers matter.

24 MR. STAUDAHER: Correct. But that's one of the
25 reasons why we never -- we're getting the documents to try and

1 parse out exactly what portion is related to the fraudulent
2 theft and what's not. The reason that this statute is in
3 place, the reason that the case law shows that we don't get to
4 count or that we get to count the entire amount is it's not
5 the obligation of the State to try and figure out what portion
6 of the theft was theirs and which was not. That's the state
7 of the --

8 THE COURT: Except that's a tip jar where they're
9 pooling tips. I mean, I guess you could have done it in that
10 case. This is a little different. This is like they -- the
11 surgery took seven and a half minutes so they'd be entitled to
12 seven and a half and they bill for 33. So what number is
13 that? I mean, to me -- first of all, I don't know that this
14 is -- I mean, assuming you get convicted and this is your
15 theory, I mean, I see a great appellate argument here and I'm
16 not sure how the Nevada Supreme Court is going to look at the
17 applicability of your tip case in this statute to the facts
18 here.

19 It should would be nice if you had some numbers to
20 back up your theory. I'm not telling you how to do it. But,
21 you know, that's -- I think that they're entitled to know,
22 first of all, where you're going with this and what numbers.
23 Because they're going to spin it how they're going to spin it
24 and we'll deal with instructions. I'm assuming you're going
25 to ask for this kind of an instruction and I suggest you

1 provide the cites and I'm glad you brought it up now because I
2 don't know if they were aware that this is what you were going
3 to do, even though you sent the instructions over already
4 because I'm sure they're going to want to do that.

5 Just right now, based on what I've heard, I'm not
6 real comfortable with giving that, but I might. But I'm going
7 to have to research it.

8 MR. STAUDAHER: This has been in the case since the
9 writ in this particular matter.

10 THE COURT: Okay. Well, I mean, again, you start all
11 over with the jury instructions. I didn't rule on the writ.

12 MR. STAUDAHER: I know. I'm just saying that it's
13 not like it's brand new news to the defense.

14 THE COURT: Okay. And maybe it's not. I mean, I
15 haven't had an opportunity sitting in here all day, every day,
16 haven't had an opportunity to consider what instructions I'm
17 going to be giving. I'm assuming, anticipating that you're
18 going to want this as an instruction and I'm anticipating they
19 might oppose it. I'm glad now I have a heads up so I can
20 start considering it. I certainly am going to read the case
21 that you just alluded to and if there's any other cases out
22 there, I'm going to read them.

23 This is, you know, an unusual theory, maybe not --

24 MR. STAUDAHER: And I want to be clear with the
25 Court. It's two theories, Your Honor, it's two theories.

1 THE COURT: Okay. So there's that.

2 MR. STAUDAHER: The first theory is the one -- or the
3 second theory is the one I just articulated to the Court. The
4 first was the one that the Court articulated, which is if they
5 do what they did with the insurance fraud, that they weren't
6 entitled to any of the money because they wouldn't have had to
7 process the claim, the company would not have had to pay any
8 money for the claim.

9 THE COURT: Here's the problem --

10 MR. STAUDAHER: So those are the two theories, Your
11 Honor.

12 THE COURT: I was looking at this yesterday, your
13 insurance fraud on page five, line 25. The way you've pled
14 it, which exceeded that which would have normally been allowed
15 for said procedure. You pled it, you prove it. That means
16 you're stuck with what you pled. You pled or you or Scott
17 Mitchell, whoever wrote this, which exceeded that which would
18 have normally been allowed for said procedure. That's the
19 pleading in the indictment, so that's what you have to prove.

20 Again, how you choose to prove that, as long as it's
21 admissible, is entirely up to you. But, you know, there's
22 been a lot of litigation on the sufficiency of this
23 indictment. I upheld the indictment. The Nevada Supreme
24 Court, with the exception of the RICO parts, as you know,
25 upheld the indictment. The whole big issue was notice of what

1 they should have known and everything like that. So you put
2 them on notice this is what you're going to be proving. So
3 that's what you're going to have to be proving, in my view.

4 So that's one issue. How you choose to go about that
5 -- Ms. Weckerly made it known yesterday that there's other
6 witnesses on the list. So as long as you notice a witness,
7 you can call them, as long as they're noticed. So how you
8 choose to proceed is up to you.

9 On the other issue, you know, again, I'm happy to
10 have a little heads up. I'm certainly going to read that
11 case.

12 MR. SANTACROCE: Wasn't that an embezzlement case?

13 MR. STAUDAHER: That was an embezzlement case, but
14 it's a theft case.

15 THE COURT: It was the tip jar.

16 MR. SANTACROCE: Yeah, it was embezzlement. We're
17 charged with insurance fraud.

18 THE COURT: And theft.

19 MR. STAUDAHER: No, you're charged with theft.

20 MR. SANTACROCE: And theft.

21 MR. STAUDAHER: And that's why it's applicable to the
22 theft --

23 THE COURT: So even for your insurance fraud, which
24 doesn't have the dollar threshold, you still -- you know,
25 again, you pled it.